var title_f10_11_10416="Toxic megacolon in C diff";
var content_f10_11_10416=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F59217&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F59217&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Toxic megacolon",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 369px; height: 352px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFgAXEDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5YWpF+tMFPXrQB3PwsuLm31vdZzSQS4H7xCRjrn9K+jrbV77UY7eK4u28lUCsAMA47nHWvnf4Up/p9w5UEAKOR9a9ttSRYEKOpHT05/wpoR2lnc+btAOIh0AroLQkgYNcjo7ZRc4/Kuusui9Bn2pgasJ96tLwDyarRemPpVuMAHjn8KQEsYJ4P51Ko7E8UxcDrz+FPyDgj1oGPH44pe57UzPHWjHv19ulADwcUA8n0pvQcUvpkc0AL29aU8ZpM/L+NKOvb3x3oAU8mgnrj/PSk/X60dB04xQA735oP5mkPNL8vI6mgBCfrSZH1oIBGKY3X/61ADsrx7UmV96YTgCoyyrzmgCbICnn9KY5X5iTkDr1qOWVEjJLYP0zWVNPbzZTzmXPQ9qBE93cwQMAzDnkVRfUIwThwPzrktb1aNrxhDIrRKMBueTWVFqbST/MeO/WmB6HFdb2znIqylxukCqc5rmdPmLR5XkN0Are05Qp3Mcsfb3pAa8ZParCnjniqiSDPFTpIOM4zQBLIuRnkGs+cHPTitHqBj9KhmQMCeKBmFMmckVy3iZwImXoO/5V1uokRIxXqK898SXe95FcDIPGfpTEed+Is72KnjngVwesTNghl4wev0rutcbLsc9ugriNbh8yNmH3gCenXikwOPvpuWy3PT6VjSHcTnvVy/Y+YQRyOuRVFyaQxpoDbWGDzTgOTmmkc0AF3IZZAx67QKr1JJ16VH3oAKQ0vak70AGD6Gil59v0ooAeKevpTBTloA7/AOGEiiedOQ2Q3Ttg17PayAxxxqegBPvx/wDrrwr4eOV1CUjIOB/WvX9KuTJORzlcDp7U0I9A0Qgomeg4/Suv04M2MdPU1yGiqSIx/Ea7OwUruQKAvZs53cUwNeFQg4/SrA4z06VUV8Hk8VLG2W68YpAWlPAApwPzA9f5VEnYYp+QB04oC5KDxj+lLn0xVGa8jjyDyfas+fUSeBwvagDbaZQaaZ1xwB9a5iTUTnAJqP8AtLGCTmgDrROuOR+lPWRSP/rVzFrel+hIH0rSju1H3iTQBsgnn0pelUkuUIGD+dWEbdyKBkoOT0zTugGRj8Kj9OKf370AI3HQfhUTkDOOalbpz0qKTA69KAKrue1Q7TkEnjvUk3lqxOcMepxUHmgkbefagRFcvujKnuOa57V4GESRqfvHJPtW5LHI2c445qvdQA26swGRxQBxN1pJMQwec8kiorXSpEnJYKD0xiutaJAxCgsfUkULCqtvIG7oP/r0wGWtu0UaLgYHpWtaqVGeo6Cq0ZwDgVKkgPygZz60gLwbjGeacJNi7h19Koo7RzSGVh5fG0Acj1zUrSpLKFBOSOOlAGhbTb+D0PrVpWyAaoWsbAjcMVI1yqNjGQetAFfWLZpIWaMds15D4uEsc0m5dvuB7V7MblAdrEEnPHtXLeLtCtr63knh3K/cDGOlMDwPUJiWO7n3xXM6tkrhRnIPau68R6LLBKwP3SD3Fcfd2/lsUcHB9KQzgtVt+SQBke1Y+w7uRXe6jpTyspAxGOp/+tXM6parAMIOhxnHWkBkMAKjbrTmPOKYevWgCOTrUdSP1plACdqDR2oPWgBtFOx9aKAHCnjFMWng+9AHV+BSRfSY9B+PWvV/DRLzs4JI3Z/nXkXg+fyZ5myPu969h8HqNsQb+IZIpoD1DQgI4EZvvkZzn1FdTbvsXrzXK6TOAoyMAf4VvWjk8k8+9MRtQMT9e9W4sgdetUoWz2zn1qWS6WGPLlR3HPWkBcklSIbnbH5c1iaprSIpWNjmsjWNb/2uPY1yF9rJ3NjkH3pgdNPqRkJ+cmqst66/dbHtXMJqjMwwQPTNaFvdkAMSGYkd8UAa6TtIASSo/WgXCo3zHPpn0rKkvgB8nGDk571CLkMfmoA6GLUs47fjzV+LUFVAC2f1rjvtAD/LxViG6OeTwaAOuXUnyMtgZxjitSzviVBDfoK4k3RZcAitPTLw7DuYZzigDv7a6DgEnNXQwNcnZXLLjBxiugs7nzFAJBb60gLw/I02RQ/pzSo3H/16cOeKBmfdRbjmoY4AuCw5PNaUhAA71XJTcef8KBGdLI6ggEcdAAKqyOSGyQBg5JA9Kt3CxLnL49ulUJfKYFWYkH/aoAxJLgrdygN8oHXAxTZb1F6hsUPHE0jlGGORkGq00UfJBPtzxTA1be6DsFzkVeBRY9/SuTa/itHIMgLjtmrVjqv2hWBcbj09KAKeua21tdlVfcxGSRjjk1Ss/ELteCOKceYFDsmOQpJAP5g/lWF4gcxaq6yHnqv0pdMlCtjPFAHq9lrKzRRwlgZQoJ6c064nDRgxn+tedaHqbDVQGOCTjn8a7m2IkVwcHv1oAtRTmSENnpwc1DPLvidNwAYFeT3qCefyo8cADnFV0l875wcA+/Q0Aef+Jrv7LcPHMA3qGAritXaPG5VXDDggCu7+I9oXZLkD74O7HY4FeeFSy+U59cE0Ac9PdNvaI9G4Hsa5zU7cs3zAjrniuvvLVd24dRyKw75xLuR8Bs4yTUjOLuY9jnsKqsMVramoRzkjI4rIkPzGgBjU2lakoASg0Uh60ALx6mijFFADlp1NWnUwN3wqA9+sRPD9c/Q17b4WQKpPHAAFeJeEcnV4v89jXuOgxlLaIgH5xnNCEd1YTbI1AwSeTXR2MgJGa46wlyyk5x05rp7CTcvI5z3pgb/2hIYmd24AJ61y+t62WJ+cewz0pviXUTGhiB6c/jXn+pagckbic+poAv6lqe4kBuvvWV5pkfhvwrMkmMnJzzU8biJd+0lj70Aa0Dqmcnkdake+OAI2+SsU3IkDckHPPNSW7fISvA96ANy1mVsnjqM5q8HyFwenOa563l2gEEkDsTWmlyHUAZHHWgCwSUYkNxn1qWKbPynAPaqLSELuJJBpI5S7AgHOaANZZ8Zye/HNaem3OyTaSOegJrldT1CHTrOS7uWkESddiM5/JQTV+C5XzQeQcbuc0AejWLhlzkDIwBn3/wDrVu6aT8pU57fnXHaVP5jKA2QeOtdfY/KiYztzQBtRuBgZqZTuA5qirEOST15qzA2SeKQwkHvUBXuCelWpMcZAx9aiO0EE8dqAM66iEikH7x6EGua1yRrODhiJGzgdwPWuvIDNnOawvElkZ0DbeTjkUCOJWd44sg85JPNQ3N64jkfPABIq1e2pjXac45rF1FGjtHB4JB/KmBzVzfTec8jtkk8/nWjomqMbgLnGR/XpWPdKS2OufWm2IKSpngqc8fWgDpfE0XnxJeKeUAVgD1Gaz9Nkyp9Rzmty2jM0BjIyhGCKz7awktryVGXKH7vXkUAS6RGZNWiCjh2GK9OtbdkDjGfpXM+EtLPn/aZY8BBhc+9d/bRDySSuKAOS1RtkZ6A9/aslb1rdjuYlT2zW9rQjBYlMnPHNcteAs7HgUAWNWt11DTriMOGXBZWB7gZxXkmrK0F0RnkHmvRItSNldFASUPvwa4/xOI5p3kwF5OeaAOZ1B/vMPu9etcJr12VfBIBB4Arf8SaoI7XZbtg5KlhXAXsrSuzOSc+pzUjGzzGQ5JP4mq7HJoJ60h6mgBppKU0lACdu1FHajvQAc+v60Uv4/wA6KAFXvTqavWnUwN7wecasn0OPyNe06Nf4t4kGQVGMf414h4XbZqKtnAFer6TISqjd1HWhAd9pkpbYS3HX9K6q1kCxknoMnn6VxGmSDCDOPaunjkJgc542n+VMRgeIr0tO5JPP61xtzNvmPOBWhr1zmdxngVzjzHcSDxQBpI21Nx5HYUG66LnJPqazBeZJ25AHrVZrvfluVA6mkM34PlJ4HrmrCyhG4JbPUVird7YFG7II696sxyZ4U5OOvegDWSZFYBcirTMwj4zzjrWTZtv/ANZ94dDVxrhmibKHK8AetAi+su5AQeB0xVi2JXnk5NZFm7CTbztPrWnG5zgg8UwLhkwp5I+lETAnjP1qMkFGBGM5pLYqXwfTqaAOq0aYKQ57Dg5PrXW2d4zhEifcV5JUkVxdk4FrgAAdsV0OjKWCssgy3BxmgDsrK5aSPD8kcZzWhan5iQeKyLCFog2XDZx2PWtW3Hy8HOaQFiTlOajGTgdGp56VBIT6nJ9KBkM8iwgsAc9qzproSfK/Iq1dn5SeeO1YV7MVjcJ97BGT1oEY+qOouJFycDkfSsHUcSoAp6A9e9X7mV5J3DthsnnFZ138rkZ4HpTAxZtMkY5RNwz0HapbbRpXcfumBz1IOK0rSRg3PTNaKXLBwVOfWgDQ0vSTGqqSrEdea34dNttqh4lYgdTWbYTnGD1966Gz2yqM8k44oAdbWyrhUVQo7Cr12wjgCA84qSGAIcnj0qpfSxg8kgj05pAcxq0oCMhHzdevSuSvpyN2P511WtxRSyErNjofu1zOoW8XUzE+4WmBy99MRcI2Dn0rlfG8zR2cjqCAyE8H2rs9SjgVdzFietcl4iVL6wnUDJCHA59KGB41PdtsKAnBJJzWdI2ScVZv+J34xgnAqkepqRhQaKKYDT7dKSlNJSATtQaO1BoAPxoowPeigBw70opo707NAGnoI/0wV6ppDYCDpgCvK/D/APyEFx/nivUNLJ2occ4zTA7LTHxtyRXU2jgrjtnHSuO09uFyMV0tnIep5piOG8SkxX8ytxhiK5t7oJLtYAgiuu8dW7i8MgHDrn9BXn84Ytwo4pMZHq16Qq+Vg59R19qlsZQyqW+8RgjHFVJIlkdmI+boMjjrU1qTBkyAEngLjIFIDctFjZUKsoPU8VfU5bagyOmf61mWqjyjyNx9Pr0q/bSbPvAMDx0pgacMixrgADHQ461MJ25DAfXFUokLE7Qce/ap44zK3yHgcZoEXbOQswG3n3rUQAnawGeoxWXECowv3q0bfcz7pD7YxTAmkVhwOce1Io2yYABPpipnbKnAAJNJAhaXnnFAG/pyM0KqELcZIxXW+Go1hzHIR5h5HH3ea5K1kaPy9udzcAYzzXZaDYOJEll+VlGdh/TNAHSqcR7iB97nA96sxzII+3pVe2cSRuMDrSCPCnI49aQF/wAzpjGKQc9h0FMiX5QCOMVK/CnA9hQBWmjkAXOGU8EBenHWsHVWjhjcuqhjkDjGTituSWRNzZ46AVha7idSuBuTB5+n/wBegDl5E5ZivJOelZt3HuLHoK1JSQMY2/UVmXTYJB54yKYFSLO4/wBO9aNqvOGAArMWQCTpjvWnaMHAK4NAG5ZMoAIAxnGK3bLgA/0rAslGcHP1xWzana2OcZoA6SCXegHHArG1Ll92cHNaFgx447c8VQ1BlU425HUGkBgXTKxIcY464rCurBzksxAB4546Y5reu5cLnYtZ95K08BVQoOeOPamBwOrAxyMpOT9OK5ucETkAfK3XvXX61BPHKVKDHrisowhkdXRM4PIGDmgDxHxzYGx1mRlH7mYlozjjryPwrmq9j8UaEuoWjxTlUmXJjbGSD/8AXxXkV3C8FxJFJ96Nip+opDIaKKQ0AIf1pKVutNNIA7UUdqSgAwfeil59BRQAop305ptLQBp6CcX6fWvTdMYbEPPIH8q8s0oj7WuelekaI4MI+YngUAdlYuOOK6Czk6Y9cda5SzcMF4/Wt60YDB7iqEWPEtqLmz37clAfyrzHUbQiY7d2D+R6V6w8imIqxyCOc+mK5PX9K2MzxKfLwSucUMDgmGyUgg4XnGPergVJYw6JhvwqWe3G8/Lx1wKfbIu0jggHoBSGU4Y5Un3lWOCOh4IrZgO4g4DBjkYqSCJcqcfKfarkMCBshTuHQjpQBMkRKkNkYHGO9WLcIo2KCCeaIoM/f3YI6GpHULggk0CJYzjoo/HvWlbgtGTjPNZaDcQAB+Na0a7IsCmBHMT2OMd6fblwRycnpUcxxnnpTbduMZ560AdPors8gYFdycjcAfSu00+8kFxGGRQCQCR65rz3S2f7UmwHJ46iux0syCRDITwQTjHr60AdnGfkJChe5AGM1ZgkHksXB7VmpIMhQDk+tXnwIyvQAA8UgHRzeY+FOOKnVzgKxJxzzVC2CBsnPXtU1zllUBsDHOBQAy7kjJURtj8ODWH4hiL2onty3mqcHjtitPyC+MlcH3xVHVpIYLSYupJAPA69KAOVnbz4izDDDk8d6xb9iz5HvVoS7wcdM9PSq1xHuJx3pgZ8ZLMAwJGeK3NOTBUEEHrWXBCdwwD1rasoiSOn40AalsxAw3fmtPT3yeeQTVCG2JUbR05FadnbnODjPtQBu27AW7H0HpWFqEzLna1bLxmO2AAz64rBvkGflbH1oAybq4+TkjNZcs3zEAmrt4gKtn+dZrqB95sHPagCvcQtcuGTO7GD70+902DT7Nrm5GHbO1Mg9B1qaBlVxtyRVLxUxlYKrblVeAT0yO1AHn+uSNdSszZHJKiuA8R6C12Wlto8XPcAgB+ev1r0K7QBju9fxFc/rVzHawMy/e7eppDPKJ4nhleOQFWUlSD2NR1raveJeTHzIVRv7yjn8aymAHQ5oAYaaacaSkAnakNHalPWgBOPU0U78P0ooAB1p1NpR060AWLRikykcV3Xh5y+xi2WAz1/pXBQH94vpXbeG2wQCe3IoA7uxbIBB4PT2rat32p1HHpWBYScBSRtPP41qxynGM9KYjYhkLZJ61fgZW+VxwRg571hwSEE98VctrsHGTjHvTAo674dicNNallJJ3KxyK59NMEB2k4A9Oa9Chk3nPao7jSI7ksVO1z3zQByenWyKRlgQeDViSJY5Gwc4OMVtLoMyuQjKw7YpbrRpVzIR3+b2oAwC2TgGk2sQG5JxWslgQQCpz04qY6eqnDc/Q0WAo2cXAZiBjtn2q48p9eB70hjI/l0prRlVJzxmgCG4fIJH5UWfIORinzRDBJOSau6bbDYc8n1zQBa00lLqMfwscMc9s16dpGnFI42Lcdck4zXF6dCkJSQIMgjHtXdaXMWtYGz1U9f940AaSApMozirbkhGc42leKqTsdivwMdaqzzuWzu+UDoTSAmEhZ8YXbVmQKwUYzxiqNuQ8qjoP5VfmJiUEDJ2+tAGbdAKcqT781R8QFZdMKFxuU5B+g6VsBlnDK4HTIOawPE/FpGI2AXzCCMdeKAOLiBZnHJyeCPWlCHLenStBYU8wnHPrT3tg2WU4x70wKkUBB69O1a9hEQwBJHHNQxx4IPJ/Gr0AYJxxnigDTsoTOSq42jknNWpnjtFwpy3c5ptg3lQNnrXP6nfK8zAtjBxjPvQB0NlqUcj+U7ABumT0NVtRhKHP5H1rj5Lx45AwYEZzjNdZbX323TEfKsMDIz3xQBz98Sc96ypc9x0PrW1euMHaoHbNYtySSeaAFt5/LOFPJzyap6vKjwnoScjOaXLB8sVqOZUkRg3Q9qAOF1SUx72OM5PWvN/EuoO0zKD8xyP92vUPFVoYwSBlDnmvG9e4uDzkknJpMZkSvkk5yT71ETmlfrSUgGtTacabQAdqQ9aKOtAC4H+TRSfiKKAHUo9uKSloAfD98Zrq9CuAuAfukAc1yScHNaVjcNGRgk/jQB6fYz7kBDZzW1FMGUf3h+tcJpN277R8wGO1dHHOUG5j+NMDoop1BxnA+tK1xbq/8ArQPbrXB6zrrRuVhY7QDuIJGay7PWpSH+dmPuegouKx6/Y6xAjYbJHTrXQ2Oo20u0K43ehGK8d0nU/tK8khu+K6WyvPJwzuVAPvRcD1S3dXZcKPr61qW6k89T3BrzC08WpbHao3fia008YSHJjDgHnG88UwO4m0VJTuiAX2JJFZeoaRKilvLbHqQcVkWnjR0dRIrfUOf5V0ul+KILkAMQwPYnmgDmWsmGQQRVg2Ba3DKuWU9PWuzW2069G5NquexJqf8AsmCKE/Lnv1NAHnP2KSWbAic46jBrcsLDyY8uuK3pIVRiEjAGDn3qu8LHIweKAK8CZm2qrbScHuK67TQkkSxhcbF+UjPFZNtEioBIMAex5rc0sJHu2HJI6c+tAF0phVTtioJrNPLLsfmIzgHtmrTJ5hABORUdwow3B9B3pAZtmjQuSclfbpWvMS8PyjJx0qmoAXJ69RxUl1KsUQVD8xGcUAMZTHEeQGIxgVzuvBtuwgbc+YOeelXsTFssdw9OakurQz2sgMZ3EfePGKYHMqFJBHI/nWhaRB1bC5J4wKI7MqgUKQBxWzo1iy5MnA+nWgDLfT3AXCnA6itKx03MYLjap9utaspggUFwAPfNUrrU0WLMeSOhPpQBl6/cCG3eGEgMRyQenNcJfzOJfnzj1ro9VlFz5ssRbBPPPQ1zbssgMbDigCi92zqRzj1rd8FXe2aWCTJjYAgZ471ki1QsADj2zWrpECwTK4wMUAa99EAWw3H61iTKA3c9a3rpS8JI6Vg3SuGwfX8aAKc+Cx4z9KozZVjxxjrWiyE8nio3iUg55I6cmgDHuohd2zQvyT715H410eS3kYtC+Nx+bnkZ7V7VJb4ywyD7CsHWLaO5QpOm9e350MD54niYE5GPwqAjBr1TWPCvmlmhI2+mOa5HVPDF3CxMMDsAOcA889qQzl2pKmuoZLeZo5o2jdcZVgQagNIA7Uh60vag9TQAmD6Gil2migBaKKKAHCrdr98Y5Paqa1atskgA0AdboY6HJNa+sztbaazL1Y7c+xFYWj4JVcZ+natTxIN+jsT0DDt16igDkLiaSfgn5R+tT2qBBjPbP/1qpH7w55PNatioldd3Ibjp0oA2tHWOAPL8wAHIPfmrc2oO7/I5wDn6VhXF2I127sAHGMVT+0NI23nbn86AOqt7tVJ3OTz15rRttRG5hu4J6muNhbAGB+hq/aOQwbd36GgDrheHg7qv2OotG2Vcg+1czBKAo3MOcDpWhC4YDmmB3ukeJJo9oeT5fXmu10nxIzFRI4ZffNeLxSFSMGtzSr14yCepPemI95tY7a9i3wEZxnbzxSS2G0ggH8q4zwvrLK3UZzmvRreZLiHehBXHIPagChb2m44AJrUgs2UfKCDinWjIXC4VeOCO9XVZM9RSAbDEVBPemT4RSDjcaseYF471TvgWYbWwRg4/GgCi7yA8fyqrdx3MmxozkgY4Ga0kikJHINXo4SEUkjkDtQByyxXgZdwfr2WtNIXeACSRyxPcmtkwgYzj1xiq1/cRW8LO+FAGd2OlAFSKyVdzMc+1Jc3K277IwOO555xXLarrYlbIwFHAArFm1Zi4VJACOQOefamB02q3pnJX5vMQkgetZIvDlo3Y7TxTIr1btVfpMvUAVWvYSWDoTk84x0oAh3YldM4XpjHWs++tyh3pnBPYU+6mWNQ8jAOo6Y5PNLaX8Fw4jVwd3GCKAKkcmfmPpVuC52gEkcU77LC8pWBgzf3RSx20KHDcNjpjNAG9p5+1RtnOMCqt7Cqlh95vWr2kqIrY4HB5pl4VZW4XnrxQBzM7FW2jpTERmP8AM1duQVY5VR2xiolJCsx4GPSgCvcMFAUZOawNWGB8v3ifStm6kATdXP3cpeViQNoJFAFORcL3B71j3jtuOfwrTuXwpxjFc/fzqiuzEfjSA8z8Vktr9ycYOV7n0rGrR16UTarPIOQSP5Vn0hidqQ0vakPWgBKKdxRQAtFApewoAUVYt8FwD+dVhjNTQnDigDq9HOSB8vTkd6ua5MslmY8jk9zzxWHY3P2eLcG7eo64qGa6LkgZ2+9AFWQASf8A1q0rOdbeGRmGTjAHvVDAYjp680pDykbQSO1ADpSZWLnknqKljUDgjnpSxW03ZeQeeRV/VdHvtE1A2up2sltPtDhHwQVYZVgRwQQeCMigBkCnI4+gxV6ElQT06Hke9UoSM56dORirqYPPWgDRgO7b6kitCDO4EdxxxWZasoKnPT0/GtO3UbSRmmBbU8D/AAq/auUbjOKoRHJq9bA7xnGKAOo0S78ubJBwfSvTdD1VI0A3AhuD715NYkAg5rYW7kiQFWwcnmmI9hD4kDp909MVdinJlVe9cN4L1x57lLaVgyAZ+bHr0rv1MbosiJtYjuKQErPmTtmmyjcMjtUcLL5mBzzzUNxI0bN15OaALEHr9KsNOdwCjNVbfM8R4weDU48tY/mPI6k0AONx1Dde3vxXI67qZkkltj90Z5x3q9rN5b20SyRl3we2MVwd1fNcTysxwxYkHsRTAj1AkNuGCMcVhyMfNU5P0FXp5MFgxJHPSs6ZSsw6kN0oA3dGnMlwpGMjr+daWp3S2jDcN289BjiqHh21xukbgdqj1XLk555PYGgDI1G4Mszn+EnI46VmQswkDLnrzVq7jccgcd/zquRgqw655oA0LO9a1ujI5yoPGO1bf2v7QEkLZx2Fc1PHGF8wZA4wDV7T38xVC4AA5GKAO3RZZNJF7byCURcTRqPmjHY+6n17VX88PkKwJrFhv7rTUNzbPslTOMgFWBH3SOhB6EGq160dzA+r6H8scfN5ZZy1sT/EPWMnoe3Q9iQDZuT8pIwT6VnyuQpz39KyE1qRDH9rilSOVd8TMu0OucZHYjIPIqSS+SVCYyD+NAEGpufLIU1hyttGCcHNaF1NnORWPdSfeP1oAp3cuA3QCuW1ucbXXgqByK2b6YKrZ6Vxet3a73IbJ59KQzltR/4+5OnX+lVqknO6Vm96iNIBKDRSnqaAD8D+VFJn6flRQA4UUUUAKOtPjOGGKYOtPXkjAoAvo+IsZ56gURxyTNhASOuelaem6enkiSXkkZI3dPrTriTYdse0qDnPr+NAENtbIgLSHn3xU8kqrgKBgf5zVWR2aT5n4+tOAGT8345oAsQXJWbcMZB6mvRfDWu2eraVFoXiWUR26ZFhfkbjaMT91u7QknkdVPI7g+bpHnPfjOM1p2eeEGMdqAN3W9DXSNSmsdQt/IuI8H5eVdSMq6EcMpGCCOCKpHTonC/ZnIOCdr45/Gum0bU7TVNNi0HxLN5cC5+waiRlrJifut3aEnqOqnkdwcvUdJvNC1Gay1BPLnQhhtYFXB5DK3RlIOQRwRQBlrbSwyIsy7STwfWtGNgoChxn0J6VOkqzR7JMEds81Wa28pgAOM5JHWmBZhl4yOfer9vITzk5rPhjVUX/ABq/apuHFAGvaykDknpWujmeEKp5BrBTeOvP0rq/Ddk8sRJ6k9KYje8H28Mc+9ZlB3dHOOM16jayK8CFZIzjk4YetcbpOgMyKwkAPcFua6vTbIxKUZu2KAL8MQHIZT+NOaJWYZxn6impHsIA/P2qG44fKnJ9jxSAmQeSecbe/wAwqPUInkiPl9HFZWo3D4ATIPQ1a02V5YgkpO0jjnpQBmvZie2e3kGDg4+tclPotykrokbPtOVbpkYruLxp7Zz+9YqvIzzVOXUJZ/lViQeD0pgeey2UombKMCB04qO2sWaYqQTg5r0H7IJFJxjtyKgSwjglLBAG9aAMmWH7JaqoG1jnkVnrGZcqBz1rob4iQEDnFU7BUjvP3gAB/wAaAOemtM5V4/vDqOxrBuYlSXbv71639kidW3Y+boAa5zVvC0VxK00MgRumGcYJz9KAOL+aWFw2cjrVzRYgrLnPvzW3aeGmjeRJ7iNUx680yXToYFwJWBA4+Yf4UAZ/iCZEtQiEA4z+lZPw6v8ATNN8Y293rt1Jb2ihgzIpZXyMbXA/gOeeD6dKk1l48FQwPGMk+1c1d26lTgn65oYHvHxm0q08TeAU1jQZoLg6bmVHt2DAxYG9Rj04OO20185WmpTxMy+a3TPar2mavqeh3Lvpl5NbMw2sFOVkHoynhh7EGsrHVieaQzSg1J2IDnKn9KfduSu4c5rGUmPJH4VdaXfaITkcUAY+ry4jbsfpXC6s4MjEHPv611muSfKyqy4/lXD3zHzGyaQFB+WNMNOb7xptACfzo+nSig8mgAooyfU0UAOooooAUdat2iqql369Bziqi1KrnHA6dKAOhtrjEBAIxg/KD7VVd8g4zn2NRacxZgCfzq5OgDsD+NAFNzhj9KkhJGPQe9NmXDYGc1PZQNIwCjJPFAE8TYAI+96E1ftWZcHILdeKiuFWJ8HJI6H0p0bAhdxIAOeTQBsQ4dNo6N2ycDmvcPgd4Yg8a6ZJB4n8m7sNKlX7InmYnTOSyEg58rocHv0I+bPhFlKAxzzk89RW1YXt5Z3kdzp1zNazpyssLlGH4igD0b44eD4vDXi4TWFusGm36ebCqDCRuOHQDt2P/Aq8/SMnr0rtNY8fan4m8MrpPiGKK9lidZLe8A2SIw4O7AwwIJHY98nFc9ZwSCQYHPv0pgUEi5GcYrS0+0aXhAcZ5Jq89rFbx73ILN8yjmq76gSNsQ2r6UCNPZb2hBO2RgOzcVpaZ4kezl3JEki427SeK5XdvOcnJ9a0rTT5Z1JjAI9M0wPTrLX1uR5kDhAeTGrYK8+veui0zVGlj3M+5sZGTz1rhPDOleQ+6+O1TwMHoTXX2tiIU8yN/Mz93HSgDrbOYSx5YY/GiaJcnkfnWNbyywKA4Yg45ArTXfJAjKDu+vPWkBDdWQkClMbgMdTU9pbi3jjTI3AetOidh94H27U/y3kIOcEUAPnhS4i2sEbtWdJosSyF0ZQB7mtNImRcenpVS9uDsKDIzxjmgDPwsbsqupwOu6nSx7o9wAOPxrNcv9oZQpXHBrStJsqUPPqDQBhcKWjdTnJ5z71VYpEWdjhR3Jrc1ZVhAOM7uhri9euNsZDnBJ4HrTAS98QMXeNXYRdAA+M89ayLjU/LVn+0N1yFVqw7yXEjHvmsyaYnq1AGtdeJJ9py7H6uan0XX/tMpjuJhtbjDNnbXF3TsxwMmq1k7W8xLYyfekFjudatXjkDnDIe4PtWMxySAOtdH4a1CK+0w29xglfu5Oe1UdWsWgZhEoCZ4IpgYsqIRggE84welULqDaw2nI71flymSeWNQodxw+R34pAZcikAL61Gz7QFJ4+ta1xbb13KM56Vk3cbIjbgeOOKBnN64Tub5gR9a4+8ILtg/rXSa3KC8mBzn1rl7lssc0gKzdaaetObrTTQAlB60Z4oPXpQA7I/yTRTc0UAOooFA60AA60+PqKaPrinp1GKAL2nMfPUAn8K2bmIk7hk54wKw7MkTLziun2iW2Ujlh1x6UAZLoWOPX2rpNAsVSB52ByM4BqpYaebibHQZ9DXU3gisrFkIAwDkUAcVKxluHc9SxPI96swlfvMeSeMd62tO8Ow6xoM1xos8kusWm97uwdRl4Rz5kOPvbR95eo+8MjOMSyR5WHJPPagCzaRs7kgEBj0xXR2ELSAAgg/SqdjD8vsf8a17T5H+UZNMDQt7URcyHA7VZMp4jjXGRxx+tOjgcxIXJbJwMiptgRmVAS2MFu9AhkkP7hd7sW5OCMf1qpLbISdhKse9XwW34cE8Y/SkeDClhzzjIoAoR2zh8OjccggHBrsNHtpGUKisH9MVlabO8cxGcexrr9JuZbVCoj3M3LAqf50wNVIXZNpG1RnBPFRS380YxHklDgDB5OalSK6nZjbsG4ORzkfWsJre+M5DLNnOO/40Aay3184wsrgk8jnj6V1OhXFz5DCRmbnndnFcbbJdLKpJdlH8RU/1rtNDlK22Z1A39OCKANqCTJyfarqHIBHH4VQXapDADnvViN8jJH04pASuxwfmP4Vj3zFGcbzg9/atc8jg5qhq1o0kBeIFn6HFAHO3lwxdWUDHQtz0oS+EbfKMDHXmortYIIv3shwDkd6oi4QxEoDwM9KYG7cObqy3AE461wfi8CKJGGT1x710ek6vm5EU3MTnacg0nijSori1GCSCSQeaAPI5pGZif8AJrNmcluScDrXW3+iNGDt5wegFYVxZGNj5oZR7gikBjlDgms6dXLqqHBJ69a3jBvx5X8qWGwjVw7ZJ9xQMm0nzLSAEM2SMc/Stq3vjPGY7kZ54bngYrJbcF/lTWm2qVDfN1J9KBF26st7lo/mX1GaqSWTLk8rmpbS8kgGM7lParktwsiblII96YGZ/q8FyR9KqahEkyZj+8alvZM5way5bgxqSWIFIDhfEcJgnkVwR+HXmuVlOWOetem6/ZJq1g7xkfa1Hyn19jXmMwZJHVwQykggjkGkMjPWmmlpDQAlFFB70AJRS8+9FADqKKKAAU9Oopo605e3H4UAWYeWHf8ACuv0MpJhWXjPTtXHw9Qa6jw+S8iDb68kUAdnpNtHFyoyfwrI8QM0l48fRRzmtyzzjpwaw9bjcahLhcg9+9MDL0+e40/UoLuwmktruCTfHMjbWQg8EEV6BJp1r4ttJdV0q3jttaiUy3+nxJtWcD708Kjp6sg6dRxkDg4UO7cQc59OtbmjTz2V7Fd2crwXMLB45IztKEHqDSAkhHICgADHatiwi6Ej36ZrdmsoPFNrJqGlQxwaxGu+9sY1wso7zQj9WQdOo4yBYj8P3+nCzbUrKW3FyoeLzFwWGfTt+PsaYETIylI9oLBM80s0Ygg3Nt3N0q1NCWuC+MjAIOKpajkqqjHA5470xFEtlie1WYnYwuvXIPNVkUBBwCc9KlDFeg4NIBbZ9j7+nPpXomk7bu186369Ppx0rzhEPmc4/wAa7nwdM8Cuqorq45BHTpzTA27NJoZTIqHkFRnjPv8Azq5EzyS4K9ATyM/hVtLQKC7PuI5x6VXebyjuVVXPfH8qALa+XCoZlHIzgDmmpqgdgqgYHt71QunZmSRjkFOPzqrFtEgPfOfrQB22nXQmGx1H1x0rQkcIFwu6ud0mQhAwPHvXQxlZYQx60gESYHjAFQXNy6cKeegp0SfNg4wD6UX0YWJiQS2ODjpQByOtQlrly8YVh29TWIHYSEADniuwvbP7S26XA4z0qumhW6OWK7vrTA5yG0LsrRrznJHpzXWraM+mrHKPn9KkjW1tV+6oPoFpJb9BxjP+FAHB+IoWt7hlAAHrXCam7+YSTkV63q0cN6pV1wzdGxXn+u6K9vMcjI5wcdeaAOU3HhiPpU6sSASO1Nlt2WTbt6e1TeXti5z9KQFOdmxnjFVXLFiSB+VWpBuyPypFiOCTyBQBCZdkYBHOatWsmYn5IAqpMuckgcVLCGWJio6/yoArXj7c+9c/q1wscLEqCMHOa1dSY+UzR9c9hXK63P8AusEEYz9P/rUDMmXVpIJVIYjHOO1YurSrdXL3CIF3Y3gDHzev4028cGRsDGTUCPwVI+VuDSAhPWkNLTTQAUUUYoAOPQ0UZ9hRQA6iiigBR1py4OKb34p6daAJ4eWFdNokm2Vdoz9celc/bp839K6DSAEkXPrjHWgDtbBvkXtkVDq8ZExITIb6ccVJY7to39a1JrUTw/LgsBxzTA5UQEsOMDPXHvWhZQgPu4HJGPbNPkhKSd8jsKs2SlpBn6daAOt+Guo6foXiy21HV7aWeCDJTyiMo/QNg9cc8ZH9K958VT6V438LNc6LdRXNzZnz0QcSAfxKVPI49uSBXzzp1jJcFUjUtjnA710+l2zafPHILg20qngo+GHPqKLCKolRpiD8oz14rMuxl2B65ya1rnyUnm8vPzHcCe9Z8m50yB0pgUWi5B7VPb25mmCjkdamEAZPnbGeuCK3dMaK3t9gUiXduYkcY7UAU4NHTzSZm2BRnqBj61r2Os2FkXhs/mIGfMxwawdZvy08iRMVj747+1UrSPzQxHAz0PFAHdQ6m7zqVbIY4GMYx+FakrJMqhSdxPQ1y2iBooju7cLx6nmtaG5kWVcZx60AbQWAgRdkGDz3qFY495z94H8KqJIRE2Sfm7ntS20rMmT1HBP40AbtuxSIMoz2+tbWmzlsKxHPTFcwlyAoHIBHPNbmguJQeuAeM8UAbKMBnA9qUtzz0pksiwoOeao3N78pwcHqfekA+/uUt15Az9KwdQ1faAd2Oo4AqXWrpZYVlU8kHiuI1O7KjBJ4zTA15NTLOQG74zVpJfMTeGJIGO1ccl3luW5zW9pc4VwpJwy8/nQBckYljzjmpsRywYnClF/vU4Q7kZ2PTvWDr1+IImBbBPp9aAKepWdqzsLVkyPUgGuYvLeWH7wIH86q3mquZBhjtx/jU2ma2GPlzPuXt04oAZFasyZ24Hc/hUMsZyVHC10Kyw4w4+Ujgg1UuIYjna2B6dKAMNk+Y9MdhSTELGQc+/SrsgjQEgnIzWTeTDJJJpAZuokMgAPA64rhtek+Zs8nOK6zUblEUqTwfeuJ1uTzJiE+7k80hmJKckk9ahJqWXg+1RHrQAhptOptABQetAooAOKKOKKAHUUUUAKPrViBdxxVcdRV3T8GZQcfnigDRs4DwRkA9RXRafCM5HBpNLtt6K232P5VtRWxXkevagC7ZEbQPT3rdtB9OfesW1j5Az+VblmhGOvTimIln0pbpg8TbWPJBNTWeipbMHuZAAD91Tya1bGPAUnG3Paq96rtdv8APlQeBmmBoQ6rBZjy7eMYAxVOCd5pZHbO5jkgnpUH2YqSxPX36VZtR5bN1wB0BoASfIkSVmBZeCuRiiEoXEZPykYOKS4lO7awXb6A80+22SHaSBtAHX9aAGmNo5eOx4qeec+VsGT+lRtISm4JwMg896SyBuJGBGB9fzoAoyQGU9NpB6npV+3g8vADZJHWp5liQYEy8ZOAc5qZGheRcSAcfxZFAGtYoWjjTKnHJ59//wBVa8FoDKhU5IPQ+mapWEO3Bxw3cHitZXCRg4G76+9AFa8X52VuN5wQKrqxjGwnOOPrzU8s/nMDv289CaqTyEM65ycgKQcUAI9z5eR/EeQDXX6HmK1iLEbmTex9M1xWk2Ut3ervOVTlufyrrryb7DZHcRuYgcGgBNW1JlXIkAP1FZUWriSXbJtBOfmDcVz+p3zncshwPUmsr7eo+TdjJzkHNAHa3MiyqyNgg5CnPeuT1RGViGHrjmtKwvdybZTlgM5J71LrFsZoRMgDKAcnPNAHIW4xcKSTgH7vrXV6am52X+EJuGO3f+tZdvaBrlOMEnAJ7c10unQL5rbcHjH1FACy3Rs4Dg/exgntXA+KrxmZiWz37etdx4kAjtMqRx1zXl2tysXfuB1GaAOX1S9MalieRWPBqjCcbJMbqfr0mcbWBwOm6uaLlW6nOOKkZ6doevmSMRztvUDgnGRW5LKGBKvuXse1eX6NfCPquR7Gu70W4E9sQrZ68E0xEl5KwzyCKxb2RyPlI4BPWta6GCaxr9sg46EGgZy+pylnbLYA61zt3IMsSOTxya29UbBJLDJzge1c1dtztBye/NICtK2WJ71GetObnNNoAKQ0tJ70AJQTmjtQaAEop34D86KAFooooAUcVLA+1wQSD7VEKUUAd34ZuQ6qBuJAwTzXYQqGA4JzXk2kahJZzBlJFep6NfC4jX1PemBqW0AzyOK2LNehGR+NQ20IK5Az7f1q5BEQWwD/ADpiNqwjBAJJyOT6dadJYH7RI4BOST36U7S87wB+Oe1dRBAssKsVwR6ZoA5aWxY4GCoPtTfsZViACQBzXX/ZIvvEkleoxTdltb7pJc4HO49sc0AcJeWrliNjZHOMH86qW6qk2HfH49ai1fxfcXrn9zDBDn5REDuI5xkknP6ViJeNI5IOM9M9aAOrSZNrBucgkkdKUyY/dq2xT/CD1OKzrfBhXBJHXp3xVmAMMs3Hpkd8UASsm9flHGMkelaOnWbOCWUketVLWNi+4lgD6Ct2zLrKo3ZXHTH0/wDr0AbFivkxYHrwDVR7h2mA/hzzWu6IkTcYyB6nmsx7bup5z0oAlS2AG/BHPNEkDSbUXG48LitSygMiLuQkn0rVt9OS3bzJQN55Ge1AFfTLBbOFML85ALH1OP5Vy/jS+XzFjXPy9ec11Wp6ktnGCxGeymvKdUvvPcsxOc85oAzbq+kAI3kp/dJJqnFdeZLzlefWo7r5iT2qKEEk9jmkB0tlcFgAzEe9dVpN0rQiOXG1sjPPHtXB28gXcMsw6ZHY11mjtE0O4yYYegNMDXuNMa3dnCnyz9zGeOelW9LHlli2QoBHfrWlYSLdW4gcAqehXNTNaRxLjaTz+YoA5bxG4ltpdoJUcH868p1Y4kfdnHf869b1q3crL5QP+PNeZ65YOI5CwbO7+tAHm+qoSxxnGc/L6c1iSISQDk5HBzya6u8tP3h4yPTHasqazCY5JDDcQM8VIzJgJXA5/wAOK7Dw9eNFOG3ZAyDz1rmRGUbnO055A5rY0xGjkBX5lzycYzQB2V6p2E/zrBuVYq3ODg1vSsPJTnOVrB1SQIj4OOCc0wOP1hDGXP1I5PXNcvcNuY+2a2NauizMA27nmsJzkmkA2iiigApDS0mKAEooo/CgAyfU0UlFAD6KKKAF70o6UgHtSj1xQA9Otdh4Pv5I3VN2VyePTiuPTrW54ffFyB78YHtQB7NYTEYIbrzW9a7WGVHbk46VhWEf+hW7kfeTn1rRglHm4ViR7VQjZs32uAoKj+9XT6beBcKeEPBzniuVVSGXP09au27HzR0wPbpQB2YhMp3JyB1P9a5/xrFKnh69ZCVIjAGB2LAH9KvaJf8AlsocAoT+YrotVsIdV0iaNSpWRcc+tAHzdJEQBj86ltkwc1fvLN7eRo5Vw6nBHpUFspD47UgNzTWCwbG6ZyKvAAsoyQOuKyrSQbmPboMVoQybjlsfhTA0o22kgYI9a3tLj3qGcHd/SsC23mTCxjB7kZrsNHUbTkfPn6+lAF2RTKkecDcTkH606OzXzFOTkVMYirhWx3q5BFh1OBg5BoAu2NuiojMP0pdQuUihd5DwtTAhYgByMVzvimUC1MYBywH0pAcZ4i1WSeYOSBjgdeBXG3lyCw28g1qasD83PX8q5qWVIj8w3GmBOxEicdcd6bv8pMAkHOahiuST8qZx60sjs/8ACo98UgJRKwXI5rodDvgY2QA8c4xWBbtE+FZdrZ9OK6Tw/aCCdpJFBXbx70wOr0TU7i3wzLGE6AMDk/rXXWV5HeQZyBIPvKO1cU5+UelX9EmeLUIQvPmMIz9CRQB1FxYxSoxGTnn6GuE8W6Ixt5fIUknnoeTmvSFQoBnH1rO1WSNImMiqePTk0gPmrUbV4mO8Mvtg1iPbSSSAoGCjPXIFe565p1jcvua0iGR1VQK5e80CIA+WwVT/ALNFgPKfsDmYs2dwyOlbWj6c5cNtIB9RxXVrosEYJd/MAzwBimzKkKPtUKvbAosBn6i6xqVXsDxXBeJL85ZFYKVz178VteINU2K/lgAnPXqK881K5aaRicc9/WgZUnlMjEk5qHNK1NPJpAFFFFABSfSlpP50AIOlBHaiigAxRRn2FFADqKKKAFB9qUdKTvQOvtQA8GtTRWKXiMPWsoda1dLCG7hEmNu7JycZHpQB7opdLC2UqV2wrn8eat2akgGMZYj0p2ixWmq2UMrXkaEJsZdwzxiuot49N0sgOvmOB3I/lVCKMdlM8aPtOMcnIHep4wVXLfePr3rRGuoxxCiCIEgIUGOtWkvNMujtnhMT+qAAD8KAM2JiCAvUHJxXYeHrvfC0RPB4Brm7nT9hL2rrLEecAjI/CnaPcNBdqX4G4ZoAzvHGmC6xqFqiKThZlUD73PP4/wBK88kJBwOucV7HeqIbl1kA8p+QCMhlPIrzLxZpZsrvfGMwseCMUAUIZADir0JIkABBrIQgMAvcdT9Ku2smGxng0gOt01uAOMn8q7HQ/kPbceSa4aykUgAdcexrstHkbyD8o3DjOKYHRxqsj9ffp0q5FGoXKkgVStidq8cfWrQYAcUgLE2UT1z6VyviZl2u7kYAGOOvNdLMwMYySSOtcr4okQwmM9xnPHHNMDzTWbjzGwoJC1y94G3qeM+9dZe2q5JLLgepxXN6mgWX5SNuKAIIZSgAIG36Vejj3ZI/Ks2M5GO4rSsdix5Y85x1pATRwNJLx0xXSabOFj8hf4BuBNcvNcFW/dngc1p6LIzTuT93ac0wOqtrgugBrc8Lwfa9agxwsR3nj0NctbS4XnGcV33hgLpmkPfSqBI4IXPUnP8AhQBt6zeLaFhxv9+wrjNSvnkY4PzZ60y9vnu5ndn3gkk9PWqTuMbsAHHcAmgCpds7OM4x2yazLpn8sbgAPUd6u3jnbkg9ulVJPNeEZU7cYOcUAZE8u2EkDPNc5qtw5jcjOBk4rYv32kg4GT7Yrn9TAaOZc9Iznn2pAeda/dvJO2T1Nc+5y1amsIyXDgjjJxWS3U0hjWpKU0lABRRRQAGkpTSUAJQaKDQAUUUUAOooooAB1pRjNJS0AOU45q1C2G4JqoKngOW55HNAHpXgS4mW2YyOfKDYH6V6raXcc0IO4sCM5OMjivIfC87BW3twT/hXoejkg7A3BHGKaEdXbxncGJJBOBg1q2yqUCkZz2Nc/a3EioozyM9PrWtYXJDrvAHPHNMC9cwSRRhrViHxnGfftTIHMkn78ETdN3+NWncbSc85zjNQSI0pE8QBAOG+nY0AXtSje5sIJQTuiHlnB7DkVzs0C6lE1pLyw+aM/QHI/l+VdTYjzbOeNuQQrDnkY4/rXKX8jWl0JARlWxkdqAOMurHypWXoynpmpbezdjwAce4ro9Yt0v0N7BzL/wAtFB4OB1FZcDlTj+dAGxpdkw+YgAYrttHi2RZJ3HJ5IrjNOutx5+lddZXY2jOMAetAG0ZdrZXPXFSpJ0HPB61Q80NgLIv54qaKTO0FlPpmgC1Ow2k5Ga5PxMVeAso5U45roZZPlYEjn9axr0K+5WwVPWgDzDVXcjAY4B4Fc7es+3Oc16Fq+jGVSYG3H0zzXKXGmyrlWRhigDnYZTn5s1fjcgYWkbTpN+3bk+1a9hoUg/eTnbGOcdzxSGUre3luSdik+9dFa26WibN2WPUiox5dumyPheuCeSaYZi8gJPI70xG/o0H2jUIIxyGcD9a7HxbfRwRRWSPxEuD9TjNZfgSz3Xn2qfAij5z71n63N9ovri5cjEkjMq56DNADLU7vuk46DkfrXRaZ4YvNRRJxGfJOAGLhQRn35P4VseA/C4jt4dU1EZlbEkMPQIMnDMMck8Ee36d4SeSST3ouBwv/AAgzkZFzbp/wAt+uRWFqngbW43H2VLa9RuvluEI69mIH5GvVwfcUueQc0rjPlnV7FknmgkjeCaNsNHKMFSO2K52e0lXcxXGMg457V9XeLfDtp4m0o2l4SkiEtDOoG6NsED6jnkd/brXyb8TbbU/DWq3mk39yjzRKP9Ux2OrLkMuQDjn8DkUAed+L7mKS8eONssnBIxwfrXMk1ZuM7yWOT1PNVmpANNFB60UAFFFFABTePenU00AFFFB60AGTRSUUAPFFIKWgApRSou5gM4z3o28GgAHStLTrR5ip28HkZ71HYm0jO64iaU9gWwPxFaseoK82eFb+9jNAHVaRYmEA9B2Ga7LSC5bHzAj37Vx+iXLu53yZ44HY12Wnyjy/lPc4wP0pgddbAON24Anrz3q3tUMCOo561R0tv9G+cnPJxz61cVwW2KB6Hr60xGkpLxBjyQMVo20ZWzB6buSaz9LBk/d4bOe5966G0jBtHST5QvIbFABp0e51RSuWUgc98VyfidAl24bof54rstKX/TIiPmOeeveuM8TfO7yZO3ftH60AYOn3DRSABiAffireoWqyI1zDjj76A+3WsyRGQrjJXv7VpWN40aqGBH170AVLWby35OPxro9Puxjazdc85/rWXe6d56mewXnGWjGc/h6/SqVrNIkhR1IPpyMUAd2kg3Dn9atRycA5x+Nc/Z3ACoHBcgdM1e+0k/dUKCc4BoAvzXGOAeT796pPMCCSeR71UmuGZzg8+tVhI4Y7mzk8c0AWnwSD0Prmq8uNuCRUMk4z/wDXqnLc4IGQT9aAHsAAcflVK6l2jrn8aZNegDj6E5rLurpnHWgAuW3uW/HOataNave3ARACTySeiisuKO4vrsRQIzYGT6KPUnsK7LT1is7dba1cvg/PJ03tx+lAHWxOkemzQW2UiiTaOfUgE/qazPCWnf2v4pi37TFAfPZT3VWGB+ZAqe5SS20RTzumOM9zjr/StL4XQn+1L+UklhEEA54BbP8AQUAekE5yaQdc4/OjvnGOfWlB9aQxByRTu46ZpPz/ADo5J6UALkY9K8p/aS8NrrXgGbUIIozeaUxuPMJIYwbSJEHr/C3P92vVj0+tZHjOBbnwb4ggkHyTadcxtk9jEwP86APzsvFKysKqN/kVo36Yl3ZByoOfwrOYgk0gGHrRQaKACiiigAptKaSgAoNBooASinZ+v50UAf/Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Plain film of the abdomen from a patient with toxic megacolon associated with C. difficile infection. The large and small intestines are grossly dilated. Dilatation of the small bowel, which has the thin transverse folds of the valvulae conniventes (short arrow), is seen best in the left lower quadrant. Large bowel dilation occupies most of the right lower quadrant and has characteristic thick haustral markings that do not extend across the entire lumen (long arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of J Thomas LaMont, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_11_10416=[""].join("\n");
var outline_f10_11_10416=null;
var title_f10_11_10417="TTO2 patient photo";
var content_f10_11_10417=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F77845&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F77845&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    TTO2 patient photo",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 273px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_11_10417=[""].join("\n");
var outline_f10_11_10417=null;
var title_f10_11_10418="Bloody stools in children";
var content_f10_11_10418=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Bloody stools in children (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?10/11/10418/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/11/10418/contributors\" id=\"au5192\">",
"       George D Ferry, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?10/11/10418/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/11/10418/contributors\" id=\"se4415\">",
"       William J Klish, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?10/11/10418/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/11/10418/contributors\" id=\"de1276\">",
"       Alison G Hoppin, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?10/11/10418?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      INTRODUCTION",
"     </span>",
"    </p>",
"    <p>",
"     Seeing blood on your child's stool can be frightening. However, this is a common condition in children and is usually not serious. There are many possible causes of bloody stools, with the most likely cause depending upon your child's age. A healthcare provider can help to determine the source of the bleeding and the most appropriate treatment.",
"    </p>",
"    <p>",
"     This article will review some of the common causes of bloody stools and tests that may be used to evaluate your child. Bloody stools in adults is discussed separately. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?17/10/17569?source=see_link\">",
"      \"Patient information: Blood in the stool (rectal bleeding) in adults (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      WHEN TO SEEK HELP",
"     </span>",
"    </p>",
"    <p>",
"     Most children with minor rectal bleeding do not have a serious condition. However, it is not possible to know the cause of rectal bleeding without an examination. Thus, if you notice that your child has rectal bleeding, you should talk to your child's healthcare provider to determine if an examination is needed. (See",
"     <a class=\"local\" href=\"#H8\">",
"      'Rectal bleeding tests'",
"     </a>",
"     below.)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      TYPES OF RECTAL BLEEDING",
"     </span>",
"    </p>",
"    <p>",
"     There are two possible sources of bloody stools: the upper digestive tract (stomach and small intestine) and the lower digestive tract (the colon, rectum, and anus).",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Bleeding from the upper digestive tract usually causes black, tarry stools.",
"      </li>",
"      <li>",
"       Bleeding from the lower digestive tract usually causes the stool to be coated or mixed with bright red blood.",
"      </li>",
"      <li>",
"       Certain foods and medications can also cause the stool to appear bloody. A list of these foods and medications is provided in table 1 (",
"       <a class=\"graphic graphic_table graphicRef61276 \" href=\"UTD.htm?6/7/6267\">",
"        table 1",
"       </a>",
"       ).",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     However, it is not always possible to know the source or type of rectal bleeding based upon the appearance of the stool alone. An evaluation and physical examination is necessary in most cases. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/52/29513?source=see_link\">",
"      \"Diagnostic approach to lower gastrointestinal bleeding in children\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H4\">",
"     <span class=\"h1\">",
"      RECTAL BLEEDING CAUSES",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Anal fissure",
"     </span>",
"     &nbsp;&mdash;&nbsp;An anal fissure is a tear or crack in the anus that can develop when an infant or child passes a large or hard stool. Anal fissures can occur in all age groups, from newborns to school-aged children and even adults. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?43/31/44529?source=see_link\">",
"      \"Patient information: Anal fissure (Beyond the Basics)\"",
"     </a>",
"     .) The symptoms of an anal fissure include pain, straining or grunting during a bowel movement, and bright red blood on the outside of the stool or with wiping.",
"    </p>",
"    <p>",
"     Many infants and children with anal fissures also have a history of constipation or fairly hard stools. Treatment of constipation is discussed separately. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?15/7/15477?source=see_link\">",
"      \"Patient information: Constipation in infants and children (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Milk or soy protein intolerance",
"     </span>",
"     &nbsp;&mdash;&nbsp;Milk or soy protein intolerance, also known as milk allergy, milk-induced enterocolitis, or protein-induced proctitis or proctocolitis, is a condition that can develop in infants. It is caused by a sensitivity to the protein in cow's milk or soy, and usually develops after starting formula. It can also occur in infants who breastfeed as a result of cow's milk or soy products consumed by the mother. The protein intolerance usually resolves by one year of age.",
"    </p>",
"    <p>",
"     Symptoms of milk or soy protein intolerance may include vomiting and diarrhea, in addition to blood-tinged or bloody stools. If milk or soy protein intolerance seems to be the most likely cause after an evaluation by the medical provider, a milk-free diet is often prescribed. This is described in a separate article. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?16/16/16643?source=see_link&amp;anchor=H8#H8\">",
"      \"Patient information: Acid reflux (gastroesophageal reflux) in infants (Beyond the Basics)\", section on 'Milk-free diet'",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Less common causes",
"     </span>",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Inflammatory bowel disease, also known as Crohn's disease or ulcerative colitis, is a condition in which the lining of the bowels become inflamed. The inflammation leads to symptoms, such as bloody stools, diarrhea, lack of appetite, and weight loss. Crohn's disease and ulcerative colitis are discussed in more detail in a separate article. (See",
"       <a class=\"medical medical_review\" href=\"UTD.htm?24/7/24693?source=see_link\">",
"        \"Clinical manifestations of Crohn's disease in children and adolescents\"",
"       </a>",
"       and",
"       <a class=\"medical medical_review\" href=\"UTD.htm?4/34/4650?source=see_link\">",
"        \"Treatment of ulcerative colitis in children and adolescents\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       Infectious diarrhea is diarrhea caused by a virus, bacterium, or parasite that can cause bloody stools in preschool and school-aged children. Infectious diarrhea can develop as a result of eating or drinking contaminated",
"       <span class=\"nowrap\">",
"        foods/drinks,",
"       </span>",
"       or less commonly, after taking a course of antibiotics. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?28/30/29156?source=see_link\">",
"        \"Patient information: Food poisoning (food-borne illness) (Beyond the Basics)\"",
"       </a>",
"       and",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?18/52/19267?source=see_link\">",
"        \"Patient information: Antibiotic-associated diarrhea caused by Clostridium difficile (Beyond the Basics)\"",
"       </a>",
"       .)",
"       <br/>",
"       <br/>",
"       Symptoms of infectious diarrhea usually include bloody diarrhea, fever, and abdominal pain. Treatment of diarrhea in children is discussed separately. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?0/1/27?source=see_link\">",
"        \"Patient information: Acute diarrhea in children (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       Juvenile polyps are growths that can develop between the ages of two and eight years. Symptoms usually include painless rectal bleeding. Juvenile polyps are not usually cancerous or pre-cancerous but should be evaluated by a healthcare provider and usually require removal.",
"      </li>",
"      <li>",
"       A number of other, more serious conditions, including intussusception (a form of bowel obstruction) or Hirschsprung's disease (a form of colon obstruction that develops before birth) can also cause rectal bleeding. Obstruction is the medical term for a blockage in the bowels. Most of these conditions cause the infant or child to become ill suddenly. If your child suddenly develops bloody stools and becomes lethargic, has abdominal pain, fever, or other unusual symptoms, call your child's healthcare provider immediately. (See",
"       <a class=\"medical medical_review\" href=\"UTD.htm?34/20/35145?source=see_link\">",
"        \"Intussusception in children\"",
"       </a>",
"       and",
"       <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41848?source=see_link\">",
"        \"Congenital aganglionic megacolon (Hirschsprung disease)\"",
"       </a>",
"       .)",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H8\">",
"     <span class=\"h1\">",
"      RECTAL BLEEDING TESTS",
"     </span>",
"    </p>",
"    <p>",
"     Sometimes a clinician can determine the cause of the bleeding by inspecting the outside of the anus. This may include a brief examination of the inside of the anus using a finger (rectal examination). The clinician can also test a sample of stool to be sure whether or not it contains blood.",
"    </p>",
"    <p>",
"     This examination may be all that is necessary. If the cause of the bleeding is not clear based upon the examination, further testing may be recommended. This might include a colonoscopy, which is an examination of the inside of the lower part of the gastrointestinal tract (also known as the colon or large bowel). Imaging tests (x-ray or ultrasound examinations) might also be helpful in some cases. The clinician chooses between these tests depending on the child&rsquo;s history and symptoms.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H9\">",
"     <span class=\"h1\">",
"      RECTAL BLEEDING TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     As discussed above, there are a number of potential causes of bloody stools. Your child's healthcare provider will determine if the underlying condition requires treatment. Even if your child's bleeding seems minor or resolves on its own, your child should be evaluated by a healthcare provider.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H10\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your child's healthcare provider is the best source of information for questions and concerns related to your child's medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H170235459\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13063776\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?41/29/42450?source=see_link\">",
"      Patient information: Bloody stools (The Basics)",
"     </a>",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/60/24515?source=see_link\">",
"      Patient information: GI bleed (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?40/54/41826?source=see_link\">",
"      Patient information: Angiodysplasia of the GI tract (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?42/22/43361?source=see_link\">",
"      Patient information: Meckel&rsquo;s diverticulum (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?37/33/38418?source=see_link\">",
"      Patient information: Ulcerative colitis in children (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13063791\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?17/10/17569?source=see_link\">",
"      Patient information: Blood in the stool (rectal bleeding) in adults (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?43/31/44529?source=see_link\">",
"      Patient information: Anal fissure (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?15/7/15477?source=see_link\">",
"      Patient information: Constipation in infants and children (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?16/16/16643?source=see_link\">",
"      Patient information: Acid reflux (gastroesophageal reflux) in infants (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?28/30/29156?source=see_link\">",
"      Patient information: Food poisoning (food-borne illness) (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?18/52/19267?source=see_link\">",
"      Patient information: Antibiotic-associated diarrhea caused by Clostridium difficile (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?0/1/27?source=see_link\">",
"      Patient information: Acute diarrhea in children (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/52/29513?source=see_link\">",
"      Diagnostic approach to lower gastrointestinal bleeding in children",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/39/41591?source=see_link\">",
"      Clinical features and diagnosis of necrotizing enterocolitis in newborns",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/25/27034?source=see_link\">",
"      Clinical features and diagnosis of inflammatory bowel disease in children and adolescents",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/52/34631?source=see_link\">",
"      Food protein-induced proctitis/colitis and enteropathy of infancy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/5/35928?source=see_link\">",
"      Management of necrotizing enterocolitis in newborns",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/7/24693?source=see_link\">",
"      Clinical manifestations of Crohn's disease in children and adolescents",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/34/4650?source=see_link\">",
"      Treatment of ulcerative colitis in children and adolescents",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/20/35145?source=see_link\">",
"      Intussusception in children",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41848?source=see_link\">",
"      Congenital aganglionic megacolon (Hirschsprung disease)",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/ency/article/003130.htm\">",
"      www.nlm.nih.gov/medlineplus/ency/article/003130.htm",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Institute of Diabetes and Digestive and Kidney Diseases",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://digestive.niddk.nih.gov/ddiseases/pubs/constipationchild/\">",
"      file://digestive.niddk.nih.gov/ddiseases/pubs/constipationchild/",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?10/11/10418/abstract/1-3\">",
"      1-3",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 27, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?10/11/10418?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/11/10418/abstract/1\">",
"      Balkan E, Kiritiolu I, G&uuml;rpinar A, et al. Sigmoidoscopy in minor lower gastrointestinal bleeding. Arch Dis Child 1998; 78:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/11/10418/abstract/2\">",
"      Latt TT, Nicholl R, Domizio P, et al. Rectal bleeding and polyps. Arch Dis Child 1993; 69:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/11/10418/abstract/3\">",
"      Teach SJ, Fleisher GR. Rectal bleeding in the pediatric emergency department. Ann Emerg Med 1994; 23:1252.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f10_11_10418=[""].join("\n");
var outline_f10_11_10418=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           INTRODUCTION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           WHEN TO SEEK HELP",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           TYPES OF RECTAL BLEEDING",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H4\">",
"           RECTAL BLEEDING CAUSES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H8\">",
"           RECTAL BLEEDING TESTS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H9\">",
"           RECTAL BLEEDING TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H10\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          TABLES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_table\" href=\"UTD.htm?6/7/6267\" title=\"table 1\">",
"           Causes of bloody stool appearance PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f10_11_10419="Sweet syndrome skin appearance";
var content_f10_11_10419=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F61290&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F61290&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Sweet syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 349px; height: 292px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A sudden, painful eruption that developed in a 50-year-old female who was febrile and had general malaise. There are multiple very edematous and erythematous papules and plaques, most of which appear vesicular or bullous on initial examination, but are firm with palpation (pseudovesiculation). However, the confluent lesions in the lower part of the picture are indeed bullous and here there is also exudation and crusting. Systems review in this patient revealed myelocytic leukemia.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Fitzpatrick, TB, Johnson, RA, Wolff, K, Suurmond, D. Color Atlas of Clinical Dermatology: Common and Serious Diseases. McGraw Hill, New York 2001. p.494. Copyright &copy; 2001 McGraw-Hill Companies, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_11_10419=[""].join("\n");
var outline_f10_11_10419=null;
var title_f10_11_10420="Acamprosate: Patient drug information";
var content_f10_11_10420=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Acamprosate: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/22/1381?source=see_link\">",
"     see \"Acamprosate: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F129071\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Campral&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F4663219\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Campral&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10014909\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691411",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to keep an alcohol-free state.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10014908\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701407",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to acamprosate or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703777",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701026",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are addicted to drugs or are having withdrawal signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10014913\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698562",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take good care of your teeth. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10014914\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698279",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Nervous and excitable.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10014916\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699075",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of low mood (depression), thoughts of killing yourself, nervousness, emotional ups and downs, thinking that is not normal, anxiety, or lack of interest in life.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10014911\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695714",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swallow whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10014912\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10014917\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10014918\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11267 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-197.136.42.3-9ACE31C43F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_11_10420=[""].join("\n");
var outline_f10_11_10420=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129071\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4663219\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014909\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014908\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014913\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014914\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014916\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014911\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014912\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014917\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014918\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?1/22/1381?source=related_link\">",
"      Acamprosate: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_11_10421="Calcitriol: Patient drug information";
var content_f10_11_10421=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Calcitriol: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/13/40152?source=see_link\">",
"     see \"Calcitriol: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/58/35751?source=see_link\">",
"     see \"Calcitriol: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F144219\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Calcijex&reg; [DSC];",
"     </li>",
"     <li>",
"      Rocaltrol&reg;;",
"     </li>",
"     <li>",
"      Vectical&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F144220\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Calcijex&reg;;",
"     </li>",
"     <li>",
"      Rocaltrol&reg;;",
"     </li>",
"     <li>",
"      Silkis&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F12676147\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10014997\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691428",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop and treat low calcium levels.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705551",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Skin:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat psoriasis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10014996\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to calcitriol or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703612",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: High calcium levels or too much vitamin D in the body.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10015001\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid other sources of vitamin D.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696860",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take cholestyramine, mineral oil, antacids that have magnesium, or orlistat with this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10015002\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698141",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       High calcium level. Signs include weakness, confusion, feeling tired, headache, upset stomach and throwing up, hard stools (constipation), or bone pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698344",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin irritation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10015004\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10014999\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695852",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug at the same time of day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695700",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swallow capsule whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694286",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There is a liquid (solution) if you cannot swallow pills.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696107",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the liquid. Flush the feeding tube before and after this drug is given.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694865",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow the diet and workout plan that your doctor told you about.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705551",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Skin:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694772",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take this drug by mouth. Use on your skin only. Keep out of your mouth, nose, and eyes (may burn).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694431",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put a thin layer on the affected part and rub in gently.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10015000\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696583",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696485",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use 2 doses or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10015005\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699341",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature. Do not refrigerate or freeze.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699249",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect capsules from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10015006\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11634 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-41.222.196.37-1E842E28B5-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_11_10421=[""].join("\n");
var outline_f10_11_10421=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144219\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144220\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12676147\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014997\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014996\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015001\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015002\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015004\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014999\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015000\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015005\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015006\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?39/13/40152?source=related_link\">",
"      Calcitriol: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/58/35751?source=related_link\">",
"      Calcitriol: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_11_10422="Air bronchogram CT I";
var content_f10_11_10422=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F57246%7EPULM%2F70172&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F57246%7EPULM%2F70172&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pneumonia with air bronchogram",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 269px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Severe pneumonia with dense consolidation of the right upper lobe and marked air bronchogram formation, characteristic of air space disease.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pneumonia with air bronchogram",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 325px; height: 211px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Lymphocytic interstitial pneumonia in a patient with HIV infection. The main changes are ground glass opacification in the right middle lobe and consolidation suggestive of air space disease in the right lower lobe with a clearly visible air bronchogram.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_11_10422=[""].join("\n");
var outline_f10_11_10422=null;
var title_f10_11_10423="Ixabepilone: Drug information";
var content_f10_11_10423=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ixabepilone: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?7/26/7589?source=see_link\">",
"    see \"Ixabepilone: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708959\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F5376467\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Ixempra&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F5376473\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antineoplastic Agent, Antimicrotubular;",
"     </li>",
"     <li>",
"      Antineoplastic Agent, Epothilone B Analog",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F5376533\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Details concerning dosing in combination regimens should also be consulted.",
"     <b>",
"      Note:",
"     </b>",
"     Premedicate with an H",
"     <sub>",
"      1",
"     </sub>",
"     -antagonist (eg, oral diphenhydramine 50 mg) and H",
"     <sub>",
"      2",
"     </sub>",
"     -antagonist (eg, oral ranitidine 150-300 mg) ~1 hour prior to infusion. Patients with a history of hypersensitivity should also be premedicated with corticosteroids (orally 1 hour before or I.V. 30 minutes before infusion). For dose calculation, body surface area (BSA) is capped at a maximum of 2.2 m",
"     <sup>",
"      2",
"     </sup>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     <b>",
"      Breast cancer (metastatic or locally advanced):",
"     </b>",
"     I.V.: 40 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose over 3 hours every 3 weeks (maximum dose: 88 mg) either as monotherapy or in combination with capecitabine",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Endometrial cancer (unlabeled use):",
"     </b>",
"     40 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose over 3 hours every 3 weeks (Dizon, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Dosage adjustment with concomitant strong CYP3A4 inhibitors/inducers:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     <i>",
"      CYP3A4 inhibitors:",
"     </i>",
"     Avoid concomitant administration with strong CYP3A4 inhibitors; if concomitant administration with a strong CYP3A4 inhibitor cannot be avoided, consider a dose reduction to 20 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     . When a strong CYP3A4 inhibitor is discontinued, allow ~1 week to elapse prior to adjusting ixabepilone dose upward to the indicated dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     <i>",
"      CYP3A4 inducers:",
"     </i>",
"     Avoid concomitant administration with strong CYP3A4 inducers; if concomitant administration with a strong CYP3A4 inducer cannot be avoided and after maintenance on the strong CYP3A4 inducer is established, consider adjusting the ixabepilone dose gradually up to 60 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     (as a 4-hour infusion), with careful monitoring. If the strong CYP3A4 enzyme inducer is discontinued, reduce ixabepilone dose to the dose used prior to initiation of the CYP3A4 inducer.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F5376528\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F5376529\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Pharmacokinetics (monotherapy) are not affected in patients with mild-to-moderate renal insufficiency (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;30 mL/minute); monotherapy has not been studied in patients with serum creatinine &gt;1.5 times ULN. Combination therapy with capecitabine has not been studied in patients with Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;50 mL/minute.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F5376530\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Ixabepilone monotherapy (initial cycle; adjust doses for subsequent cycles based on toxicity):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     AST and ALT &le;2.5 times ULN and bilirubin &le;1 times ULN: No adjustment necessary",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     AST and ALT &gt;2.5  to &le;10 times ULN and bilirubin &gt;1 to &le;1.5 times ULN: Reduce dose to 32 mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     AST and ALT &le;10 times ULN and bilirubin &gt;1.5 to &le;3 times ULN: Reduce dose to 20-30 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     (initiate treatment at 20 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     , may escalate up to a maximum of 30 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     in subsequent cycles if tolerated)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     AST or ALT &gt;10 times ULN or bilirubin &gt;3 times ULN: Use is not recommended",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Combination therapy of ixabepilone with capecitabine:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     AST and ALT &le;2.5 times ULN and bilirubin &le;1 times ULN: No adjustment necessary",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     AST or ALT &gt;2.5 times ULN or bilirubin &gt;1 times ULN: Use is contraindicated",
"    </p>",
"   </div>",
"   <div class=\"block dot drugH1Div\" id=\"F5376526\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adjustment for Toxicity",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Hematologic:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neutrophils &lt;500/mm",
"     <sup>",
"      3",
"     </sup>",
"     for &ge;7 days: Reduce dose by 20%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neutropenic fever: Reduce dose by 20%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Platelets &lt;25,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     (or &lt;50,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     with bleeding): Reduce dose by 20%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Nonhematologic:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuropathy:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Grade 2 (moderate) for &ge;7 days: Reduce dose by 20%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Grade 3 (severe) for &lt;7 days: Reduce dose by 20%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Grade 3 (severe or disabling) for &ge;7 days: Discontinue treatment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Grade 3 toxicity (severe; other than neuropathy): Reduce dose by 20%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Grade 3 arthralgia/myalgia or fatigue (transient): Continue at current dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Grade 3 hand-foot syndrome: Continue at current dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Grade 4 toxicity (disabling): Discontinue treatment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Adjust dosage at the start of a cycle are based on toxicities (hematologic and nonhematologic) from the previous cycle; delay new cycles until neutrophils have recovered to &ge;1500/mm",
"     <sup>",
"      3",
"     </sup>",
"     , platelets have recovered to &ge;100,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     and nonhematologic toxicities have resolved or improved to at least grade 1. If toxicities persist despite initial dose reduction, reduce dose an additional 20%.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Capecitabine dosage adjustments for combination therapy with ixabepilone:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     <i>",
"      Hematologic:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     Neutrophils &lt;500/mm",
"     <sup>",
"      3",
"     </sup>",
"     for &ge;7 days or neutropenic fever: Hold for concurrent diarrhea or stomatitis until neutrophils recover to &gt;1000/mm",
"     <sup>",
"      3",
"     </sup>",
"     , then continue at same dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     Platelets &lt;25,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     (or &lt;50,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     with bleeding): Hold for concurrent diarrhea or stomatitis until platelets recover to &gt;50,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     , then continue at same dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     <i>",
"      Nonhematologic:",
"     </i>",
"     Refer to Capecitabine monograph.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F5376539\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ixempra&reg;: 15 mg, 45 mg [contains dehydrated ethanol (in diluent), polyoxyethylated castor oil (in diluent)]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F5376469\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F5376534\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I.V.: Infuse over 3 hours. Use non-DEHP administration set (eg, polyethylene); filter with a 0.2-1.2 micron inline filter. Administration should be completed within 6 hours of preparation. If the dose is increased (above 40 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ) due to concomitant CYP3A4 inducer use, infuse over 4 hours.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F5376516\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in lactated Ringer&rsquo;s injection, adjusted sodium chloride 0.9% (pH adjusted with sodium bicarbonate); PLASMA-LYTE A Injection pH 7.4&reg;.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F5376475\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of metastatic or locally-advanced breast cancer (refractory or resistant)",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F9601126\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment (second-line) of endometrial cancer",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F5376463\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F5376502\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Percentages reported with monotherapy:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Headache (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Alopecia (48%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Nausea (42%), vomiting (29%), mucositis/stomatitis (29%), diarrhea (22%), anorexia (19%), constipation (16%), abdominal pain (13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hematologic: Leukopenia (grade 3: 36%; grade 4: 13%), neutropenia (grade 3: 31%; grade 4: 23%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Peripheral neuropathy (63%; grades 3/4: 14%; grade 3/4 median onset:  cycle 4), sensory neuropathy (62%; grades 3/4: 14%), weakness (56%), myalgia/arthralgia (49%), musculoskeletal pain (20%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Edema (9%), chest pain (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Fever (8%), pain (8%), dizziness (7%), insomnia (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Nail disorder (9%), rash (9%), palmar-plantar erythrodysesthesia/hand-and-foot syndrome (8%), pruritus (6%), skin exfoliation (2%), hyperpigmentation (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Endocrine &amp; metabolic: Hot flush (6%), dehydration (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Gastroesophageal reflux disease (6%), taste perversion (6%), weight loss (6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hematologic: Anemia (grade 3: 6%; grade 4: 2%), neutropenic fever (3%; grade 3: 3%), thrombocytopenia (grade 3: 5%; grade 4: 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Motor neuropathy (10%; grade 3: 1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Ocular: Lacrimation increased (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Dyspnea (9%), upper respiratory tract infection (6%), cough (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Hypersensitivity (5%; grade 3: 1%), infection (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Mono- and combination therapy:",
"     </b>",
"     &lt;1% (Limited to important or life-threatening): Alkaline phosphatase increased, angina, atrial flutter, autonomic neuropathy, cardiomyopathy, cerebral hemorrhage, coagulopathy, colitis, dysphagia, dysphonia, embolism, enterocolitis, erythema multiforme, gastrointestinal hemorrhage, gastroparesis, GGT increased, hemorrhage, hepatic failure (acute), hypokalemia, hyponatremia, hypotension, hypovolemia, hypovolemic shock, hypoxia, ileus, interstitial pneumonia, jaundice, left ventricular dysfunction, metabolic acidosis, MI, nephrolithiasis, neutropenic infection, orthostatic hypotension, pneumonia, pneumonitis, pulmonary edema (acute), radiation recall, renal failure, respiratory failure, sepsis, septic shock, supraventricular arrhythmia, syncope, thrombosis, transaminases increased, trismus, urinary tract infection, vasculitis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F5376481\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     History of severe hypersensitivity to polyoxyethylated castor oil or its derivatives (eg, Cremophor&reg; EL); neutrophil count &lt;1500/mm",
"     <sup>",
"      3",
"     </sup>",
"     or platelet count &lt;100,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     ; combination therapy with ixabepilone and capecitabine in patients with AST or ALT &gt;2.5 times ULN or bilirubin &gt;1 times ULN",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F5376470\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bone marrow suppression: Dose-dependent myelosuppression, particularly neutropenia, may occur with mono- or combination therapy. Neutropenic fever and infection have been reported with use. The risk for neutropenia is increased with hepatic dysfunction, especially when used in combination with capecitabine. Severe neutropenia and/or thrombocytopenia may require dosage adjustment and/or treatment delay.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cognitive impairment: Due to the ethanol content in the diluent, may cause cognitive impairment; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity: Diluent contains Cremophor&reg; EL, which is associated with hypersensitivity reactions; use is contraindicated in patients with a history of severe hypersensitivity to Cremophor&reg; EL or its derivatives. Medications for the treatment of reaction should be available for immediate use; reactions may also be managed by reducing infusion rate. Premedicate with an H",
"     <sub>",
"      1",
"     </sub>",
"     - and H",
"     <sub>",
"      2",
"     </sub>",
"     -antagonist 1 hour prior to infusion; patients who experience hypersensitivity (eg, bronchospasm, dyspnea, flushing, rash) should also be premedicated with a corticosteroid for all subsequent cycles if treatment is continued.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Peripheral neuropathy: Peripheral (sensory and motor) neuropathy occurs commonly; may require dose reductions, treatment delays or discontinuation. Usually occurs during the first 3 cycles. Use with caution in patients with pre-existing neuropathy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with a history of cardiovascular disease. The incidence of MI, ventricular dysfunction and supraventricular arrhythmias is higher when ixabepilone is used in combination with capecitabine (as compared to capecitabine alone). Consider discontinuing ixabepilone in patients who develop cardiac ischemia or impaired cardiac function.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use with caution; may have an increased risk for severe peripheral neuropathy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment:",
"     <b>",
"      [U.S. Boxed Warning]: Due to increased risk of toxicity and neutropenia-related mortality, combination therapy with capecitabine is contraindicated in patients with AST or ALT &gt;2.5 times ULN or bilirubin &gt;1 times ULN.",
"     </b>",
"     Use (as monotherapy) is not recommended if AST or ALT &gt;10 times ULN or bilirubin &gt;3 times ULN; use caution in patients with AST or ALT &gt;5 times ULN; data is limited. In mono- and combination therapy, toxicities and serious adverse reactions are increased with hepatic dysfunction; dosage reductions are necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CYP3A4 inhibitors/inducers: Avoid concurrent use with strong CYP3A4 inhibitors (eg, itraconazole, ketoconazole, voriconazole, clarithromycin, telithromycin, nefazodone, amprenavir, atazanavir, delavirdine, indinavir, nelfinavir, ritonavir, saquinavir); dosage reductions are recommended if concurrent use cannot be avoided. Allow ~1 week to elapse prior to adjusting ixabepilone dose upward after a strong CYP3A4 inhibitor is discontinued. Avoid strong CYP3A4 inducers (eg, dexamethasone, phenytoin, carbamazepine, rifampin, phenobarbital); may decrease the ixabepilone levels; alternative agents should be considered; dosage increases of ixabepilone (with careful monitoring) may be recommended if concomitant administration with CYP3A4 inducers cannot be avoided.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in the elderly; toxicities or serious adverse events with combination therapy may be increased.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F5376509\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F5376508\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May decrease the serum concentration of Ixabepilone. Management: Avoid this combination whenever possible.  If this combination must be used, a gradual increase in ixabepilone dose from 40 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     to 60 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     (given as a 4-hour infusion), as tolerated, should be considered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May increase the serum concentration of Ixabepilone.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May decrease the serum concentration of Ixabepilone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F5376512\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Food: Grapefruit juice may increase plasma concentrations of ixabepilone. Management: Avoid grapefruit juice.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herb/Nutraceutical: St John&rsquo;s wort may decrease ixabepilone levels. Management: Avoid St John&rsquo;s wort.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F5376476\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F5376477\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     In animal studies, ixabepilone caused maternal toxicity and embryo/fetal toxicity at doses ~1/10 the human dose. There are no adequate and well-controlled studies in pregnant women. Women of childbearing potential should be advised to use effective contraception during treatment.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F5376479\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F5376480\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Due to the potential for serious adverse reactions in the nursing infant, breast-feeding is not recommended.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F5376524\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid grapefruit juice (may increase plasma concentrations of ixabepilone).",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16324149\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Ixempra Kit Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15 mg (1): $1180.02",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     45 mg (1): $3540.08",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F5376537\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC with differential; hepatic function (ALT, AST, bilirubin); monitor for hypersensitivity, neuropathy",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F10961931\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Ixempra (AR, BR, CH, CN, CO, FR, IN, NZ, SG, TH, TW);",
"     </li>",
"     <li>",
"      Ixemprya (PE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F5376531\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Epothilone B analog; binds to the beta-tubulin subunit of the microtubule, stabilizing microtubular promoting tubulin polymerization and stabilizing microtubular function, thus arresting the cell cycle (at the G2/M phase) and inducing apoptosis. Activity in taxane-resistant cells has been demonstrated.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F5376517\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: &gt;1000 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: 67% to 77%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Extensively hepatic, via CYP3A4; &gt;30 metabolites (inactive) formed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: ~52 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak, plasma: At the end of infusion (3 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Feces (65%; 2% of the total dose as unchanged drug); urine (21%; 6% of the total dose as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Dendurali N, Low JA, Lee JJ, et al, &ldquo;Phase II Trial of Ixabepilone, an Epothilone B Analog, in Patients With Metastatic Breast Cancer Previously Untreated With Taxanes,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2007, 25(23):3421-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/11/10423/abstract-text/17606971/pubmed\" id=\"17606971\" target=\"_blank\">",
"        17606971",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dizon DS, Blessing JA, McMeekin DS, et al, &ldquo;Phase II Trial of Ixabepilone As Second-Line Treatment in Advanced Endometrial Cancer: Gynecologic Oncology Group Trial 129-P,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2009, 27(19):3104-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/11/10423/abstract-text/19451430/pubmed\" id=\"19451430\" target=\"_blank\">",
"        19451430",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lee JJ, Low JA, Croarkin E, et al, &ldquo;Changes in Neurologic Function Tests May Predict Neurotoxicity Caused by Ixabepilone,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2006, 24(13):2084-91.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/11/10423/abstract-text/16648510/pubmed\" id=\"16648510\" target=\"_blank\">",
"        16648510",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Low JA, Wedam SB, Lee JJ, et al, &ldquo;Phase II Clinical Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, in Metastatic and Locally Advanced Breast Cancer,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2005, 23(12):2726-34.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/11/10423/abstract-text/15837987/pubmed\" id=\"15837987\" target=\"_blank\">",
"        15837987",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mani S, McDid H, Hamilton A, et al, &ldquo;Phase I and Clinical Pharmacokinetic Study of BMS-247550, a Novel Derivative of Epothilone B,in Solid Tumors,&rdquo;",
"      <i>",
"       Clin Cancer Res",
"      </i>",
"      , 2004, 10(4):1289-98.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/11/10423/abstract-text/14977827/pubmed\" id=\"14977827\" target=\"_blank\">",
"        14977827",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Comprehensive Cancer Network&reg; (NCCN), &ldquo;Clinical Practice Guidelines in Oncology&trade;: Breast Cancer,&rdquo; Version 2.2010. Available at  file://www.nccn.org/professionals/physician_gls/PDF/breast.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Comprehensive Cancer Network&reg; (NCCN), &ldquo;Clinical Practice Guidelines in Oncology&trade;: Uterine Neoplasms,&rdquo; Version 1.2010. Available at file://www.nccn.org/professionals/physician_gls/PDF/uterine.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Perez EA, Lerzo G, Pivot X, et al, &ldquo;Efficacy and Safety of Ixabepilone (BMS-247550), in a Phase II Study of Patients With Advanced Breast Cancer Resistant to an Anthracycline, a Taxane and Capecitabine,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2007, 25(23):3407-14.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/11/10423/abstract-text/17606974/pubmed\" id=\"17606974\" target=\"_blank\">",
"        17606974",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      P&eacute;rez Fidalgo JA, Garc&iacute;a Fabregat L, Cervantes A, et al, &ldquo;Management of Chemotherapy Extravasation: ESMO-EONS Clinical Practice Guidelines,&rdquo;",
"      <i>",
"       Ann Oncol",
"      </i>",
"      , 2012, 23(Suppl 7):167-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/11/10423/abstract-text/22997449/pubmed\" id=\"22997449\" target=\"_blank\">",
"        22997449",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pivot XB, Li RK, Thomas ES, et al, &ldquo;Activity of Ixabepilone in Oestrogen Receptor-Negative and Oestrogen-Receptor-Progesterone Receptor-Human Epidermal Growth Factor 2-Negative Metastatic Breast Cancer,&rdquo;",
"      <i>",
"       Eur J Cancer",
"      </i>",
"      , 2009, 45(17):2940-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/11/10423/abstract-text/19683429/pubmed\" id=\"19683429\" target=\"_blank\">",
"        19683429",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Roche H, Yelle L, Cognetti F, et al, &ldquo;Phase II Clinical Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, as First Line Therapy in Patients With Metastatic Breast Cancer Previously Treated With Anthracycline Chemotherapy,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2007, 25(23):3415-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/11/10423/abstract-text/17606972/pubmed\" id=\"17606972\" target=\"_blank\">",
"        17606972",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sparano JA, Vrdoljak E, Rixe O, et al, &ldquo;Randomized Phase III Trial of Ixabepilone Plus Capecitabine Versus Capecitabine in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2010, 28(20):3256-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/11/10423/abstract-text/20530276/pubmed\" id=\"20530276\" target=\"_blank\">",
"        20530276",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Takimoto CH, Liu PY, Lenz H, et al, &ldquo;A Phase I Pharmacokinetic (PK) Study of the Epothilone B Analogue, Ixabepilone (BMS-247550) in Patients (pts) With Advanced Malignancies and Varying Degrees of Hepatic Impairment: A SWOG Early Therapeutics Committee and NCI Organ Dysfunction Working Group Trial,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2006, 24(18S):2004 [abstract 2004 from 2006 ASCO Annual Meeting].",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Thomas ES, Gomez HL, Li RK, et al, &ldquo;Ixabepilone Plus Capecitabine for Metastatic Breast Cancer Progressing After Anthracycline and Taxane Treatment,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2007, 25(33):5210-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/11/10423/abstract-text/17968020/pubmed\" id=\"17968020\" target=\"_blank\">",
"        17968020",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Thomas E, Tabernero J, Fornier M, et al, &ldquo;Phase II Clinical Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, in Patients With Taxane-Resistant Metastatic Breast Cancer,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2007, 25(23):3399-406.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/11/10423/abstract-text/17606975/pubmed\" id=\"17606975\" target=\"_blank\">",
"        17606975",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8909 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-218.189.88.190-75239E8C8F-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_11_10423=[""].join("\n");
var outline_f10_11_10423=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708959\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5376467\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5376473\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5376533\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5376528\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5376529\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5376530\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5376526\">",
"      Dosing: Adjustment for Toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5376539\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5376469\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5376534\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5376516\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5376475\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9601126\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5376463\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5376502\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5376481\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5376470\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5376509\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5376508\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5376512\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5376476\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5376477\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5376479\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5376480\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5376524\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16324149\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5376537\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10961931\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5376531\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5376517\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8909\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8909|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?7/26/7589?source=related_link\">",
"      Ixabepilone: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_11_10424="Rosuvastatin: Drug information";
var content_f10_11_10424=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Rosuvastatin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?1/3/1077?source=see_link\">",
"    see \"Rosuvastatin: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?41/54/42854?source=see_link\">",
"    see \"Rosuvastatin: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block spa drugH1Div\" id=\"F13842378\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Special Alerts",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      HMG-CoA Reductase Inhibitors and Risk of Increased Blood Glucose Concentrations and Diabetes",
"     </span>",
"     <span class=\"collapsible-date\">",
"      January 2013",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       Health Canada has notified healthcare professionals of updates to the product monographs of HMG-CoA reductase inhibitors (aka, &ldquo;statins&rdquo;) marketed in Canada regarding the risk of increased blood glucose concentrations and a small increased risk of diabetes mellitus following administration of these agents. The risk appears to be greatest in patients already at risk for diabetes (eg, patients with increased blood glucose concentration, hypertriglyceridemia, obesity, hypertension).  However, Health Canada continues to acknowledge that the benefits of statin therapy far outweigh the risk of dysglycemia. It is recommended that clinicians carefully monitor the use of statins in patients at high risk of developing diabetes mellitus.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       For additional information, please refer to file://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2013/16949a-eng.php.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F219522\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Crestor&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F219523\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Rosuvastatin;",
"     </li>",
"     <li>",
"      CO Rosuvastatin;",
"     </li>",
"     <li>",
"      Crestor&reg;;",
"     </li>",
"     <li>",
"      Jamp-Rosuvastatin;",
"     </li>",
"     <li>",
"      Mylan-Rosuvastatin;",
"     </li>",
"     <li>",
"      PMS-Rosuvastatin;",
"     </li>",
"     <li>",
"      RAN&trade;-Rosuvastatin;",
"     </li>",
"     <li>",
"      Sandoz-Rosuvastatin;",
"     </li>",
"     <li>",
"      Teva-Rosuvastatin",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F219543\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antilipemic Agent, HMG-CoA Reductase Inhibitor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F219526\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Doses should be individualized according to the baseline LDL-cholesterol levels, the recommended goal of therapy, and patient response; adjustments should be made at intervals of 4 weeks or more.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hyperlipidemia, mixed dyslipidemia, hypertriglyceridemia, primary dysbetalipoproteinemia, slowing progression of atherosclerosis:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Initial dose:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     General dosing: 10 mg once daily; 20 mg once daily may be used in patients with severe hyperlipidemia (LDL &gt;190 mg/dL) and aggressive lipid targets",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Conservative dosing: Patients requiring less aggressive treatment or predisposed to myopathy (including patients of Asian descent): 5 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Titration:",
"     </i>",
"     After 2 weeks, may be increased by 5-10 mg once daily; dosing range: 5-40 mg daily (maximum dose: 40 mg once daily)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     The 40 mg dose should be reserved for patients who have not achieved goal cholesterol levels on a dose of 20 mg daily, including patients switched from another HMG-CoA reductase inhibitor.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Homozygous familial hypercholesterolemia (FH):",
"     </b>",
"     Oral: Initial: 20 mg once daily (maximum dose: 40 mg daily)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment with concomitant medications:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     U.S. labeling:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cyclosporine: Rosuvastatin dose should not exceed 5 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Gemfibrozil: Avoid concurrent use; if unable to avoid concurrent use, initiate rosuvastatin at 5 mg once daily; dose should not exceed 10 mg  once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Atazanavir/ritonavir or lopinavir/ritonavir: Initiate rosuvastatin at 5 mg once daily; dose should not exceed 10 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Canadian labeling:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cyclosporine: Concomitant use is contraindicated",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Gemfibrozil: Rosuvastatin dose should not exceed 20 mg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment for hematuria and/or persistent, unexplained proteinuria while on 40 mg daily:",
"     </b>",
"     Reduce dose and evaluate causes.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F9923608\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?41/54/42854?source=see_link\">",
"      see \"Rosuvastatin: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Doses should be individualized according to the baseline LDL-cholesterol levels, the recommended goal of therapy, and patient response; adjustments should be made at intervals of 4 weeks or more.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Heterozygous familial hypercholesterolemia (HeFH):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     U.S. labeling: Children 10-17 years (females &gt;1 year postmenarche): Oral: 5-20 mg once daily; maximum: 20 mg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Dosage adjustment for rosuvastatin with concomitant cyclosporine, atazanavir/ritonavir or lopinavir/ritonavir:",
"     </i>",
"     Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Canadian labeling: Oral: 5-10 mg once daily; maximum: 10 mg daily",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F219527\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F219528\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Mild-to-moderate impairment: No dosage adjustment required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     : Initial: 5 mg once daily; do not exceed 10 mg once daily",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F11431139\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     U.S. labeling: Active hepatic disease, including unexplained persistent transaminase elevations: Use is contraindicated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Canadian labeling:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Active hepatic disease or unexplained persistent transaminase &gt;3 x ULN: Use is contraindicated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mild-to-moderate impairment: No dosage adjustment required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Severe impairment: Initial: 5 mg daily; do not exceed 20 mg once daily.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F219497\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Crestor&reg;: 5 mg, 10 mg, 20 mg, 40 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F219484\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F219500\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be administered with or without food. May be taken at any time of the day.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F219498\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Treatment of dyslipidemias:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Used with dietary therapy for hyperlipidemias to reduce elevations in total cholesterol (TC), LDL-C, apolipoprotein B, nonHDL-C, and triglycerides (TG) in patients with primary hypercholesterolemia (elevations of 1 or more components are present in Fredrickson type IIa, IIb, and IV hyperlipidemias); increase HDL-C; treatment of primary dysbetalipoproteinemia (Fredrickson type III hyperlipidemia); treatment of homozygous familial hypercholesterolemia (FH); to slow progression of atherosclerosis as an adjunct to diet to lower TC and LDL-C",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Heterozygous familial hypercholesterolemia (HeFH): In adolescent patients (10-17 years of age, females &gt;1 year postmenarche) with HeFH having LDL-C &gt;190 mg/dL or LDL &gt;160 mg/dL with positive family history of premature cardiovascular disease (CVD), or &ge;2 other CVD risk factors.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Primary prevention of cardiovascular disease:",
"     </b>",
"     To reduce the risk of stroke, myocardial infarction, or arterial revascularization procedures in patients without clinically evident coronary heart disease or lipid abnormalities but with all of the following: 1) an increased risk of cardiovascular disease based on age &ge;50 years old in men and &ge;60 years old in women, 2) hsCRP &ge;2 mg/L, and 3) the presence of at least one additional cardiovascular disease risk factor such as hypertension, low HDL-C, smoking, or a family history of premature coronary heart disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Secondary prevention of cardiovascular disease:",
"     </b>",
"     To slow progression of atherosclerosis",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F7914388\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Rosuvastatin may be confused with atorvaSTATin, nystatin, pitavastatin",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F219541\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%: Neuromuscular &amp; skeletal: Myalgia (3% to 13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     2% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (6%), dizziness (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (3%), abdominal pain (2%), constipation (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: ALT increased (2%; &gt;3 times ULN)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia (4% to 10%), CPK increased (3%; &gt;10 x ULN: Children 3%), weakness (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;2% (Limited to important or life-threatening): Alkaline phosphatase increased, amnesia (reversible),  AST increased, bilirubin increased, blood glucose increased, cataracts, cognitive impairment (reversible), confusion (reversible), depression, diabetes mellitus (new onset), GGT increased, glycosylated hemoglobin (Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     ) increased,  gynecomastia, hematuria (microscopic), hepatic failure, hepatitis, hyperglycemia, hypersensitivity reactions (including angioedema, pruritus, rash, urticaria), insomnia, jaundice, memory disturbance (reversible), memory impairment (reversible), myoglobinuria, myositis, myopathy, nightmares, pancreatitis, proteinuria (dose related), renal failure, rhabdomyolysis, thyroid function test abnormalities",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adverse reactions reported with other HMG-CoA reductase inhibitors (not necessarily reported with rosuvastatin therapy) include a hypersensitivity syndrome (symptoms may include anaphylaxis, angioedema, arthralgia, erythema multiforme, eosinophilia, hemolytic anemia, immune-mediated necrotizing myopathy (IMNM), interstitial lung disease, lupus syndrome, photosensitivity, polymyalgia rheumatica, positive ANA, purpura, Stevens-Johnson syndrome, toxic epidermal necrolysis, urticaria, vasculitis)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F219503\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to rosuvastatin or any component of the formulation; active liver disease; unexplained persistent elevations of serum transaminases (&gt;3 times ULN); pregnancy; breast-feeding",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Canadian labeling: Additional contraindications (not in U.S. labeling): Concomitant administration of cyclosporine; use of 40 mg dose in Asian patients, patients with predisposing risk factors for myopathy/rhabdomyolysis (eg, hereditary muscle disorders, history of myotoxicity with other HMG-CoA reductase inhibitors, concomitant use with fibrates or niacin, severe hepatic impairment, severe renal impairment [Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     ], hypothyroidism, alcohol abuse)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F219487\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes mellitus: Small increases in Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     (mean: ~0.1%) and fasting blood glucose have been reported with rosuvastatin; however, the benefits of statin therapy far outweigh the risk of dysglycemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hematuria/proteinuria: Hematuria (microscopic) and proteinuria have been observed; more commonly reported in patients receiving rosuvastatin 40 mg daily. Typically, transient and not associated with a decrease in renal function. Consider dosage reduction if unexplained hematuria and proteinuria persists.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatotoxicity: Postmarketing reports of fatal and nonfatal hepatic failure are rare. If serious hepatotoxicity with clinical symptoms and/or hyperbilirubinemia or jaundice occurs during treatment, interrupt therapy.  If an alternate etiology is not identified, do not restart rosuvastatin.  Liver enzyme tests should be obtained at baseline and as clinically indicated; routine periodic monitoring of liver enzymes is not necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Immune-mediated necrotizing myopathy (IMNM): IMNM, an autoimmune-mediated myopathy, has been reported (rarely) with HMG-CoA reductase inhibitor therapy.  IMNM presents as proximal muscle weakness with elevated CPK levels, which persists despite discontinuation of HMG-CoA reductase inhibitor therapy; additionally, muscle biopsy may show necrotizing myopathy with limited inflammation.  Immunosuppressive therapy (eg, corticosteroids, azathioprine) may be used for treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Myopathy/rhabdomyolysis: Patients receiving HMG-CoA reductase inhibitors have developed rhabdomyolysis with acute renal failure and/or myopathy; patients should be monitored closely. This risk is dose-related and is increased with concurrent use of other lipid-lowering medications (fibric acid derivatives or niacin doses &ge;1 g/day), other interacting drugs, other drugs associated with myopathy (eg, colchicine), age &ge;65 years, female gender, uncontrolled hypothyroidism, and renal dysfunction. The manufacturer recommends temporary discontinuation for elective major surgery, acute medical or surgical conditions, or in any patient experiencing an acute or serious condition predisposing to renal failure (eg, sepsis, hypotension, trauma, uncontrolled seizures). However, based upon current evidence, HMG-CoA reductase inhibitor therapy should be continued in the perioperative period unless risk outweighs cardioprotective benefit. Use caution in patients with renal impairment, inadequately treated hypothyroidism, and those taking other drugs associated with myopathy (eg, colchicine); these patients are predisposed to myopathy. Patients should be instructed to report unexplained muscle pain, tenderness, weakness, or brown urine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment and/or ethanol use: Use with caution in patients who consume large amounts of ethanol or have a history of liver disease. Use is contraindicated with active liver disease or unexplained transaminase elevations.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Dosage adjustment required in patients with a Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     and not receiving hemodialysis (contraindicated in the Canadian labeling).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Asian population: Increased risk of rosuvastatin-associated myopathy in certain subgroups; dosage adjustment should be considered for patients of Asian descent. Use of rosuvastatin at a dose of 40 mg/day in Asian patients is contraindicated in the Canadian labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in elderly patients as they are predisposed to myopathy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Secondary causes of hyperlipidemia should be ruled out prior to therapy. Rosuvastatin has not been studied when the primary lipid abnormality is chylomicron elevation (Fredrickson types I and V).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F219537\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2C9 (minor), CYP3A4 (minor), SLCO1B1;",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F219491\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amiodarone: May decrease the metabolism of HMG-CoA Reductase Inhibitors. Management: Dose of HMG-CoA reductase inhibitor may need to be reduced (limit simvastatin adult maximum dose to 20 mg/day, limit lovastatin adult maximum dose to 40 mg/day).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the serum concentration of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bezafibrate: May enhance the myopathic (rhabdomyolysis) effect of HMG-CoA Reductase Inhibitors. Bezafibrate may increase the serum concentration of HMG-CoA Reductase Inhibitors. More specifically, bezafibrate may increase the serum concentration of fluvastatin Management: Monitor patients closely for myopathy with concomitant use of bezafibrate and HMG-CoA reductase inhibitors. Concomitant use is contraindicated in patients predisposed to myopathy and alternative therapy should be considered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: May increase the serum concentration of Rosuvastatin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colchicine: May enhance the myopathic (rhabdomyolysis) effect of HMG-CoA Reductase Inhibitors. Colchicine may increase the serum concentration of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): May increase the serum concentration of Rosuvastatin. Management: Limit rosuvastatin to 5 mg/day in patients who are also receiving cyclosporine.  Canadian labeling contraindicates concomitant use of rosuvastatin with cyclosporine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     DAPTOmycin: HMG-CoA Reductase Inhibitors may enhance the adverse/toxic effect of DAPTOmycin. Specifically, the risk of skeletal muscle toxicity may be increased.  Management: Consider temporarily stopping HMG-CoA reductase inhibitor therapy prior to daptomycin.  If used together, regular (i.e., at least weekly) monitoring of CPK concentrations is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dronedarone: May increase the serum concentration of Rosuvastatin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eltrombopag: May increase the serum concentration of Rosuvastatin. Management: According to eltrombopag prescribing information, consideration should be given to a preventative 50% reduction in rosuvastatin adult dose when starting this combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fenofibrate: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fenofibric Acid: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fusidic Acid: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors. Specifically, the risk for muscle toxicities, including rhabdomyolysis may be significantly increased. Management: Avoid concurrent use of HMG-CoA reductase inhibitors (statins) with fusidic acid if possible.  If treatment with fusidic acid is necessary, consider temporarily stopping the statin.  With any concurrent use monitor patients closely for statin toxicity.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gemfibrozil: May enhance the myopathic (rhabdomyolysis) effect of Rosuvastatin. Gemfibrozil may increase the serum concentration of Rosuvastatin. Management: If possible, avoid concomitant use of rosuvastatin with gemfibrozil. If concomitant can not be avoided, limit rosuvastatin to 10 mg/day (US recommendation) or 20 mg/day (Canadian recommendation).  Monitor for signs/symptoms of rhabdomyolysis.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Itraconazole: May increase the serum concentration of Rosuvastatin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lanthanum: HMG-CoA Reductase Inhibitors may decrease the serum concentration of Lanthanum.  Management: Administer HMG-CoA reductase inhibitors at least two hours before or after lanthanum.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Niacin: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors. Management: This is of greatest concern with niacin doses of 1 g or greater daily.  Avoid simvastatin 80 mg in combination with niacin 1 g or greater in Chinese patients. Canadian labeling contraindicates use of niacin with rosuvastatin 40 mg.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Niacinamide: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pazopanib: HMG-CoA Reductase Inhibitors may enhance the hepatotoxic effect of Pazopanib. Specifically, the risk for increased serum transaminase concentrations may be increased.  Management: Simvastatin is specifically implicated in this interaction.  There is a lack of data regarding the risk with other statins, but caution appears warranted with any statins.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: May increase the serum concentration of Rosuvastatin. Management: Start with the lowest possible rosuvastatin dose and monitor for signs/symptoms of toxicity. In adult patients receiving atazanavir/ritonavir or lopinavir/ritonavir, initiate rosuvastatin at a 5 mg/day and do not exceed a dose of 10 mg/day.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Red Yeast Rice: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: May increase the serum concentration of Rosuvastatin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trabectedin: HMG-CoA Reductase Inhibitors may enhance the myopathic (rhabdomyolysis) effect of Trabectedin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): HMG-CoA Reductase Inhibitors may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F219518\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ethanol: Avoid excessive ethanol consumption (due to potential hepatic effects).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Food: Red yeast rice contains an estimated 2.4 mg lovastatin per 600 mg rice.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F219493\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     X (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F219506\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Cholesterol biosynthesis may be important in fetal development. Contraindicated in pregnancy. Administer to women of childbearing potential only when conception is highly unlikely and patients have been informed of potential hazards.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F219532\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/contraindicated",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F219507\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken with or without food. Red yeast rice contains an estimated 2.4 mg lovastatin per 600 mg rice.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F219505\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Crestor Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (90): $581.89",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (90): $581.89",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg (90): $581.89",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40 mg (30): $193.97",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F219495\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Baseline CPK (recheck CPK in any patient with symptoms suggestive of myopathy; discontinue therapy if markedly elevated); baseline liver function tests (LFTs) and repeat when clinically indicated thereafter. Patients with elevated transaminase levels should have a second (confirmatory) test and frequent monitoring until values normalize; discontinue if increase in ALT/AST is persistently &gt;3 times ULN (NCEP, 2002).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Lipid panel (total cholesterol, HDL, LDL, triglycerides):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      ATP III recommendations (NCEP, 2002):",
"     </i>",
"     Baseline; 6-8 weeks after initiation of drug therapy; if dose increased, then at 6-8 weeks until final dose determined. Once treatment goal achieved, follow up intervals may be reduced to every 4-6 months. Lipid panel should be assessed at least annually, and preferably at each clinic visit.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     <i>",
"      Manufacturer recommendation:",
"     </i>",
"     Upon initiation or titration, lipid panel should be analyzed within 2-4 weeks.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F219508\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Crestor (AR, AT, AU, BB, BE, BF, BG, BJ, BM, BR, BS, BZ, CH, CI, CL, CN, CO, CR, CZ, DK, DO, EC, EE, ET, FI, FR, GB, GH, GM, GN, GR, GT, GY, HK, HN, ID, IE, IL, IT, JM, KE, KP, LR, MA, ML, MR, MU, MW, MX, NE, NG, NI, NL, NO, NZ, PA, PE, PH, PR, PT, RU, SC, SD, SE, SG, SL, SN, SR, SV, TH, TN, TT, TW, TZ, UG, UY, VE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Fortius (IN);",
"     </li>",
"     <li>",
"      Lipichek (PH);",
"     </li>",
"     <li>",
"      Rolip (PK);",
"     </li>",
"     <li>",
"      Rosucol (PH);",
"     </li>",
"     <li>",
"      Rosuvaz (PH);",
"     </li>",
"     <li>",
"      Rovartal (PY);",
"     </li>",
"     <li>",
"      Rovista (PK);",
"     </li>",
"     <li>",
"      Rustor (PH);",
"     </li>",
"     <li>",
"      Softan (CL);",
"     </li>",
"     <li>",
"      Stator (IL);",
"     </li>",
"     <li>",
"      Visacor (NZ);",
"     </li>",
"     <li>",
"      Zyrova (PH)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F219486\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, the rate-limiting enzyme in cholesterol synthesis (reduces the production of mevalonic acid from HMG-CoA); this then results in a compensatory increase in the expression of LDL receptors on hepatocyte membranes and a stimulation of LDL catabolism",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F219502\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Within 1 week; maximal at 4 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 134 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 88%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic (10%), via CYP2C9 (1 active metabolite identified: N-desmethyl rosuvastatin, one-sixth to one-half the HMG-CoA reductase activity of the parent compound)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: 20% (high first-pass extraction by liver)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Asian patients have been noted to have increased bioavailability.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 19 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, plasma: 3-5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Feces (90%), primarily as unchanged drug",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Diabetes Association, &ldquo;Standards of Medical Care in Diabetes Mellitus -- 2012,&rdquo;",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2012, 35(Suppl ):11-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/11/10424/abstract-text/22187469/pubmed\" id=\"22187469\" target=\"_blank\">",
"        22187469",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Anderson JL, Adams CD, Antman EM, et al, &ldquo;ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction: Executive Summary. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients with Unstable Angina/Non ST-Elevation Myocardial Infarction) Developed in Collaboration With the American College of Emergency Physicians, The Society of Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2007, 50(7):1-157.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/11/10424/abstract-text/17692738/pubmed\" id=\"17692738\" target=\"_blank\">",
"        17692738",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Antman EM, Anbe DT, Armstrong PW, et al. &ldquo;ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction),&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2004, 44(3):671-719.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/11/10424/abstract-text/15358045/pubmed\" id=\"15358045\" target=\"_blank\">",
"        15358045",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Berglund L, Brunzell JD, Goldberg AC, et al, &ldquo;Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline,&rdquo;",
"      <i>",
"       J Clin Endocrinol Metab",
"      </i>",
"      , 2012, 97(9):2969-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/11/10424/abstract-text/22962670/pubmed\" id=\"22962670\" target=\"_blank\">",
"        22962670",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Castro C and Gourley M, \"Diagnosis and Treatment of Inflammatory Myopathy: Issues and Management,\"",
"      <i>",
"       Ther Adv Musculoskelet Dis",
"      </i>",
"      , 2012, 4(2):111-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/11/10424/abstract-text/22870499/pubmed\" id=\"22870499\" target=\"_blank\">",
"        22870499",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Crouse JR 3rd, Raichlen JS, Riley WA, et al, &ldquo;Effect of Rosuvastatin on Progression of Carotid Intima-Media Thickness in Low-Risk Individuals With Subclinical Atherosclerosis. The METEOR Trial,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2007, 297(12):1344-1353.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/11/10424/abstract-text/17384434/pubmed\" id=\"17384434\" target=\"_blank\">",
"        17384434",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      de Denus S and Spinler SA, &ldquo;Early Statin Therapy for Acute Coronary Syndromes,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2002, 36(11):1749-58.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/11/10424/abstract-text/12398573/pubmed\" id=\"12398573\" target=\"_blank\">",
"        12398573",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III),&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2001, 285(19):2486-97.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/11/10424/abstract-text/11368702/pubmed\" id=\"11368702\" target=\"_blank\">",
"        11368702",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fernandez AB, Karas RH, Alsheikh-Ali AA, et al, &ldquo;Statins and Interstitial Lung Disease: A Systematic Review of the Literature and of Food and Drug Administration Adverse Event Reports,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2008, 134(4):824-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/11/10424/abstract-text/18689579/pubmed\" id=\"18689579\" target=\"_blank\">",
"        18689579",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fihn SD, Gardin JM, Abrams J, et al, &ldquo;2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2012, 126(25):3097-137.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/11/10424/abstract-text/23166211/pubmed\" id=\"23166211\" target=\"_blank\">",
"        23166211",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fleisher LA, Beckman JA, Brown KA, et al, &ldquo;2009 ACCF/AHA Focused Update on Perioperative Beta Blockade Incorporated Into the ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery. A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2009, 54(22):e13-118.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/11/10424/abstract-text/19926002/pubmed\" id=\"19926002\" target=\"_blank\">",
"        19926002",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Heeschen C, Hamm CW, Laufs U, et al, &ldquo;Withdrawal of Statins Increases Event Rates in Patients With Acute Coronary Syndromes,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2002, 105(12):1446-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/11/10424/abstract-text/11914253/pubmed\" id=\"11914253\" target=\"_blank\">",
"        11914253",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hillis LD, Smith PK, Anderson JL, et al, &ldquo;2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 124(23):2610-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/11/10424/abstract-text/22064600/pubmed\" id=\"22064600\" target=\"_blank\">",
"        22064600",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      LaRosa JC, Grundy SM, Waters DD, et al, &ldquo;Intensive Lipid Lowering With Atorvastatin in Patients With Stable Coronary Disease,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2005, 352(14):1425-35.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/11/10424/abstract-text/15755765/pubmed\" id=\"15755765\" target=\"_blank\">",
"        15755765",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      LeManach Y, Godet G, Coriat P, et al, &ldquo;The Impact of Postoperative Discontinuation or Continuation of Chronic Statin Therapy on Cardiac Outcome After Major Vascular Surgery,&rdquo;",
"      <i>",
"       Anesth Analg",
"      </i>",
"      , 2007, 104(6):1326-33.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/11/10424/abstract-text/17513620/pubmed\" id=\"17513620\" target=\"_blank\">",
"        17513620",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McPherson R, Frohlich J, Fodor G, et al, &ldquo;Canadian Cardiovascular Society Position Statement--Recommendations for the Diagnosis and Treatment of Dyslipidemia and Prevention of Cardiovascular Disease,&rdquo;",
"      <i>",
"       Can J Cardiol",
"      </i>",
"      , 2006, 22(11):913-27; published erratum appears in",
"      <i>",
"       Can J Cardiol",
"      </i>",
"      , 2006, 22(12):1077.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/11/10424/abstract-text/16971976/pubmed\" id=\"16971976\" target=\"_blank\">",
"        16971976",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nissen SE, Nicholls SJ, Sipahi I, et al, &ldquo;Effect of Very High-Intesity Statin Therapy on Regression of Coronary Atherosclerosis: The ASTEROID Trial&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2006, 295(13):1556-65.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/11/10424/abstract-text/16533939/pubmed\" id=\"16533939\" target=\"_blank\">",
"        16533939",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pasternak RC, Smith SC Jr, Bairey-Merz CN, et al, &ldquo;ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins,&rdquo;",
"      <i>",
"       Stroke",
"      </i>",
"      , 2002, 33(9):2337-41. Available at file://stroke.ahajournals.org/cgi/content/short/33/9/2337",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/11/10424/abstract-text/12215610/pubmed\" id=\"12215610\" target=\"_blank\">",
"        12215610",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Poldermans D, Bax JJ, Kertai MD, et al, &ldquo;Statins Are Associated With a Reduced Incidence of Perioperative Mortality in Patients Undergoing Major Noncardiac Vascular Surgery,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2003, 107(14):1848-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/11/10424/abstract-text/12695283/pubmed\" id=\"12695283\" target=\"_blank\">",
"        12695283",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ridker PM, Danielson E, Fonseca FAH, et al, &ldquo;Rosuvastatin to Prevent Vascular Events in Men and Women With Elevated C-Reactive Protein,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2008, 359(21):2195-207.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/11/10424/abstract-text/18997196/pubmed\" id=\"18997196\" target=\"_blank\">",
"        18997196",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sever PS, Dahlof B, Poulter NR, et al, &ldquo;Prevention of Coronary and Stroke Events With Atorvastatin in Hypertensive Patients Who Have Average or Lower-Than-Average Cholesterol Concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid-Lowering Arm (ASCOT-LLA): A Multicentre Randomised Controlled Trial,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2003, 361(9364):1149-58.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/11/10424/abstract-text/12686036/pubmed\" id=\"12686036\" target=\"_blank\">",
"        12686036",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shepherd J, Cobbe SM, Ford I, et al, &ldquo;Prevention of Coronary Heart Disease With Pravastatin in Men With Hypercholesterolemia. West of Scotland Coronary Prevention Study Group,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1995, 333(20):1301-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/11/10424/abstract-text/7566020/pubmed\" id=\"7566020\" target=\"_blank\">",
"        7566020",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Smith SC Jr, Benjamin EJ, Bonow RO, et al, &ldquo;AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update: A Guideline From the American Heart Association and American College of Cardiology Foundation,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 124(22):2458-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/11/10424/abstract-text/22052934/pubmed\" id=\"22052934\" target=\"_blank\">",
"        22052934",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10282 Version 47.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-61.234.146.186-FE4A772EBF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_11_10424=[""].join("\n");
var outline_f10_11_10424=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13842378\">",
"      Special Alerts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219522\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219523\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219543\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219526\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9923608\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219527\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219528\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11431139\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219497\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219484\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219500\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219498\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7914388\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219541\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219503\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219487\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219537\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219491\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219518\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219493\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219506\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219532\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219507\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219505\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219495\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219508\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219486\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219502\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10282\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10282|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?1/3/1077?source=related_link\">",
"      Rosuvastatin: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?41/54/42854?source=related_link\">",
"      Rosuvastatin: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_11_10425="Prevention and treatment of acute graft-versus-host disease: Recommendations";
var content_f10_11_10425=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Prevention and treatment of acute graft-versus-host disease: Recommendations",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/11/10425/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/11/10425/contributors\">",
"     Nelson J Chao, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/11/10425/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/11/10425/contributors\">",
"     Robert S Negrin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/11/10425/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/11/10425/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/11/10425/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinically significant acute graft-versus-host disease (GVHD) occurs in 9 to 50 percent of patients who receive an allogeneic hematopoietic cell transplant from a genotypically HLA-identical sibling, despite intensive prophylaxis with immunosuppressive agents, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    , corticosteroids, or antithymocyte globulin. Acute GVHD is also common in matched unrelated donors and in haploidentical related donors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/38/26218?source=see_link\">",
"     \"Donor selection for hematopoietic cell transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic review will present our current approach to three major issues in acute GVHD: prophylaxis, diagnosis, and treatment. The clinical trials upon which these recommendations are based, the clinical manifestations and diagnosis of acute GVHD, and issues related to chronic GVHD are discussed separately. &nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/22/25960?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and grading of acute graft-versus-host disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/1/34842?source=see_link\">",
"     \"Overview of immunosuppressive agents used for prevention and treatment of graft-versus-host disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/32/6666?source=see_link\">",
"     \"Treatment of acute graft-versus-host disease: Clinical trials\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/13/24792?source=see_link\">",
"     \"Prevention of acute graft-versus-host disease: Trials of T cell depletion\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/3/42041?source=see_link\">",
"     \"Prevention of acute graft-versus-host disease: Trials of pharmacologic therapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/24/18826?source=see_link\">",
"     \"Pathogenesis of graft-versus-host disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;Development of moderate (grade II) or severe (grade III or IV) acute GVHD after hematopoietic cell transplantation (HCT) is associated with a significant decrease in survival. Furthermore, once GVHD occurs, it may not respond to treatment. Thus, intensive study has been directed toward prophylaxis of GVHD, a process that is mediated by activated T cells from the donor. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/24/18826?source=see_link\">",
"     \"Pathogenesis of graft-versus-host disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although prophylaxis is clearly effective, an important concern had been that such therapy would also diminish the graft-versus-leukemia (GVL) effect, increasing the likelihood of recurrent leukemia. The potential importance of GVL was illustrated in a review from 163 transplant centers which compared the results of 103 identical twin (syngeneic) and 1030 HLA-identical sibling (allogeneic) transplants for leukemia [",
"    <a class=\"abstract\" href=\"UTD.htm?10/11/10425/abstract/1\">",
"     1",
"    </a>",
"    ]. The three-year probability of relapse of leukemia was substantially higher in the syngeneic than allogeneic transplants in acute myeloid leukemia (52 versus 16 percent) and chronic myeloid leukemia (40 versus 7 percent); the GVL effect was less apparent and not statistically significant in acute lymphoid leukemia (36 versus 26 percent).",
"   </p>",
"   <p>",
"    In the past, investigators would attempt to minimize or avoid immunosuppression in the hopes that a GVL effect would occur. However with the advent of donor leukocyte infusions for the treatment of recurrent leukemia [",
"    <a class=\"abstract\" href=\"UTD.htm?10/11/10425/abstract/2\">",
"     2",
"    </a>",
"    ], avoiding GVHD prophylaxis became less attractive as a method to decrease relapses. As a result, almost all allogeneic HCT currently use some form of prophylaxis.",
"   </p>",
"   <p>",
"    The presence of GVHD remains the most important post-transplant factor influencing outcome following allogeneic HCT. As an example, in a study of 4174 HLA-identical sibling transplants for chronic myeloid leukemia in first chronic phase, acute GVHD of grades III and IV significantly increased transplantation-related mortality (TRM) during the first 100 days post-transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?10/11/10425/abstract/3\">",
"     3",
"    </a>",
"    ]. For the period from 100 days to 3 years post-transplant, hazard ratios (HR) for TRM increased with increasing grades of acute GVHD:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Grade 0 &mdash; HR for TRM 1.0",
"     </li>",
"     <li>",
"      Grade I &mdash; HR 1.5 (95% CI 1.2-2.0)",
"     </li>",
"     <li>",
"      Grade II &mdash; HR 2.5 (95% CI 2.0-3.1)",
"     </li>",
"     <li>",
"      Grade III &mdash; HR 5.8 (95% CI 4.4-7.5)",
"     </li>",
"     <li>",
"      Grade IV &mdash; HR 14.7 (95% CI 11-20)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Conversely, increasing degrees of acute GVHD reduced the risk of relapse:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Grade 0 &mdash; HR for relapse 1.0",
"     </li>",
"     <li>",
"      Grade I &mdash; HR 0.94 (95% CI 0.8-1.2)",
"     </li>",
"     <li>",
"      Grade II &mdash; HR 0.60 (95% CI 0.5-0.8)",
"     </li>",
"     <li>",
"      Grade III &mdash; HR 0.48 (95% CI 0.3-0.8)",
"     </li>",
"     <li>",
"      Grade IV &mdash; HR 0.14 (95% CI 0.02-0.99)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PROPHYLAXIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two major approaches to the prophylaxis of GVHD following hematopoietic cell transplantation (HCT): pharmacologic therapy, and T cell depletion [",
"    <a class=\"abstract\" href=\"UTD.htm?10/11/10425/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/3/42041?source=see_link\">",
"     \"Prevention of acute graft-versus-host disease: Trials of pharmacologic therapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/13/24792?source=see_link\">",
"     \"Prevention of acute graft-versus-host disease: Trials of T cell depletion\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The most widely used regimen is the combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    . This regimen is summarized in the table (",
"    <a class=\"graphic graphic_table graphicRef60951 \" href=\"UTD.htm?8/19/8509\">",
"     table 1",
"    </a>",
"    ); dose adjustments are made according to the serum creatinine and bilirubin concentrations (",
"    <a class=\"graphic graphic_table graphicRef79917 \" href=\"UTD.htm?24/26/25004\">",
"     table 2",
"    </a>",
"    ).",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     Prednisone",
"    </a>",
"    is not part of the standard prophylactic regimen but can be used if there are concerns about administering methotrexate, in patients who do not tolerate methotrexate, and in those at high risk of venoocclusive disease (",
"    <a class=\"graphic graphic_table graphicRef60951 \" href=\"UTD.htm?8/19/8509\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/4/40009?source=see_link&amp;anchor=H4#H4\">",
"     \"Pathogenesis and clinical features of hepatic sinusoidal obstruction syndrome (veno-occlusive disease) following hematopoietic cell transplantation\", section on 'Risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The efficacy of this combination was illustrated in a controlled trial in which 150 patients transplanted for leukemia or lymphoma were randomly assigned to receive either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    or cyclosporine and prednisone [",
"    <a class=\"abstract\" href=\"UTD.htm?10/11/10425/abstract/5\">",
"     5",
"    </a>",
"    ]. Patients receiving cyclosporine, methotrexate, and prednisone had a significantly lower incidence of grade II-IV acute GVHD than those receiving only cyclosporine and prednisone (9 versus 23 percent) (",
"    <a class=\"graphic graphic_figure graphicRef79413 \" href=\"UTD.htm?27/49/28432\">",
"     figure 1",
"    </a>",
"    ). The lower incidence of acute GVHD did not result in a higher relapse rate of the underlying disease, as the disease-free survival at three years was the same in the two groups (64 versus 59 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Glucocorticoids for prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of the addition of glucocorticoids to standard prevention with",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"      cyclosporine",
"     </a>",
"     /",
"     <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"      methotrexate",
"     </a>",
"    </span>",
"    is uncertain [",
"    <a class=\"abstract\" href=\"UTD.htm?10/11/10425/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. While the addition of glucocorticoids was shown in a meta-analysis to significantly reduce the risk of both mild and severe acute GVHD, their use did not result in alterations in overall survival, disease-free survival, or the incidence of relapse [",
"    <a class=\"abstract\" href=\"UTD.htm?10/11/10425/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Cyclosporine and tacrolimus",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     Cyclosporine",
"    </a>",
"    is administered from day minus 2 (",
"    <a class=\"graphic graphic_table graphicRef60951 \" href=\"UTD.htm?8/19/8509\">",
"     table 1",
"    </a>",
"    ). It is usually given intravenously for the first several weeks. During this period, the patient is usually recovering from the preparatory regimen; the oral mucosa and gastrointestinal tract are not healed so that oral cyclosporine may be erratically absorbed if administered orally. Cyclosporine is administered to reach a therapeutic target concentration. Studies to date have not demonstrated a clear correlation of blood cyclosporine levels to prevention [",
"    <a class=\"abstract\" href=\"UTD.htm?10/11/10425/abstract/8\">",
"     8",
"    </a>",
"    ]. However, the ability to deliver the target doses of cyclosporine is related to a better outcome with less GVHD.",
"   </p>",
"   <p>",
"    In a phase II study in matched unrelated donors,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    (FK506) was shown to be active in preventing acute GVHD [",
"    <a class=\"abstract\" href=\"UTD.htm?10/11/10425/abstract/9\">",
"     9",
"    </a>",
"    ]. This agent was compared with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    in a randomized study in matched sibling transplantation. While the incidence of acute GVHD was lower with the combination of tacrolimus and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    compared to cyclosporine and methotrexate, overall survival was similar [",
"    <a class=\"abstract\" href=\"UTD.htm?10/11/10425/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     Cyclosporine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    are nephrotoxic. As a result, other nephrotoxic drugs should be avoided so that the agent can be delivered at the target doses. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/27/28090?source=see_link\">",
"     \"Pharmacology and side effects of cyclosporine and tacrolimus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If nephrotoxicity becomes a problem, alternative agents can be employed (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    [rapamycin], mycophenolic acid, daclizumab), although there are no data to guide one's choice in this matter. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/1/34842?source=see_link&amp;anchor=H8#H8\">",
"     \"Overview of immunosuppressive agents used for prevention and treatment of graft-versus-host disease\", section on 'Sirolimus'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/1/34842?source=see_link&amp;anchor=H11#H11\">",
"     \"Overview of immunosuppressive agents used for prevention and treatment of graft-versus-host disease\", section on 'Mycophenolate'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/32/6666?source=see_link&amp;anchor=H9#H9\">",
"     \"Treatment of acute graft-versus-host disease: Clinical trials\", section on 'Anti-interleukin-2 receptor antibodies (daclizumab)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Methotrexate",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     Methotrexate",
"    </a>",
"    is administered on days +1, +3, +6, and +11 (",
"    <a class=\"graphic graphic_table graphicRef60951 \" href=\"UTD.htm?8/19/8509\">",
"     table 1",
"    </a>",
"    ). As with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    , all efforts should be made to administer the target dose of methotrexate. The urine should be alkalinized to a pH above 7.0 with bicarbonate to aid in the excretion of methotrexate and to minimize its precipitation in the tubules, which can lead to acute renal failure. This can be achieved by the administration of roughly 3 liters per day of dextrose in water to which 44 to 66 meq of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/52/840?source=see_link\">",
"     sodium bicarbonate",
"    </a>",
"    has been added. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/2/34857?source=see_link\">",
"     \"Crystal-induced acute kidney injury (acute renal failure)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Care should be exercised to avoid other factors that might predispose to severe",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    toxicity. The dose of methotrexate is usually reduced in patients who have hyperbilirubinemia, severe mucositis or renal insufficiency (",
"    <a class=\"graphic graphic_table graphicRef79917 \" href=\"UTD.htm?24/26/25004\">",
"     table 2",
"    </a>",
"    ). Use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    rescue may be necessary in certain patients with severe side effects. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/61/11223?source=see_link\">",
"     \"Major side effects of low-dose methotrexate\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Tapering of cyclosporine",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the patient is doing well and does not have any evidence of GVHD,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    may be tapered at approximately day +90 and discontinued by the end of six months in a matched-related sibling transplant (",
"    <a class=\"graphic graphic_table graphicRef60951 \" href=\"UTD.htm?8/19/8509\">",
"     table 1",
"    </a>",
"    ). In mismatched related sibling or matched unrelated donor transplants, cyclosporine may need to be continued for much longer, sometimes even years. In addition, a slower taper may be preferable in older patients to prevent chronic GVHD.",
"   </p>",
"   <p>",
"    It is important to follow the patients carefully during the taper to avoid missing the onset of chronic GVHD. The same concern applies to patients who receive",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    either as part of the prophylaxis regimen or for the treatment of acute GVHD. The onset of chronic GVHD can be fulminant at times, requiring intensive treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/25/23962?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and grading of chronic graft-versus-host disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Sirolimus (rapamycin)",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     Sirolimus",
"    </a>",
"    is a lipophilic macrolide produced by a strain of streptomyces hygroscopicus isolated from a soil sample from Easter Island (Rapa Nui). The interest in sirolimus as an immunosuppressive agent coincided with a discovery of the immunosuppressive activity of FK 506, since the structure of both of these molecules contained a distinctive hemiketal-masked",
"    <span class=\"nowrap\">",
"     alpha/beta-diketopipecolic",
"    </span>",
"    acid amidic component. Sirolimus binds to the same family of intracellular receptors as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    , termed tacrolimus binding proteins (FKBPs). In a similar fashion to tacrolimus, sirolimus has two domains, a domain bound by FKBP and an effector domain forming a composite surface that interacts with the mammalian target of rapamycin [mTOR]. While sirolimus and tacrolimus bind to the same family of intracellular binding proteins, the mechanisms of immunosuppression are clearly distinct. While sirolimus inhibits the growth of hematopoietic and lymphoid cells in vitro, it also suppresses cytokine-driven growth of these cells.",
"   </p>",
"   <p>",
"    Initial data indicated that the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    and low dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    was associated with tolerable toxicity and a low rate of acute GVHD [",
"    <a class=\"abstract\" href=\"UTD.htm?10/11/10425/abstract/11\">",
"     11",
"    </a>",
"    ]. In contrast to the renal side effects common with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    and tacrolimus, nephrotoxicity is rarely encountered with sirolimus, although it may potentiate the nephrotoxicity of cyclosporine. Sirolimus is toxic to the GI system, including elevation of liver function tests and diarrhea.",
"   </p>",
"   <p>",
"    The use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    has been associated with sinusoidal obstruction syndrome (SOS) following myeloablative conditioning regimens, especially when myeloablative doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/10/10408?source=see_link\">",
"     busulfan",
"    </a>",
"    were employed [",
"    <a class=\"abstract\" href=\"UTD.htm?10/11/10425/abstract/12\">",
"     12",
"    </a>",
"    ]. On the other hand, sirolimus-based GVHD prophylaxis without",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    was associated with the greatest overall survival. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/3/42041?source=see_link&amp;anchor=H10#H10\">",
"     \"Prevention of acute graft-versus-host disease: Trials of pharmacologic therapy\", section on 'Toxicity of other sirolimus combinations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other toxicities include hypertriglyceridemia, a decrease in platelets and leukocytes, epistaxis, blood pressure changes, headaches, nausea, mucous membrane irritation, and infections. Adverse reactions previously observed with other macrolide antibiotics are also of concern. Testicular atrophy has been observed in both mice and non-human primates. These early observations suggest that liver function abnormalities, thrombocytopenia, and neutropenia may be its dose limiting toxicity.",
"   </p>",
"   <p>",
"    The use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    without",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/3/42041?source=see_link&amp;anchor=H9#H9\">",
"     \"Prevention of acute graft-versus-host disease: Trials of pharmacologic therapy\", section on 'Tacrolimus plus sirolimus'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Mycophenolate mofetil",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     Mycophenolate",
"    </a>",
"    Mofetil (MMF) is a morpholinoethyl ester of mycophenolic acid (MPA). MPA is produced by several species of Penicillium molds and possesses antibacterial, antifungal, antiviral, antitumor and immunosuppressive properties. MMF's immunosuppressive activity occurs after hydrolysis to MPA, the active moiety. This medication is formulated as MMF to enhance its bioavailability.",
"   </p>",
"   <p>",
"    MMF inhibits the proliferation of T and B cells and the production of antibodies through the inhibition of inosine monophosphate dehydrogenase (IMPDH). This enzyme catalyzes oxidation of inosine monophosphate to xanthine monophosphate, a required intermediate in the synthesis of guanosine triphosphate and a critical enzyme for the de novo biosynthesis of purine nucleotides, specifically guanosine monophosphate (GMP). Blockade of GMP synthesis leads to a negative feedback inhibition of 5-phosphoribosyl-1-pyrophosphate and prevention of T cell activation. The therapeutic index of MMF depends on the lymphocyte's reliance on de novo synthesis of purines, allowing for greater immunosuppressive activity with less toxicity.",
"   </p>",
"   <p>",
"    Studies in a dog model of allogeneic transplantation have demonstrated that the combination of MMF and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    was highly effective for the prevention of both the host-versus-graft (rejection) and graft-versus-host (GVHD) reactions following a non-myeloablative regimen [",
"    <a class=\"abstract\" href=\"UTD.htm?10/11/10425/abstract/13\">",
"     13",
"    </a>",
"    ]. These studies have led to the marked increase in this form of transplantation worldwide.",
"   </p>",
"   <p>",
"    Side effects of MMF at commonly employed doses have been low. The major effect has been suppression of the hematopoietic system with neutropenia as an important side effect. Gastrointestinal side effects have also been reported. While the optimal dose of MMF has not been determined, doses as high as 15",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    four times daily have been reported to be tolerable. Of note, MMF does not seem to deplete GTP in neutrophils in contrast to lymphocytes and monocytes. Its selective action on lymphocytes seems to spare the higher risk of acute infections. Doses up to 1.5",
"    <span class=\"nowrap\">",
"     grams/day",
"    </span>",
"    have shown no nephrotoxicity, myelosuppression, or other serious side effects in patients with rheumatoid arthritis. Methods to monitor drug levels of MMF are being developed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Suppression of growth of intestinal bacteria prevents the development of acute GVHD in animals receiving mismatched transplants, providing the rationale for the use of antibiotics to prevent or modify acute GvHD in humans [",
"    <a class=\"abstract\" href=\"UTD.htm?10/11/10425/abstract/14\">",
"     14",
"    </a>",
"    ]. To test this hypothesis, 134 marrow transplant recipients were randomly assigned to receive either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    or ciprofloxacin plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    for five weeks following transplantation. Among HLA-identical sibling transplants, combination antibiotics were associated with a significantly lower incidence of grades II to IV acute GVHD (18 versus 54 percent with ciprofloxacin alone) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/11/10425/abstract/14\">",
"     14",
"    </a>",
"    ]. However, the incidence of acute GVHD did not differ significantly for recipients of partially-matched family or matched unrelated transplants (36 versus 46 percent). There was no statistically significant difference between the two antibiotic treatment groups in the incidence of chronic GVHD or five-year survival.",
"   </p>",
"   <p>",
"    Based upon this study and many others suggesting that suppression of gut flora may ameliorate acute GVHD, we currently use a quinolone for this purpose. We start on the day before the initiation of the preparatory regimen and continue it until patients have engrafted or are started on intravenous antibiotics.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     DIAGNOSIS OF ACUTE GVHD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute GVHD can involve the skin, gastrointestinal tract, and liver. The diagnosis can be made readily on clinical grounds in the patient who presents with a classic rash, abdominal cramps with diarrhea, and a rising serum bilirubin concentration within the first 100 days following HCT, most often within two to three weeks following HCT. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/22/25960?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and grading of acute graft-versus-host disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In many cases, however, the diagnosis is less straightforward and competing causes for isolated abnormalities must be considered and excluded. A skin rash alone may be caused by antibiotics or a myriad of other drugs with which these patients are often treated, diarrhea may be infectious in nature, and hyperbilirubinemia may be related to biliary sludge or a side effect of multiple drugs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/50/42790?source=see_link\">",
"     \"Diagnostic approach to the patient with jaundice or asymptomatic hyperbilirubinemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/63/29690?source=see_link\">",
"     \"Drugs and the liver: Patterns of drug-induced liver injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Histologic confirmation may be helpful to corroborate a clinical impression of possible acute GVHD. The skin and gastrointestinal tract are relatively easy to biopsy. Percutaneous liver biopsy poses a greater risk since most patients are thrombocytopenic at the time of GVHD. Percutaneous transjugular liver biopsy is a safer alternative when performed by experienced personnel.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Glucocorticoids",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Standard dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the patient develops acute GVHD, the first and most effective treatment option is the use of glucocorticoids. The most commonly used glucocorticoid is",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    , which differs from",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    only by the addition of 6-alpha-methyl group. If the patient has not received glucocorticoids for GVHD prophylaxis, methylprednisolone (2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day in divided doses) is begun. Several investigators have used a different regimen consisting of very high doses of steroids. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/32/6666?source=see_link\">",
"     \"Treatment of acute graft-versus-host disease: Clinical trials\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In an attempt to compare these different approaches, a multicenter trial randomly assigned 95 patients with acute GVHD to receive early treatment with either low (2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) or high dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    (10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/11/10425/abstract/15\">",
"     15",
"    </a>",
"    ]. On day five of therapy, almost one-half of patients in the low dose group were switched to a higher dose because of lack of response or progression. With this strategy, there were no differences in mean response rates or actuarial survival at three years (63 versus 62 percent).",
"   </p>",
"   <p>",
"    These data suggest that starting with low dose steroids (ie, 2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) may be an appropriate regimen. Steroids are continued for several weeks in responders and then gradually tapered over a period of several months [",
"    <a class=\"abstract\" href=\"UTD.htm?10/11/10425/abstract/16\">",
"     16",
"    </a>",
"    ]. Gradual tapering is important to prevent a flare of GVHD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Use of lower doses",
"    </span>",
"    &nbsp;&mdash;&nbsp;A retrospective study analyzed transplant outcomes among 733 patients who received initial treatment for acute GVHD with either standard dose (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    -equivalent dose of 2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) or low-dose (1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) glucocorticoids [",
"    <a class=\"abstract\" href=\"UTD.htm?10/11/10425/abstract/17\">",
"     17",
"    </a>",
"    ]. It was concluded that initial treatment with low-dose glucocorticoids for patients with grades I-II acute GVHD did not compromise disease control or mortality and was associated with decreased length of hospitalization, as well as reductions in the incidence of invasive fungal infection and Gram-negative bacteremia.",
"   </p>",
"   <p>",
"    However, this was a retrospective study and the reasons why certain patients began at a lower glucocorticoid dose compared to others likely reflect many different aspects of their GVHD, including physician preference as well as the pace of onset of signs and symptoms. A prospective, randomized trial will be required before a lower glucocorticoid dosage can be recommended for this subgroup of patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Nonresponders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonresponders to the above treatment at day 5 are treated with higher dose steroids (eg, 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day). If they respond within three to five days, the dose is lowered to 2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day and the subsequent course is similar to that in responders to low dose therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Second line agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;If higher doses of steroids are not successful in controlling GVHD by three to five days, second line treatments are required, but are generally less successful than steroids. These include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    , antithymocyte globulin,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/9/40086?source=see_link\">",
"     pentostatin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?10/11/10425/abstract/4,16,18-21\">",
"     4,16,18-21",
"    </a>",
"    ]. One limitation to mycophenolate is that it is only available in oral form; absorption of this preparation is uncertain in patients with severe gut GVHD. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/32/6666?source=see_link\">",
"     \"Treatment of acute graft-versus-host disease: Clinical trials\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other forms of treatment of GVHD are more anecdotal in nature. Agents that can be tried include extracorporeal photopheresis, and monoclonal antibodies directed against such targets as CD25, TNF-alpha, the T cell receptor, and the IL-2 receptor [",
"    <a class=\"abstract\" href=\"UTD.htm?10/11/10425/abstract/16,19\">",
"     16,19",
"    </a>",
"    ]. The use of nonabsorbable steroids (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/7/33904?source=see_link\">",
"     beclomethasone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/7/32880?source=see_link\">",
"     budesonide",
"    </a>",
"    ) may be helpful for gastrointestinal GVHD. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/32/6666?source=see_link&amp;anchor=H3#H3\">",
"     \"Treatment of acute graft-versus-host disease: Clinical trials\", section on 'Beclomethasone'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In our center, patients failing high dose steroids usually are treated with MMF. The efficacy of these agents has been limited, illustrating the need for enrollment of these patients into well-designed clinical trials in order to develop better treatment regimens [",
"    <a class=\"abstract\" href=\"UTD.htm?10/11/10425/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/32/6666?source=see_link\">",
"     \"Treatment of acute graft-versus-host disease: Clinical trials\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Patient outcomes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reports from Minnesota and Seattle have evaluated the outcomes in different groups of patients with acute GVHD. The Minnesota study evaluated 469 patients receiving histocompatible allogeneic bone marrow transplants, 197 of whom (42 percent) were treated for grade II-IV acute GVHD [",
"    <a class=\"abstract\" href=\"UTD.htm?10/11/10425/abstract/23\">",
"     23",
"    </a>",
"    ]. The following results were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Forty-one percent achieved a complete and continued resolution of acute GVHD after a median of 21 days of therapy. Treatment in these responders consisted primarily of corticosteroids or, in a small number of patients, other immunosuppressive therapies including",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      , anti-T cell antibodies, or antilymphocyte globulin.",
"     </li>",
"     <li>",
"      Sixty-one patients not responding to initial therapy received high dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      , antithymocyte globulin plus methylprednisolone, or other therapies. Only seven of these patients (11 percent) eventually obtained a complete continued remission.",
"     </li>",
"     <li>",
"      The overall rate of chronic GVHD was 70 percent; thus, 30 percent of patients were cured. In a later report from the same group, a response to primary therapy for acute GVHD was the most important factor predicting a lower risk of subsequent chronic GVHD [",
"      <a class=\"abstract\" href=\"UTD.htm?10/11/10425/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The clinical features associated with a complete response to therapy for acute GVHD included the absence of liver or skin involvement, acute lymphoblastic leukemia as the underlying disease, and",
"      <span class=\"nowrap\">",
"       donor/recipient",
"      </span>",
"      pairs other than male recipients with female donors.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although these results are good (30 percent cure of moderate to severe acute GVHD), many of these patients were transplanted before the availability of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    . GVHD prophylaxis at that time consisted predominantly of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    -based regimens either alone or in conjunction with antithymocyte globulin and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    or ex vivo T cell depletion. The more recent patients transplanted with cyclosporine-based prophylactic regimens who developed GVHD did not respond as well to the various treatments.",
"   </p>",
"   <p>",
"    The report from the Seattle group was a retrospective analysis of 427 patients who did not have a durable response to primary therapy for acute GVHD [",
"    <a class=\"abstract\" href=\"UTD.htm?10/11/10425/abstract/25\">",
"     25",
"    </a>",
"    ]. The most common manifestations were rash (75 percent), liver disease (59 percent), and gastrointestinal dysfunction (53 percent). Secondary treatments consisted of glucocorticoids in the majority of the patients (n = 249), antithymocyte globulin (n = 214),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    (n = 80), or a monoclonal antibody (n = 19). Most of the patients received single agent therapy. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Some response to therapy was seen in 40 percent. Improvement in or resolution of GVHD in the respective organs was seen in 45 percent of patients with skin disease, 25 percent with liver disease, and 35 percent with gut disease.",
"     </li>",
"     <li>",
"      The highest complete response rate was seen when GVHD recurred during the taper phase of primary glucocorticoid therapy. Increasing the dose of glucocorticoids in such patients often resulted a second complete response.",
"     </li>",
"     <li>",
"      Severe dysfunction in the skin, liver, or gut at the beginning of treatment was associated with lower incidence of response or improvement in outcome.",
"     </li>",
"     <li>",
"      Less than one-half of patients showed a durable overall improvement.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H63502617\">",
"    <span class=\"h1\">",
"     PREVENTION OF INFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who undergo HCT are at risk for bacterial, viral, and fungal infections, the time course of which varies in the post-transplant period, according to the degree of immune deficiency and cytopenia induced by the transplantation procedure. Organ damage related to acute or chronic GVHD, as well as the immunosuppressive regimen used to treat GVHD, further increase the risk of infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/30/25066?source=see_link\">",
"     \"Overview of infections following hematopoietic cell transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As a result, prophylactic therapies are used to prevent infections. Strategies to prevent infections in HCT recipients with GVHD include the use of neutropenic (and HCT) precautions, antibacterial drugs, antiviral drugs, antifungal drugs, immunoglobulin infusions, and vaccinations. Recommendations for use of these strategies differ from one institution to another; the approach to prophylaxis in HCT recipients is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/31/29178?source=see_link\">",
"     \"Prophylaxis of invasive fungal infections in adult hematopoietic cell transplant recipients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/57/32666?source=see_link\">",
"     \"Prophylaxis of infections in hematopoietic cell transplant recipients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/41/30362?source=see_link&amp;anchor=H18#H18\">",
"     \"Induction therapy for acute myeloid leukemia in younger adults\", section on 'Infections'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/57/25498?source=see_link\">",
"     \"Immunizations after hematopoietic cell transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H63501692\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Graft-versus-host disease (GVHD) occurs when immune cells transplanted from a non-identical donor (the graft) recognize the transplant recipient (the host) as foreign, thereby initiating an immune reaction that causes disease in the transplant recipient. The pathogenesis of GVHD is a complex, multistep process, but is primarily a T cell mediated process. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/24/18826?source=see_link\">",
"       \"Pathogenesis of graft-versus-host disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pharmacologic agents used for the prevention and treatment of GVHD include non-specific immunosuppressive drugs, such as corticosteroids and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      , as well as more specific T cell immunosuppressive drugs, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      , and rapamycin. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/1/34842?source=see_link\">",
"       \"Overview of immunosuppressive agents used for prevention and treatment of graft-versus-host disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      GVHD prophylaxis is typically administered as a combination of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      with or without corticosteroids (",
"      <a class=\"graphic graphic_table graphicRef60951 \" href=\"UTD.htm?8/19/8509\">",
"       table 1",
"      </a>",
"      ):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Four doses of intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      (MTX) are commonly used for the prevention of GVHD. Prior to each dose, patients should be very well hydrated, and have their urine alkalinized with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/52/840?source=see_link\">",
"       sodium bicarbonate",
"      </a>",
"      ; MTX should not be administered until the urine pH is &ge;8.0. Dose attenuation should be considered for elevations of creatinine or bilirubin or the presence of grade III-IV mucositis (",
"      <a class=\"graphic graphic_table graphicRef79917 \" href=\"UTD.htm?24/26/25004\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/1/34842?source=see_link&amp;anchor=H4#H4\">",
"       \"Overview of immunosuppressive agents used for prevention and treatment of graft-versus-host disease\", section on 'Methotrexate'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Calcineurin inhibitors (CNI;",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      ) are initially administered intravenously, followed by an oral formulation when patients are able to eat sufficiently. Drug levels are followed carefully to maintain a therapeutic range and avoid toxicities. Many different drugs have been implicated in increasing or decreasing calcineurin levels in patients (",
"      <a class=\"graphic graphic_table graphicRef50343 \" href=\"UTD.htm?3/10/3245\">",
"       table 3",
"      </a>",
"      ). In addition, CNIs are nephrotoxic and the concomitant administration of other nephrotoxic drugs should be followed carefully. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Cyclosporine and tacrolimus'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/1/34842?source=see_link&amp;anchor=H6#H6\">",
"       \"Overview of immunosuppressive agents used for prevention and treatment of graft-versus-host disease\", section on 'Cyclosporine'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Corticosteroids are not part of the standard prophylactic regimen but can be used if there are concerns about administering",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      , in patients who do not tolerate methotrexate, and in those at high risk of venoocclusive disease. When used for prophylaxis, the corticosteroid of choice has been",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      , followed by oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      when patients are able to eat sufficiently so that one can be confident that they will absorb the medication without difficulty. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Glucocorticoids for prophylaxis'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/1/34842?source=see_link&amp;anchor=H3#H3\">",
"       \"Overview of immunosuppressive agents used for prevention and treatment of graft-versus-host disease\", section on 'Corticosteroids'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An acceptable alternative is the combination of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"       sirolimus",
"      </a>",
"      . (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/3/42041?source=see_link&amp;anchor=H9#H9\">",
"       \"Prevention of acute graft-versus-host disease: Trials of pharmacologic therapy\", section on 'Tacrolimus plus sirolimus'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The diagnosis of acute GVHD can be made readily on clinical grounds in the patient who presents with a classic maculopapular rash, abdominal cramps with diarrhea, and a rising serum bilirubin concentration within the first 100 days following hematopoietic cell transplantation (HCT), most often within two to three weeks following HCT. In many cases, however, the diagnosis is less straightforward and competing causes for isolated abnormalities must be considered and excluded. Histologic confirmation may be helpful to corroborate a clinical impression of possible acute GVHD. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/22/25960?source=see_link&amp;anchor=H12#H12\">",
"       \"Clinical manifestations, diagnosis, and grading of acute graft-versus-host disease\", section on 'Diagnosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Corticosteroids are the most widely used \"front-line\" therapy for the treatment of clinical GVHD. We begin with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      (2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day). This regimen continued for several weeks in responders and then gradually tapered over a period of several months. If the GVHD does not improve after five days, other agents are often added.",
"     </li>",
"     <li>",
"      Patients who undergo HCT are at risk for bacterial, viral, and fungal infections, the time course of which varies in the post-transplant period, according to the degree of immune deficiency and cytopenia induced by the transplantation procedure. Organ damage related to acute or chronic GVHD, as well as the immunosuppressive regimen used to treat GVHD, further increase the risk of infection. (See",
"      <a class=\"local\" href=\"#H63502617\">",
"       'Prevention of infection'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/30/25066?source=see_link\">",
"       \"Overview of infections following hematopoietic cell transplantation\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/11/10425/abstract/1\">",
"      Gale RP, Horowitz MM, Ash RC, et al. Identical-twin bone marrow transplants for leukemia. Ann Intern Med 1994; 120:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/11/10425/abstract/2\">",
"      Kolb HJ, Schattenberg A, Goldman JM, et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 1995; 86:2041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/11/10425/abstract/3\">",
"      Gratwohl A, Brand R, Apperley J, et al. Graft-versus-host disease and outcome in HLA-identical sibling transplantations for chronic myeloid leukemia. Blood 2002; 100:3877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/11/10425/abstract/4\">",
"      Bacigalupo A. Management of acute graft-versus-host disease. Br J Haematol 2007; 137:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/11/10425/abstract/5\">",
"      Chao NJ, Schmidt GM, Niland JC, et al. Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prophylaxis of acute graft-versus-host disease. N Engl J Med 1993; 329:1225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/11/10425/abstract/6\">",
"      Storb R, Pepe M, Anasetti C, et al. What role for prednisone in prevention of acute graft-versus-host disease in patients undergoing marrow transplants? Blood 1990; 76:1037.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/11/10425/abstract/7\">",
"      Quellmann S, Schwarzer G, H&uuml;bel K, et al. Corticosteroids in the prevention of graft-vs-host disease after allogeneic myeloablative stem cell transplantation: a systematic review and meta-analysis. Leukemia 2008; 22:1801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/11/10425/abstract/8\">",
"      Atkinson K, Downs K, Ashby M, Biggs J. Clinical correlations with cyclosporine blood levels after allogeneic bone marrow transplantation: an analysis of four different assays. Transplant Proc 1990; 22:1331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/11/10425/abstract/9\">",
"      Nash RA, Pi&ntilde;eiro LA, Storb R, et al. FK506 in combination with methotrexate for the prevention of graft-versus-host disease after marrow transplantation from matched unrelated donors. Blood 1996; 88:3634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/11/10425/abstract/10\">",
"      Ratanatharathorn V, Nash RA, Przepiorka D, et al. Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood 1998; 92:2303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/11/10425/abstract/11\">",
"      Antin JH, Kim HT, Cutler C, et al. Sirolimus, tacrolimus, and low-dose methotrexate for graft-versus-host disease prophylaxis in mismatched related donor or unrelated donor transplantation. Blood 2003; 102:1601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/11/10425/abstract/12\">",
"      Cutler C, Stevenson K, Kim HT, et al. Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation. Blood 2008; 112:4425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/11/10425/abstract/13\">",
"      Storb R, Yu C, Wagner JL, et al. Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. Blood 1997; 89:3048.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/11/10425/abstract/14\">",
"      Beelen DW, Elmaagacli A, M&uuml;ller KD, et al. Influence of intestinal bacterial decontamination using metronidazole and ciprofloxacin or ciprofloxacin alone on the development of acute graft-versus-host disease after marrow transplantation in patients with hematologic malignancies: final results and long-term follow-up of an open-label prospective randomized trial. Blood 1999; 93:3267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/11/10425/abstract/15\">",
"      Van Lint MT, Uderzo C, Locasciulli A, et al. Early treatment of acute graft-versus-host disease with high- or low-dose 6-methylprednisolone: a multicenter randomized trial from the Italian Group for Bone Marrow Transplantation. Blood 1998; 92:2288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/11/10425/abstract/16\">",
"      Deeg HJ. How I treat refractory acute GVHD. Blood 2007; 109:4119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/11/10425/abstract/17\">",
"      Mielcarek M, Storer BE, Boeckh M, et al. Initial therapy of acute graft-versus-host disease with low-dose prednisone does not compromise patient outcomes. Blood 2009; 113:2888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/11/10425/abstract/18\">",
"      Mollee P, Morton AJ, Irving I, Durrant S. Combination therapy with tacrolimus and anti-thymocyte globulin for the treatment of steroid-resistant acute graft-versus-host disease developing during cyclosporine prophylaxis. Br J Haematol 2001; 113:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/11/10425/abstract/19\">",
"      Couriel D, Caldera H, Champlin R, Komanduri K. Acute graft-versus-host disease: pathophysiology, clinical manifestations, and management. Cancer 2004; 101:1936.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/11/10425/abstract/20\">",
"      Van Lint MT, Milone G, Leotta S, et al. Treatment of acute graft-versus-host disease with prednisolone: significant survival advantage for day +5 responders and no advantage for nonresponders receiving anti-thymocyte globulin. Blood 2006; 107:4177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/11/10425/abstract/21\">",
"      Schmitt T, Luft T, Hegenbart U, et al. Pentostatin for treatment of steroid-refractory acute GVHD: a retrospective single-center analysis. Bone Marrow Transplant 2011; 46:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/11/10425/abstract/22\">",
"      Bola&ntilde;os-Meade J, Vogelsang GB. Novel strategies for steroid-refractory acute graft-versus-host disease. Curr Opin Hematol 2005; 12:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/11/10425/abstract/23\">",
"      Weisdorf D, Haake R, Blazar B, et al. Treatment of moderate/severe acute graft-versus-host disease after allogeneic bone marrow transplantation: an analysis of clinical risk features and outcome. Blood 1990; 75:1024.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/11/10425/abstract/24\">",
"      Hings IM, Severson R, Filipovich AH, et al. Treatment of moderate and severe acute GVHD after allogeneic bone marrow transplantation. Transplantation 1994; 58:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/11/10425/abstract/25\">",
"      Martin PJ, Schoch G, Fisher L, et al. A retrospective analysis of therapy for acute graft-versus-host disease: secondary treatment. Blood 1991; 77:1821.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3542 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-61.234.146.186-B64CF0B05F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_11_10425=[""].join("\n");
var outline_f10_11_10425=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H63501692\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PROPHYLAXIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Glucocorticoids for prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Cyclosporine and tacrolimus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Methotrexate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Tapering of cyclosporine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Sirolimus (rapamycin)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Mycophenolate mofetil",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Antibiotics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      DIAGNOSIS OF ACUTE GVHD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Standard dosing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Use of lower doses",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Nonresponders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Second line agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Patient outcomes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H63502617\">",
"      PREVENTION OF INFECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H63501692\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/3542\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/3542|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?27/49/28432\" title=\"figure 1\">",
"      GHVD rates with prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/3542|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/19/8509\" title=\"table 1\">",
"      CYE MTX regimen prevent GVHD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?24/26/25004\" title=\"table 2\">",
"      Dose adj prevention GVHD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/10/3245\" title=\"table 3\">",
"      Drugs affecting cyclosporine",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/22/25960?source=related_link\">",
"      Clinical manifestations, diagnosis, and grading of acute graft-versus-host disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/25/23962?source=related_link\">",
"      Clinical manifestations, diagnosis, and grading of chronic graft-versus-host disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/2/34857?source=related_link\">",
"      Crystal-induced acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/50/42790?source=related_link\">",
"      Diagnostic approach to the patient with jaundice or asymptomatic hyperbilirubinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/38/26218?source=related_link\">",
"      Donor selection for hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/63/29690?source=related_link\">",
"      Drugs and the liver: Patterns of drug-induced liver injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/57/25498?source=related_link\">",
"      Immunizations after hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/41/30362?source=related_link\">",
"      Induction therapy for acute myeloid leukemia in younger adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/61/11223?source=related_link\">",
"      Major side effects of low-dose methotrexate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/1/34842?source=related_link\">",
"      Overview of immunosuppressive agents used for prevention and treatment of graft-versus-host disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/30/25066?source=related_link\">",
"      Overview of infections following hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/4/40009?source=related_link\">",
"      Pathogenesis and clinical features of hepatic sinusoidal obstruction syndrome (veno-occlusive disease) following hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/24/18826?source=related_link\">",
"      Pathogenesis of graft-versus-host disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/27/28090?source=related_link\">",
"      Pharmacology and side effects of cyclosporine and tacrolimus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/13/24792?source=related_link\">",
"      Prevention of acute graft-versus-host disease: Trials of T cell depletion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/3/42041?source=related_link\">",
"      Prevention of acute graft-versus-host disease: Trials of pharmacologic therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/57/32666?source=related_link\">",
"      Prophylaxis of infections in hematopoietic cell transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/31/29178?source=related_link\">",
"      Prophylaxis of invasive fungal infections in adult hematopoietic cell transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/32/6666?source=related_link\">",
"      Treatment of acute graft-versus-host disease: Clinical trials",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_11_10426="Initial evaluation and management of transient ischemic attack and minor stroke";
var content_f10_11_10426=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Initial evaluation and management of transient ischemic attack and minor stroke",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/11/10426/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/11/10426/contributors\">",
"     Karen L Furie, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/11/10426/contributors\">",
"     Hakan Ay, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/11/10426/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/11/10426/contributors\">",
"     Scott E Kasner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/11/10426/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/11/10426/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/11/10426/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 30, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transient ischemic attack (TIA) is now defined as a transient episode of neurologic dysfunction caused by focal brain, spinal cord, or retinal ischemia, without acute infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?10/11/10426/abstract/1\">",
"     1",
"    </a>",
"    ]. The end point is biologic (tissue injury) rather than arbitrary (24 hours). In keeping with this definition of TIA, ischemic stroke is defined as an infarction of central nervous system tissue.",
"   </p>",
"   <p>",
"    TIA was originally defined as a sudden onset of a focal neurologic symptom",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    sign lasting less than 24 hours and caused by reversible cerebral ischemia. However, this classic definition of TIA was inadequate for several reasons. Most notably, there is risk of permanent tissue injury (ie, infarction) even when focal transient neurologic symptoms last less than one hour. Furthermore, about one-half of patients with classically defined TIA syndromes (&lt;24 hours in duration) have corresponding appropriate ischemic lesions by brain MRI on diffusion-weighted or perfusion-weighted imaging. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/21/18773?source=see_link&amp;anchor=H6#H6\">",
"     \"Definition of transient ischemic attack\", section on 'Relationship of symptom duration and infarction'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thus, the benign connotation of the term TIA has been replaced by an understanding that even relatively brief ischemia can cause permanent brain injury.",
"   </p>",
"   <p>",
"    Of greater importance, patients with TIA or minor nondisabling stroke are at increased risk of recurrent stroke, and therefore require urgent evaluation and treatment since immediate intervention may substantially reduce the risk of recurrent stroke.",
"   </p>",
"   <p>",
"    This topic will review the diagnostic approach and early management of TIA and minor nondisabling stroke.",
"   </p>",
"   <p>",
"    Other aspects of transient cerebral ischemia are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/21/18773?source=see_link\">",
"     \"Definition of transient ischemic attack\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/46/40678?source=see_link\">",
"     \"Etiology and clinical manifestations of transient ischemic attack\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/37/36439?source=see_link\">",
"     \"Differential diagnosis of transient ischemic attack and stroke\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The management of patients hospitalized with acute stroke is reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/29/33242?source=see_link\">",
"     \"Initial assessment and management of acute stroke\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INITIAL EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who have had a suspected TIA require urgent evaluation due to the high stroke risk associated with TIA [",
"    <a class=\"abstract\" href=\"UTD.htm?10/11/10426/abstract/1\">",
"     1",
"    </a>",
"    ]. Furthermore, immediate intervention after a TIA may prevent a significant number of strokes. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Prognosis'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H17\">",
"     'Urgent treatment'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The initial evaluation of suspected TIA and minor nondisabling ischemic stroke includes basic laboratory studies that are suggested by the history and physical examination, an electrocardiogram, brain imaging, and neurovascular imaging. Laboratory testing is helpful in ruling out metabolic and hematologic causes of neurologic symptoms, including hypoglycemia, hyponatremia, and thrombocytosis.",
"   </p>",
"   <p>",
"    Several neurologic disorders give rise to transient focal neurologic symptoms, and these should be considered before establishing a diagnosis of TIA. In addition to TIAs, the most important and frequent causes of discrete self-limited attacks include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Seizures",
"     </li>",
"     <li>",
"      Migraine auras",
"     </li>",
"     <li>",
"      Syncope",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Less frequent causes include pressure- or position-related peripheral nerve or nerve root compression that causes transient paresthesias and numbness; peripheral vestibulopathies that cause transient episodic dizziness; and metabolic perturbations such as hypoglycemia and hepatic, renal, and pulmonary encephalopathies that can produce temporary aberrations in behavior and movement. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/37/36439?source=see_link\">",
"     \"Differential diagnosis of transient ischemic attack and stroke\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Hospitalization versus ambulatory evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whether hospitalization is required for TIA evaluation is not clear, but urgent assessment and management is essential regardless of inpatient or outpatient status [",
"    <a class=\"abstract\" href=\"UTD.htm?10/11/10426/abstract/1-5\">",
"     1-5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Possible advantages of hospitalization include facilitated early use of thrombolytic therapy and other medical management if symptoms recur, expedited TIA evaluation, and expedited institution of secondary prevention [",
"    <a class=\"abstract\" href=\"UTD.htm?10/11/10426/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The 2009 American Heart Association and American Stroke Association",
"    <span class=\"nowrap\">",
"     (AHA/ASA)",
"    </span>",
"    guidelines for the definition and evaluation of TIA state that it is reasonable to hospitalize patients with TIA who present within 72 hours of symptom onset and meet any of the following criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?10/11/10426/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      ABCD",
"      <sup>",
"       2",
"      </sup>",
"      score (",
"      <a class=\"graphic graphic_table graphicRef62381 \" href=\"UTD.htm?18/54/19308\">",
"       table 1",
"      </a>",
"      ) of &ge;3",
"     </li>",
"     <li>",
"      ABCD",
"      <sup>",
"       2",
"      </sup>",
"      score of 0 to 2 and uncertainty that the diagnostic workup can be completed within two days as an outpatient",
"     </li>",
"     <li>",
"      ABCD",
"      <sup>",
"       2",
"      </sup>",
"      score of 0 to 2 and other evidence that the event was caused by focal ischemia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The ABCD",
"    <sup>",
"     2",
"    </sup>",
"    score (ie, ABCD squared, for Age, Blood pressure, Clinical features, Duration of symptoms, and Diabetes) is a simple prognostic assessment tool with moderate predictive accuracy that was designed to identify patients at high risk of ischemic stroke in the first two days after TIA, as discussed later in detail (",
"    <a class=\"graphic graphic_table graphicRef62381 \" href=\"UTD.htm?18/54/19308\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H16\">",
"     'ABCD2 score'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The 2006 National Stroke Association (NSA) guidelines systematically reviewed, critically evaluated, and updated prior published guidelines for the management of TIA [",
"    <a class=\"abstract\" href=\"UTD.htm?10/11/10426/abstract/2\">",
"     2",
"    </a>",
"    ]. The following consensus recommendations regarding initial management were proposed, based mainly on evidence from observational studies and clinical experience:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The National Stroke Association recommends that hospitalization be considered for patients with a first TIA within the past 24 to 48 hours, and is generally recommended for patients with the following conditions:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Crescendo TIAs",
"     </li>",
"     <li>",
"      Duration of symptoms &gt;1 hour",
"     </li>",
"     <li>",
"      Symptomatic internal carotid artery stenosis &gt;50 percent",
"     </li>",
"     <li>",
"      Known cardiac source of embolus such as atrial fibrillation",
"     </li>",
"     <li>",
"      Known hypercoagulable state",
"     </li>",
"     <li>",
"      High risk of early stroke after TIA (see",
"      <a class=\"local\" href=\"#H16\">",
"       'ABCD2 score'",
"      </a>",
"      below)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients who need urgent evaluation and are not hospitalized should have rapid access to the following studies:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Brain imaging with head CT",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      MRI",
"     </li>",
"     <li>",
"      Neurovascular studies such as CT angiography (CTA), MR angiography (MRA),",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      ultrasound",
"     </li>",
"     <li>",
"      Electrocardiogram (ECG)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      All patients with a TIA within the past two weeks who are not hospitalized should undergo investigations within 24 to 48 hours to determine the mechanism of ischemia and subsequent preventive therapy.",
"     </li>",
"     <li>",
"      Patients who are not admitted should be informed that they need to go to an Emergency Department immediately if symptoms recur.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Hospital admission for TIA may be cost effective compared with no admission or specific intervention, particularly for high-risk patients eligible for intravenous (IV) tPA treatment. Supporting evidence comes from a cost-utility analysis of 24-hour hospitalization in the United States for patients diagnosed with recent TIA [",
"    <a class=\"abstract\" href=\"UTD.htm?10/11/10426/abstract/6\">",
"     6",
"    </a>",
"    ]. The study assumed that only those patients without absolute contraindications for IV tPA treatment would be admitted, and that hospitalized patients who developed a new stroke would be identified and treated with tPA within one hour of stroke onset. The overall cost effectiveness ratio was 55,044 dollars per quality adjusted life year, a value considered borderline cost effective. However, admission was cost effective for patients with a 24-hour stroke risk &gt;5 percent. In contrast, a subsequent report found that hospital admission for TIA was not cost effective in the United States compared with urgent (same-day) outpatient clinic evaluation [",
"    <a class=\"abstract\" href=\"UTD.htm?10/11/10426/abstract/7\">",
"     7",
"    </a>",
"    ], despite increased access to tPA in the hospital.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Brain imaging studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Brain imaging with CT or MRI is indicated in all patients with suspected TIA or minor nondisabling stroke as soon as possible, particularly those with symptoms suggestive of hemispheric TIA [",
"    <a class=\"abstract\" href=\"UTD.htm?10/11/10426/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The 2009",
"    <span class=\"nowrap\">",
"     AHA/ASA",
"    </span>",
"    guidelines recommend neuroimaging within 24 hours of symptom onset and further recommend MRI and diffusion-weighted MR imaging as preferred modalities [",
"    <a class=\"abstract\" href=\"UTD.htm?10/11/10426/abstract/1\">",
"     1",
"    </a>",
"    ]. Head CT is recommended if MRI cannot be performed.",
"   </p>",
"   <p>",
"    The presence of a brain infarct on CT or MRI scan located in an area suggested by the anatomy of the TIA or stroke (eg, in the left precentral gyrus or left internal capsule in a patient with transient right arm and leg weakness) identifies a vascular etiology of symptoms. Many patients whose clinical history and neurologic examination suggest that an attack was transient have infarcts in brain areas appropriate to the neurologic symptoms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/21/18773?source=see_link&amp;anchor=H6#H6\">",
"     \"Definition of transient ischemic attack\", section on 'Relationship of symptom duration and infarction'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Infarction is more likely to be identified acutely on MRI than on CT. Diffusion-weighted MRI imaging (DWI) and the apparent diffusion coefficient (ADC) map that is derived from DWI can discriminate tissue injury very early after the onset of ischemic symptoms. DWI reliably confirms whether only ischemia has occurred or if there has also been an element of infarction. These techniques can differentiate stroke from TIA within the first hours after symptom onset. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/56/17290?source=see_link\">",
"     \"Neuroimaging of acute ischemic stroke\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other diseases that mimic TIAs usually can be identified by neuroimaging techniques, although pathological biopsy examination is occasionally needed (eg, temporal artery biopsy or examination of the cerebrospinal fluid). In rare cases, brain biopsy is indicated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/37/36439?source=see_link\">",
"     \"Differential diagnosis of transient ischemic attack and stroke\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Neurovascular evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The single most important issue to resolve in the initial evaluation of TIA and ischemic stroke is whether or not there is an obstructive lesion in a larger artery supplying the affected territory. Noninvasive options for evaluation of large vessel occlusive disease include magnetic resonance angiography (MRA), computed tomography angiography (CTA), carotid duplex ultrasonography (CDUS), and transcranial Doppler ultrasonography (TCD). The choice among these depends upon on local availability and expertise as well as individual patient characteristics and preference [",
"    <a class=\"abstract\" href=\"UTD.htm?10/11/10426/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/56/17290?source=see_link\">",
"     \"Neuroimaging of acute ischemic stroke\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The 2009",
"    <span class=\"nowrap\">",
"     AHA/ASA",
"    </span>",
"    guidelines recommend routine noninvasive imaging of the cervicocephalic vessels as part of the evaluation of patients with suspected TIA [",
"    <a class=\"abstract\" href=\"UTD.htm?10/11/10426/abstract/1\">",
"     1",
"    </a>",
"    ]. The guidelines note that it is reasonable to obtain noninvasive testing of the intracranial vasculature if knowledge of an intracranial stenosis or occlusion will alter management.",
"   </p>",
"   <p>",
"    Although noninvasive studies are considered reliable for the exclusion of intracranial stenosis, the 2009",
"    <span class=\"nowrap\">",
"     AHA/ASA",
"    </span>",
"    guidelines conclude that reliable diagnosis of the presence and degree of intracranial stenosis requires evaluation with catheter angiography to confirm abnormalities detected with noninvasive testing [",
"    <a class=\"abstract\" href=\"UTD.htm?10/11/10426/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A focused Doppler and neuroimaging test (eg, MRI or CT angiography) can be used to establish an arterial source of the embolism or low flow. These tests can exclude an arterial source in cases where the symptoms are due to proximal embolism from the heart, aorta, or an unknown source, and in cases where the symptoms are due to small vessel disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/19/31033?source=see_link\">",
"     \"Evaluation of carotid artery stenosis\"",
"    </a>",
"    .) The following are important aspects regarding such testing:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Duplex ultrasound and transcranial Doppler studies require considerable technical skill to perform and an experienced interpreter. They should be used only if there is adequate confidence that the testing and interpretation is reliable.",
"     </li>",
"     <li>",
"      Conventional angiography is associated with a small risk of stroke and should be performed by experienced physicians. It should only be considered when the diagnosis is uncertain by noninvasive methods, and when proof of the diagnosis is essential for proper stroke preventive therapy. As an example, if one of the stroke-producing arterial lesions noted above is suspected but not confirmed by conventional noninvasive Doppler, MRI, or CT methods, then angiography can be considered.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The distinction between artery-to-artery and other (mainly cardiac) sources of embolism can be difficult. Suspicion of the former typically arises once vascular pathology in a large vessel has been identified (eg, with noninvasive testing). Repetitive spells within a single vascular territory are also suggestive of an artery-to-artery source, as is a normal echocardiogram.",
"   </p>",
"   <p>",
"    The following sections review the diagnostic studies are useful to confirm the origin of transient cerebral ischemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Anterior circulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;MRI with MR angiography or CT with CT angiography can be used to identify the source of the stenosis when TIA or minor nondisabling stroke due to low-flow or artery-to-artery embolism is suspected in the anterior cerebral circulation (",
"    <a class=\"graphic graphic_figure graphicRef51410 \" href=\"UTD.htm?2/4/2122\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef65199 \" href=\"UTD.htm?41/34/42531\">",
"     figure 2",
"    </a>",
"    ). Diffusion and perfusion-weighted MRI imaging can describe areas of the brain that are focally ischemic or infarcted.",
"   </p>",
"   <p>",
"    Duplex ultrasound and transcranial Doppler can evaluate flow at the bifurcation of the common carotid artery, in the siphon portion of the internal carotid artery, in the ophthalmic artery, and in the middle, anterior, and posterior cerebral artery stems. A positive test rapidly identifies the location of the arterial pathology giving rise to the hemodynamically significant low-flow symptoms. However, a negative test does not rule out such a phenomenon. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/19/31033?source=see_link\">",
"     \"Evaluation of carotid artery stenosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Extracranial carotid artery evaluation is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/19/31033?source=see_link\">",
"     \"Evaluation of carotid artery stenosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Posterior circulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with symptoms referable to the posterior circulation should have MRA or CTA of the neck. Extracranial vertebral disease is a relatively uncommon source of stroke, but dissection and vertebral origin atherosclerosis can be missed if these vessels are not imaged [",
"    <a class=\"abstract\" href=\"UTD.htm?10/11/10426/abstract/8\">",
"     8",
"    </a>",
"    ]. The vertebral origins are best imaged noninvasively using MRA with contrast or CTA.",
"   </p>",
"   <p>",
"    Duplex ultrasound of the proximal vertebral artery or transcranial Doppler insonation of flow in the distal vertebral arteries and in the basilar artery can give reliable clues to the presence of posterior cerebral circulation disease (",
"    <a class=\"graphic graphic_figure graphicRef81813 \" href=\"UTD.htm?9/51/10042\">",
"     figure 3",
"    </a>",
"    ). However, the diagnosis is confirmed only by MRA or CTA.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Vertebral artery stenosis is suspected when duplex ultrasound of mid-vertebral artery flow shows a reduced peak systolic velocity. MR angiography of the aortic arch and CT angiography can identify vertebral origin lesions.",
"     </li>",
"     <li>",
"      Distal vertebral lesions and proximal basilar lesions that give rise to embolism can be confirmed by CTA or MRA.",
"     </li>",
"     <li>",
"      Transcranial Doppler assessment of flow at the top of the basilar artery may be helpful in identifying emboli there that obstruct flow but may not block it completely. The demonstration of normal flow at the top of the basilar artery does not exclude such a lesion, and CTA or MRA are suggested in this setting if clinical suspicion is high. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/22/39273?source=see_link\">",
"       \"Posterior circulation cerebrovascular syndromes\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Rarely, conventional angiography with its risks is necessary to confirm the diagnosis of posterior cerebral circulation disease in order to plan for therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Intracranial large vessels",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atherosclerotic stenosis of the major intracranial arteries (carotid siphon, middle cerebral artery, vertebral artery, and basilar artery) is an important cause of ischemic stroke, especially in blacks, Asians, and Hispanics. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/61/2010?source=see_link&amp;anchor=H2#H2\">",
"     \"Intracranial large artery atherosclerosis\", section on 'Epidemiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The gold standard for establishing the diagnosis of intracranial large artery disease is conventional cerebral angiography. Noninvasive studies such as TCD, MRA, and CTA may be used, but noninvasive testing may not be sufficiently reliable to diagnose intracranial arterial stenosis accurately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/61/2010?source=see_link&amp;anchor=H3#H3\">",
"     \"Intracranial large artery atherosclerosis\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Despite this limitation, we suggest the use of noninvasive methods (CTA, MRA, or TCD) for the initial evaluation of intracranial vessels in patients with the following higher prevalence situations [",
"    <a class=\"abstract\" href=\"UTD.htm?10/11/10426/abstract/8\">",
"     8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Patients of black, Asian, or Hispanic ethnicity",
"     </li>",
"     <li>",
"      Patients younger than age 50 without clear cardiac or extracranial source",
"     </li>",
"     <li>",
"      Patients with recurrent stereotyped TIAs",
"     </li>",
"     <li>",
"      Patients with posterior circulation event and no clear cardiac source",
"     </li>",
"     <li>",
"      Patients with preoperative evaluation of collateral circulation before carotid endarterectomy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In most cases, cardiac and extracranial neurovascular imaging should be performed prior to the evaluation of intracranial large arteries, as the pretest probability of these entities is higher in both younger and older patients [",
"    <a class=\"abstract\" href=\"UTD.htm?10/11/10426/abstract/8\">",
"     8",
"    </a>",
"    ]. In addition, definitive management for most causes of intracranial disease is unclear. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/61/2010?source=see_link\">",
"     \"Intracranial large artery atherosclerosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Small vessels",
"    </span>",
"    &nbsp;&mdash;&nbsp;Small vessels are not directly visible with any of the currently available imaging techniques. However, evaluation of the extracranial carotid artery is recommended for patients with lacunar infarction or suspected small vessel (lacunar) TIA referable to the anterior circulation [",
"    <a class=\"abstract\" href=\"UTD.htm?10/11/10426/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Further noninvasive neurovascular studies in the vascular territory appropriate to the symptoms may be considered in the following settings [",
"    <a class=\"abstract\" href=\"UTD.htm?10/11/10426/abstract/8\">",
"     8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Absence of vascular risk factors",
"     </li>",
"     <li>",
"      Clinically atypical lacunar syndrome",
"     </li>",
"     <li>",
"      Evidence of a lacune in an atypical territory by imaging",
"     </li>",
"     <li>",
"      Typical lacunar syndrome with nonlacunar infarct by imaging",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Lacunar infarction and small vessel disease are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/59/4026?source=see_link\">",
"     \"Lacunar infarcts\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Cardiac evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;A possible cardiac source should be considered in patients with embolic TIA or minor nondisabling stroke caused by embolism. At minimum, such patients should have a standard 12-lead electrocardiogram as soon as possible after symptom onset [",
"    <a class=\"abstract\" href=\"UTD.htm?10/11/10426/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Echocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Echocardiography is indicated for patients who are candidates for anticoagulation or for patients who have suspected endocarditis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/11/10426/abstract/8\">",
"     8",
"    </a>",
"    ]. It is not clearly indicated for patients who require anticoagulation for another reason (eg, for atrial fibrillation) unless there is a suspicion of endocarditis.",
"   </p>",
"   <p>",
"    Transthoracic echocardiography (TTE) and transesophageal echocardiography (TEE) methods each have unique advantages.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      TTE is noninvasive, but it can be limited by an inadequate window in large patients.",
"     </li>",
"     <li>",
"      TTE is better than TEE for detecting apical left ventricular thrombi and mitral annular calcification in the elderly.",
"     </li>",
"     <li>",
"      TTE can provide a better estimate of left ventricular function than TEE.",
"     </li>",
"     <li>",
"      TEE is the test of choice for evaluation of aortic atherosclerosis. However, definitive management of this entity is not clear, and some experts argue that it is not essential to make this diagnosis [",
"      <a class=\"abstract\" href=\"UTD.htm?10/11/10426/abstract/8\">",
"       8",
"      </a>",
"      ]. Suspicion for aortic disease is increased in the setting of multiple arterial territory infarcts without clear cardiac source or a history of peripheral artery disease.",
"     </li>",
"     <li>",
"      TEE is superior to TTE for detecting spontaneous echo contrast (\"smoke-like\" echoes) within the left atrium, a finding which is associated with left atrial thrombi.",
"     </li>",
"     <li>",
"      TEE is superior for detecting abnormalities of the interatrial septum (eg, atrial septal defect, patent foramen ovale, and interatrial septal aneurysm) that are associated with thromboembolism.",
"     </li>",
"     <li>",
"      TEE is also the best way to visualize the left atrium, including the atrial appendage, which is the main site of thrombus formation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    2009",
"    <span class=\"nowrap\">",
"     AHA/ASA",
"    </span>",
"    guidelines conclude that echocardiography, at least transthoracic echocardiography, is reasonable when no cause for TIA or ischemic stroke has been identified by other aspects of the work-up [",
"    <a class=\"abstract\" href=\"UTD.htm?10/11/10426/abstract/1\">",
"     1",
"    </a>",
"    ]. Transesophageal echocardiography, useful for identifying patent foramen ovale, aortic arch atherosclerosis, and valvular disease, is reasonable when identification of any of these conditions would alter management.",
"   </p>",
"   <p>",
"    The use of echocardiography for the detection of cardiac sources of embolism is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/4/12361?source=see_link\">",
"     \"Echocardiography in detection of intracardiac sources of embolism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although transthoracic echocardiography is less sensitive than TEE for most of the disorders associated with cardiac embolism, we recommend TTE with agitated saline contrast as a first test because it is noninvasive and better tolerated. We proceed to TEE if TTE is negative and treatment decisions hinge on identifying one of the possible TEE findings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Cardiac monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiac monitoring is an essential part of evaluation to exclude atrial fibrillation in the setting of embolic TIA or stroke. The 2009",
"    <span class=\"nowrap\">",
"     AHA/ASA",
"    </span>",
"    guidelines consider prolonged cardiac monitoring with inpatient telemetry or Holter monitor to be useful for patients without a clear etiology after initial brain imaging and electrocardiography [",
"    <a class=\"abstract\" href=\"UTD.htm?10/11/10426/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Holter monitoring or continuous telemetry may be most useful in patients with a history of palpitations, paroxysmal atrial fibrillation, evidence of spontaneous echo contrast on TEE, and cryptogenic TIA [",
"    <a class=\"abstract\" href=\"UTD.htm?10/11/10426/abstract/8\">",
"     8",
"    </a>",
"    ]. Although the electrocardiogram and Holter monitoring can identify patients who have atrial fibrillation, the demonstration of normal sinus rhythm does not exclude intermittent atrial fibrillation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/32/36361?source=see_link\">",
"     \"Ambulatory monitoring in the assessment of cardiac arrhythmias\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Blood cultures, an erythrocyte sedimentation rate, or antinuclear antibody testing are indicated if bacterial or nonbacterial endocarditis is suspected.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Blood tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with suspected TIA, the following blood tests should be considered [",
"    <a class=\"abstract\" href=\"UTD.htm?10/11/10426/abstract/1,2,8\">",
"     1,2,8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Complete blood count (CBC)",
"     </li>",
"     <li>",
"      Prothrombin time and partial thromboplastin time",
"     </li>",
"     <li>",
"      Serum electrolytes and creatinine",
"     </li>",
"     <li>",
"      Fasting blood glucose and lipids",
"     </li>",
"     <li>",
"      Erythrocyte sedimentation rate (ESR)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Suspicion for blood disorders as potential sources of cerebral ischemia should be raised in the following settings [",
"    <a class=\"abstract\" href=\"UTD.htm?10/11/10426/abstract/8\">",
"     8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Cryptogenic stroke or TIA",
"     </li>",
"     <li>",
"      Age 45 or younger",
"     </li>",
"     <li>",
"      History of clotting dysfunction",
"     </li>",
"     <li>",
"      Multiple venous and arterial occlusions",
"     </li>",
"     <li>",
"      Suspected or confirmed cancer",
"     </li>",
"     <li>",
"      Family history of thrombotic events",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In these settings, additional blood and coagulation studies should be considered. This topic is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/47/28410?source=see_link&amp;anchor=H39#H39\">",
"     \"Overview of the evaluation of stroke\", section on 'Blood tests'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;TIA is a neurologic emergency because patients with TIA and minor nondisabling stroke are at increased risk of recurrent stroke [",
"    <a class=\"abstract\" href=\"UTD.htm?10/11/10426/abstract/9-16\">",
"     9-16",
"    </a>",
"    ]. This risk is illustrated by the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A meta-analysis of 11 observational studies published through December 2006 found that the risk of stroke at 2 days, 30 days, and 90 days after TIA was 3.5, 8.0, and 9.2 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?10/11/10426/abstract/14\">",
"       14",
"      </a>",
"      ]. In the three studies that used active ascertainment of stroke outcome (ie, face-to-face evaluation by a practitioner at three months rather than use of administrative data), the 2, 30, and 90 day risk of stroke after TIA was even higher (9.9, 13.4, and 17.3 percent, respectively). Similar findings were reported in a meta-analysis of 18 cohorts published through June 2007 [",
"      <a class=\"abstract\" href=\"UTD.htm?10/11/10426/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A prospective observational study of 1380 patients with TIA and 3855 patients with ischemic stroke found that subsequent stroke incidence during the hospital stay was 8 percent for patients with TIA and 7 percent for patients with ischemic stroke [",
"      <a class=\"abstract\" href=\"UTD.htm?10/11/10426/abstract/18\">",
"       18",
"      </a>",
"      ]. During the first six months after the initial ischemic event, recurrent stroke incidence was 13 percent for both groups. Two percent of patients with TIA died during hospital stay, and 17 percent were dependent at follow-up.",
"     </li>",
"     <li>",
"      A well-designed prospective cohort study of 2447 participants from the Dutch TIA trial found that the risk for major vascular events and stroke was highest shortly after TIA or minor nondisabling stroke, declined to its lowest point at about three years, and then progressively increased over the remainder of the 10-year follow-up (",
"      <a class=\"graphic graphic_figure graphicRef53609 \" href=\"UTD.htm?21/7/21630\">",
"       figure 4",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?10/11/10426/abstract/19\">",
"       19",
"      </a>",
"      ]. In contrast, the risk for mortality gradually rose throughout the study. By 10 years, 60 percent had died and 54 percent had experienced new vascular events (stroke and myocardial infarction). Event-free survival was 48 percent. Predictive factors for risk of vascular events and death included age over 65 years, diabetes, claudication, previous vascular surgery, and pathologic Q waves on baseline electrocardiogram.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The urgency associated with TIA derives also from the observation that TIAs are most likely to occur in the hours and days immediately preceding ischemic stroke. As an example, a study that analyzed four cohorts of patients who had recent ischemic stroke found that TIAs occurred most often in the 48 hours prior to the stroke [",
"    <a class=\"abstract\" href=\"UTD.htm?10/11/10426/abstract/20\">",
"     20",
"    </a>",
"    ]. Another study found that the risk of ischemic stroke occurring within 24 hours of a probable or definite TIA was approximately 5 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?10/11/10426/abstract/21\">",
"     21",
"    </a>",
"    ]. Of all ischemic strokes during the 30 days after a first TIA, 42 percent occurred within the first 24 hours. This may be an overestimate related to the difficulty distinguishing a single ischemic event (stroke) with fluctuating symptoms from separate events (TIA followed by stroke) within a short period of time. Nevertheless, these observations underscore the high early risk of developing a permanent deficit after transient ischemic symptoms and the importance of urgent assessment, risk stratification, and treatment.",
"   </p>",
"   <p>",
"    Given this short time window and high risk of stroke &mdash; 4 to 10 percent in the first 48 hours after TIA [",
"    <a class=\"abstract\" href=\"UTD.htm?10/11/10426/abstract/14\">",
"     14",
"    </a>",
"    ] &mdash; neurologic evaluation of and intervention for TIA should occur urgently. Furthermore, clinical TIAs associated with evidence of infarction by neuroimaging may be a marker of particularly high risk for ischemic stroke. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/21/18773?source=see_link&amp;anchor=H5#H5\">",
"     \"Definition of transient ischemic attack\", section on 'Transient symptoms with infarction'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Recognition and urgent evaluation of TIAs can identify patients who may benefit from preventive therapy or from revascularization of large vessels such as the carotid artery. As examples, premonitory carotid territory TIAs occur in approximately 50 to 75 percent of patients with ischemic stroke from extracranial carotid disease [",
"    <a class=\"abstract\" href=\"UTD.htm?10/11/10426/abstract/22-24\">",
"     22-24",
"    </a>",
"    ], and vertebrobasilar TIAs are associated with a risk of subsequent stroke or death that is similar to or possibly higher than that seen with carotid TIAs [",
"    <a class=\"abstract\" href=\"UTD.htm?10/11/10426/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H311703\">",
"    <span class=\"h2\">",
"     TIA etiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;TIA caused by vascular pathologies (ie, large artery atherosclerosis and small vessel disease) appears to confer a higher risk of subsequent stroke than cardiac and other nonvascular subtypes of TIA. However, the available evidence is not entirely consistent:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a prospective series of 410 patients with TIA, the large artery atherosclerosis subtype of TIA was associated with a higher risk of stroke recurrence at 7 and 90 days than other TIA subtypes (cardioembolism, small vessel disease, undetermined, or other determined cause) [",
"      <a class=\"abstract\" href=\"UTD.htm?10/11/10426/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A prospective population-based study from Ireland found that carotid stenosis &ge; 50 percent was an independent predictor of stroke at 90 days after TIA, whereas no association was observed between atrial fibrillation and subsequent stroke [",
"      <a class=\"abstract\" href=\"UTD.htm?10/11/10426/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another prospective population-based study from the United Kingdom reported that TIA due to small vessel vasculopathy was associated with a higher risk of early stroke than TIA due to other causes [",
"      <a class=\"abstract\" href=\"UTD.htm?10/11/10426/abstract/28\">",
"       28",
"      </a>",
"      ]. The stroke risk was particularly elevated after multiple stereotyped small vessel TIAs occurring in a brief period of time and characterized by motor or sensory symptoms but no cortical signs &ndash; the so-called &ldquo;capsular warning syndrome&rdquo; [",
"      <a class=\"abstract\" href=\"UTD.htm?10/11/10426/abstract/29\">",
"       29",
"      </a>",
"      ] or &ldquo;stuttering lacunar syndrome&rdquo;. Although data are limited, the risk of early (within seven days) stroke after such events may be &gt;40 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?10/11/10426/abstract/28,29\">",
"       28,29",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     ABCD2 score",
"    </span>",
"    &nbsp;&mdash;&nbsp;Methods that can reliably assess the risk of stroke after TIA in individual patients would be useful for triaging patients. The discussion that follows applies to the traditional time-based definition of TIA, which is characterized clinically by the temporary nature (&lt;24 hours) of the associated neurologic symptoms.",
"   </p>",
"   <p>",
"    A simple assessment called the ABCD",
"    <sup>",
"     2",
"    </sup>",
"    score (ie, ABCD squared, for Age, Blood pressure, Clinical features, Duration of symptoms, and Diabetes) may be used to identify patients at high risk of ischemic stroke in the first seven days after TIA [",
"    <a class=\"abstract\" href=\"UTD.htm?10/11/10426/abstract/30\">",
"     30",
"    </a>",
"    ]. The ABCD",
"    <sup>",
"     2",
"    </sup>",
"    score is tallied as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Age (&ge;60 years = 1 point)",
"     </li>",
"     <li>",
"      Blood pressure elevation when first assessed after TIA (systolic &ge;140 mmHg or diastolic &ge;90 mmHg = 1 point)",
"     </li>",
"     <li>",
"      Clinical features (unilateral weakness = 2 points; isolated speech disturbance = 1 point; other = 0 points)",
"     </li>",
"     <li>",
"      Duration of TIA symptoms (&ge;60 minutes = 2 points; 10 to 59 minutes = 1 point; &lt;10 minutes = 0 points)",
"     </li>",
"     <li>",
"      Diabetes (present = 1 point)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The ABCD",
"    <sup>",
"     2",
"    </sup>",
"    score was based upon two earlier prognostic scores for TIA &mdash; the California score [",
"    <a class=\"abstract\" href=\"UTD.htm?10/11/10426/abstract/12\">",
"     12",
"    </a>",
"    ] and the ABCD score [",
"    <a class=\"abstract\" href=\"UTD.htm?10/11/10426/abstract/31\">",
"     31",
"    </a>",
"    ] &mdash; and was derived and validated using independent study populations (two derivation and four validation cohorts) from the US (California) and the UK (Oxford) that included 4809 patients with TIA [",
"    <a class=\"abstract\" href=\"UTD.htm?10/11/10426/abstract/30\">",
"     30",
"    </a>",
"    ]. The unified ABCD",
"    <sup>",
"     2",
"    </sup>",
"    score was a slightly more accurate predictor of stroke risk than either of its predecessors in these populations.",
"   </p>",
"   <p>",
"    Estimated two-day stroke risks determined by the ABCD",
"    <sup>",
"     2",
"    </sup>",
"    score in the combined derivation and validation cohorts were as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?10/11/10426/abstract/30\">",
"     30",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Score 6 to 7: High two-day stroke risk (8 percent)",
"     </li>",
"     <li>",
"      Score 4 to 5: Moderate two-day stroke risk (4 percent)",
"     </li>",
"     <li>",
"      Score 0 to 3: Low two-day stroke risk (1 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The ABCD",
"    <sup>",
"     2",
"    </sup>",
"    score was designed to be used in primary care settings to stratify patients according to stroke risk and thus identify those who required emergency assessment by specialists. However, its predictive performance is not optimal, as illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The predictive power of the ABCD",
"      <sup>",
"       2",
"      </sup>",
"      score is generally lower in hospital settings compared with population-based settings, thus limiting its utility for high-risk populations [",
"      <a class=\"abstract\" href=\"UTD.htm?10/11/10426/abstract/30,32,33\">",
"       30,32,33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A meta-analysis found that the score performance was also poor in settings of low baseline risk and in TIA diagnosed by nonspecialists [",
"      <a class=\"abstract\" href=\"UTD.htm?10/11/10426/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a large multicenter validation study in which the ABCD",
"      <sup>",
"       2",
"      </sup>",
"      score was prospectively calculated for patients with TIA at the bedside in the emergency department, the score was inaccurate as a predictor of stroke at 7 or 90 days after TIA, with poor sensitivity for threshold scores &gt;5 and poor specificity at lower thresholds [",
"      <a class=\"abstract\" href=\"UTD.htm?10/11/10426/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Other validation studies of the ABCD",
"      <sup>",
"       2",
"      </sup>",
"      score have been inconsistent, with results ranging from high predictive value to predictions slightly better than chance [",
"      <a class=\"abstract\" href=\"UTD.htm?10/11/10426/abstract/27,36-44\">",
"       27,36-44",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Nevertheless, a few studies have suggested that the ABCD",
"    <sup>",
"     2",
"    </sup>",
"    score is useful for distinguishing a true TIA from TIA mimics [",
"    <a class=\"abstract\" href=\"UTD.htm?10/11/10426/abstract/45-48\">",
"     45-48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H979759\">",
"    <span class=\"h2\">",
"     Importance of infarction",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is accumulating evidence suggesting that the findings of acute infarction on diffusion-weighted MRI (DWI) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/11/10426/abstract/39,40,49,50\">",
"     39,40,49,50",
"    </a>",
"    ] or acute or chronic ischemic lesions on CT [",
"    <a class=\"abstract\" href=\"UTD.htm?10/11/10426/abstract/51\">",
"     51",
"    </a>",
"    ] after a transient ischemic event are important predictors of stroke. In patients with an imaging-positive transient event, the 90 day risk of stroke appears to be as high as 14 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?10/11/10426/abstract/39,40,43,49\">",
"     39,40,43,49",
"    </a>",
"    ]. In contrast, after an imaging-negative transient event, the corresponding risk is &lt;1 percent.",
"   </p>",
"   <p>",
"    The improved prognostic accuracy that accrues from information about the presence or absence of infarction in TIA is particularly important when considering the impact of the modern tissue-based definition of TIA, which defined as a transient episode of neurologic dysfunction caused by focal brain, spinal cord, or retinal ischemia,",
"    <strong>",
"     without",
"    </strong>",
"    acute infarction (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/21/18773?source=see_link&amp;anchor=H2#H2\">",
"     \"Definition of transient ischemic attack\", section on 'Tissue-based definition'",
"    </a>",
"    ). One consequence is that TIA without infarction is a low-risk condition [",
"    <a class=\"abstract\" href=\"UTD.htm?10/11/10426/abstract/52\">",
"     52",
"    </a>",
"    ]. It is not an emergency anymore.",
"   </p>",
"   <p>",
"    Another consequence of the tissue-based definition of TIA is that traditionally defined TIA with infarction is reclassified as ischemic stroke. However, the early (seven-day) risk of recurrent stroke after traditionally defined TIA associated with imaging evidence of infarction is up to 15 times higher than the corresponding risk after conventionally defined ischemic stroke (ie, with symptoms that persist &ge;24 hours) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/11/10426/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]. Thus, classifying &ldquo;TIA associated with infarction&rdquo; and &ldquo;ischemic stroke&rdquo; in the same category may unintentionally obscure the high risk of recurrent stroke that follows TIA with infarction.",
"   </p>",
"   <p>",
"    Risk models that combine information from acute DWI, noninvasive angiography and presumed TIA etiology may improve the accuracy of stroke risk prediction after TIA [",
"    <a class=\"abstract\" href=\"UTD.htm?10/11/10426/abstract/39,40,53,55,56\">",
"     39,40,53,55,56",
"    </a>",
"    ]. As examples, the CIP model incorporated diffusion-weighted MRI findings with a dichotomized ABCD",
"    <sup>",
"     2",
"    </sup>",
"    score [",
"    <a class=\"abstract\" href=\"UTD.htm?10/11/10426/abstract/39\">",
"     39",
"    </a>",
"    ]. The result was improved accuracy, compared with the ABCD",
"    <sup>",
"     2",
"    </sup>",
"    score alone, for stroke risk predictions at both two days and seven days after TIA. Another prognostic instrument &ndash; the Recurrence Risk Estimator score &ndash; combines clinical and imaging information [",
"    <a class=\"abstract\" href=\"UTD.htm?10/11/10426/abstract/56\">",
"     56",
"    </a>",
"    ], and has shown promise for predicting stroke following traditionally defined ischemic stroke and following TIA with infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?10/11/10426/abstract/52,57\">",
"     52,57",
"    </a>",
"    ]. Additional research and validation of these models is needed to determine whether they have any utility for clinical practice.",
"   </p>",
"   <p>",
"    The requirement for MRI limits the widespread applicability of advanced risk prediction models.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     URGENT TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The preferred approach to treatment of TIA and ischemic stroke is to determine the pathophysiology of the event so that specific stroke preventive therapy can be prescribed. An overview of the treatment of specific causes of TIA and ischemic stroke is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/33/32281?source=see_link\">",
"     \"Secondary prevention for specific causes of ischemic stroke and transient ischemic attack\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to specific treatment, accumulating evidence suggests that immediate intervention after a TIA or minor nondisabling ischemic stroke can reduce the risk of recurrent stroke compared with delayed intervention. This point is illustrated by the following reports:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The prospective EXPRESS study evaluated the impact of expediting outpatient treatment for TIA or minor nondisabling ischemic stroke [",
"      <a class=\"abstract\" href=\"UTD.htm?10/11/10426/abstract/58\">",
"       58",
"      </a>",
"      ]. In order to compare traditional with expedited treatment, the study was conducted in two phases. In phase one, 323 patients were seen in a traditional clinic setting where evaluation required a scheduled appointment and treatment recommendations were made to referring physicians. In phase two, 297 patients were seen in an urgent walk-in stroke clinic without having to arrange an appointment, and treatment was implemented immediately by clinic practitioners. In both phases, treatment of confirmed TIA or stroke was individualized according to patient characteristics, but generally included antiplatelet or anticoagulant therapy, statin therapy, antihypertensive medication, and carotid endarterectomy as required. Although EXPRESS was not a randomized trial, the study was nested in an ongoing population-based study of stroke and TIA, thus minimizing the potential problems of incomplete ascertainment and selection bias that complicate observational studies. The following observations were reported [",
"      <a class=\"abstract\" href=\"UTD.htm?10/11/10426/abstract/58\">",
"       58",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The median delay to assessment in the outpatient clinic was significantly reduced from phase one to phase two (3 days versus &lt;1 day), as was the median delay to first prescription of treatment (20 days versus 1 day)",
"     </li>",
"     <li>",
"      The risk of recurrent stroke at 90 days was significantly lower for patients seen in phase two than for those seen in phase one (2.1 versus 10.3 percent; adjusted hazard ratio 0.20, 95% CI 0.08-0.49)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The observational SOS-TIA study analyzed the rapid assessment of 1085 patients with suspected TIA in a hospital-based clinic with 24 hour access [",
"      <a class=\"abstract\" href=\"UTD.htm?10/11/10426/abstract/59\">",
"       59",
"      </a>",
"      ]. Patients were evaluated within four hours of admission, and those with a final diagnosis of confirmed or possible TIA (n = 845) received immediate treatment with a stroke prevention program that included antiplatelet or anticoagulant treatment",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      carotid revascularization as appropriate. At 90 days, the observed stroke rate was much lower than an expected stroke rate predicted by the ABCD",
"      <sup>",
"       2",
"      </sup>",
"      scores (1.24 versus 5.96 percent). (See",
"      <a class=\"local\" href=\"#H16\">",
"       'ABCD2 score'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      The results of this study should be interpreted with caution because of methodologic limitations, including the use of ABCD",
"      <sup>",
"       2",
"      </sup>",
"      scores to predict stroke risk, rather than determination of stroke risk in a control population [",
"      <a class=\"abstract\" href=\"UTD.htm?10/11/10426/abstract/60\">",
"       60",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Early evaluation and intervention for symptomatic carotid artery disease may be an important aspect of stroke prevention. Supporting evidence comes from a pooled analysis of the NASCET and ECST trials, which found that early carotid endarterectomy (within two weeks of a nondisabling stroke or TIA) significantly improved outcome compared with later surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?10/11/10426/abstract/61\">",
"     61",
"    </a>",
"    ]. Thus, early identification of symptomatic carotid disease is critical. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/1/21530?source=see_link&amp;anchor=H9#H9\">",
"     \"Management of symptomatic carotid atherosclerotic disease\", section on 'Timing of surgery'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Given these data, we recommend that appropriate diagnostic evaluation and stroke prevention treatment be implemented without delay, preferably within one day of the ischemic event, for patients who present with TIA or minor nondisabling ischemic stroke.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?23/55/24435?source=see_link\">",
"       \"Patient information: Stroke (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?34/22/35170?source=see_link\">",
"       \"Patient information: Transient ischemic attack (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?37/37/38484?source=see_link\">",
"       \"Patient information: Stroke symptoms and diagnosis (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?20/18/20772?source=see_link\">",
"       \"Patient information: Transient ischemic attack (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The initial evaluation of suspected TIA and minor nondisabling ischemic stroke includes brain imaging, neurovascular imaging, and a cardiac evaluation. Laboratory testing is helpful in ruling out metabolic and hematologic causes of neurologic symptoms. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Initial evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      TIA and minor nondisabling ischemic stroke are associated with a high early risk of recurrent stroke. The stroke risk in the first two days after TIA is approximately 4 to 10 percent. The ABCD",
"      <sup>",
"       2",
"      </sup>",
"      score (",
"      <a class=\"graphic graphic_table graphicRef62381 \" href=\"UTD.htm?18/54/19308\">",
"       table 1",
"      </a>",
"      ) may identify patients at high risk of ischemic stroke in this time period, but its predictive performance is not optimal. Risk models that combine information from brain imaging, neurovascular imaging, and presumed TIA etiology in addition to the clinical ABCD",
"      <sup>",
"       2",
"      </sup>",
"      score may improve the accuracy of stroke risk prediction after TIA. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Accumulating evidence suggests that immediate evaluation and intervention after a TIA or minor ischemic reduces the risk of recurrent stroke. For patients who present with TIA or minor nondisabling ischemic stroke, we recommend implementation of appropriate diagnostic evaluation and stroke prevention treatment without delay, preferably within one day of the ischemic event (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Urgent treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Risk factor management is appropriate for all patients with ischemic stroke or TIA, and most patients should be treated with all available risk reduction strategies. Currently viable strategies include blood pressure reduction, statins, antiplatelet therapy, and lifestyle modification, including smoking cessation. These interventions are discussed in greater detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/61/30682?source=see_link\">",
"       \"Secondary prevention of stroke: Risk factor reduction\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      An overview of the treatment for specific causes of TIA and ischemic stroke is provided separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/33/32281?source=see_link\">",
"       \"Secondary prevention for specific causes of ischemic stroke and transient ischemic attack\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Some important recommendations apply to select patients with TIA:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For patients with TIA or ischemic stroke of atherothrombotic, lacunar (small vessel occlusive), or cryptogenic type, we recommend treatment with an antiplatelet agent (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). This issue and the choice among specific antiplatelet agents (ie,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      , aspirin plus extended-release",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/25/41366?source=see_link\">",
"       dipyridamole",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      ) are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/35/2618?source=see_link\">",
"       \"Antiplatelet therapy for secondary prevention of stroke\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients with atrial fibrillation and a recent ischemic stroke or TIA, we recommend oral anticoagulation (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). We recommend",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      for patients with atrial fibrillation and cardioembolic stroke who have contraindications to anticoagulant therapy (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Prevention of recurrent stroke in patients with atrial fibrillation reviewed in detail elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42506?source=see_link\">",
"       \"Antithrombotic therapy to prevent embolization in atrial fibrillation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Selected patients with recently symptomatic carotid stenosis of 50 to 99 percent who have a life expectancy of at least five years are generally treated with carotid endarterectomy. This issue is discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/1/21530?source=see_link\">",
"       \"Management of symptomatic carotid atherosclerotic disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients with TIA or ischemic stroke having carotid endarterectomy, we recommend",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      at a dose of 81 to 325",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      started before surgery (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/27/40378?source=see_link&amp;anchor=H93838520#H93838520\">",
"       \"Carotid endarterectomy\", section on 'Aspirin'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4629697\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The editorial staff at UpToDate, Inc. would like to acknowledge Dr. Philip Kistler for his contributions to an earlier version of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/11/10426/abstract/1\">",
"      Easton JD, Saver JL, Albers GW, et al. Definition and evaluation of transient ischemic attack: a scientific statement for healthcare professionals from the American Heart Association/American Stroke Association Stroke Council; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular Radiology and Intervention; Council on Cardiovascular Nursing; and the Interdisciplinary Council on Peripheral Vascular Disease. The American Academy of Neurology affirms the value of this statement as an educational tool for neurologists. Stroke 2009; 40:2276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/11/10426/abstract/2\">",
"      Johnston SC, Nguyen-Huynh MN, Schwarz ME, et al. National Stroke Association guidelines for the management of transient ischemic attacks. Ann Neurol 2006; 60:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/11/10426/abstract/3\">",
"      Cucchiara BL, Kasner SE. All patients should be admitted to the hospital after a transient ischemic attack. Stroke 2012; 43:1446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/11/10426/abstract/4\">",
"      Amarenco P. Not all patients should be admitted to the hospital for observation after a transient ischemic attack. Stroke 2012; 43:1448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/11/10426/abstract/5\">",
"      Molina CA, Selim MM. Hospital admission after transient ischemic attack: unmasking wolves in sheep's clothing. Stroke 2012; 43:1450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/11/10426/abstract/6\">",
"      Nguyen-Huynh MN, Johnston SC. Is hospitalization after TIA cost-effective on the basis of treatment with tPA? Neurology 2005; 65:1799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/11/10426/abstract/7\">",
"      Joshi JK, Ouyang B, Prabhakaran S. Should TIA patients be hospitalized or referred to a same-day clinic?: a decision analysis. Neurology 2011; 77:2082.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/11/10426/abstract/8\">",
"      Flemming KD, Brown RD Jr, Petty GW, et al. Evaluation and management of transient ischemic attack and minor cerebral infarction. Mayo Clin Proc 2004; 79:1071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/11/10426/abstract/9\">",
"      Dennis MS, Bamford JM, Sandercock PA, Warlow CP. A comparison of risk factors and prognosis for transient ischemic attacks and minor ischemic strokes. The Oxfordshire Community Stroke Project. Stroke 1989; 20:1494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/11/10426/abstract/10\">",
"      Coull AJ, Lovett JK, Rothwell PM, Oxford Vascular Study. Population based study of early risk of stroke after transient ischaemic attack or minor stroke: implications for public education and organisation of services. BMJ 2004; 328:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/11/10426/abstract/11\">",
"      Streifler JY, Eliasziw M, Benavente OR, et al. The risk of stroke in patients with first-ever retinal vs hemispheric transient ischemic attacks and high-grade carotid stenosis. North American Symptomatic Carotid Endarterectomy Trial. Arch Neurol 1995; 52:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/11/10426/abstract/12\">",
"      Johnston SC, Gress DR, Browner WS, Sidney S. Short-term prognosis after emergency department diagnosis of TIA. JAMA 2000; 284:2901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/11/10426/abstract/13\">",
"      Hill MD, Yiannakoulias N, Jeerakathil T, et al. The high risk of stroke immediately after transient ischemic attack: a population-based study. Neurology 2004; 62:2015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/11/10426/abstract/14\">",
"      Wu CM, McLaughlin K, Lorenzetti DL, et al. Early risk of stroke after transient ischemic attack: a systematic review and meta-analysis. Arch Intern Med 2007; 167:2417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/11/10426/abstract/15\">",
"      Shah KH, Kleckner K, Edlow JA. Short-term prognosis of stroke among patients diagnosed in the emergency department with a transient ischemic attack. Ann Emerg Med 2008; 51:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/11/10426/abstract/16\">",
"      Ois A, Gomis M, Rodr&iacute;guez-Campello A, et al. Factors associated with a high risk of recurrence in patients with transient ischemic attack or minor stroke. Stroke 2008; 39:1717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/11/10426/abstract/17\">",
"      Giles MF, Rothwell PM. Risk of stroke early after transient ischaemic attack: a systematic review and meta-analysis. Lancet Neurol 2007; 6:1063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/11/10426/abstract/18\">",
"      Daffertshofer M, Mielke O, Pullwitt A, et al. Transient ischemic attacks are more than \"ministrokes\". Stroke 2004; 35:2453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/11/10426/abstract/19\">",
"      van Wijk I, Kappelle LJ, van Gijn J, et al. Long-term survival and vascular event risk after transient ischaemic attack or minor ischaemic stroke: a cohort study. Lancet 2005; 365:2098.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/11/10426/abstract/20\">",
"      Rothwell PM, Warlow CP. Timing of TIAs preceding stroke: time window for prevention is very short. Neurology 2005; 64:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/11/10426/abstract/21\">",
"      Chandratheva A, Mehta Z, Geraghty OC, et al. Population-based study of risk and predictors of stroke in the first few hours after a TIA. Neurology 2009; 72:1941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/11/10426/abstract/22\">",
"      Mohr JP, Caplan LR, Melski JW, et al. The Harvard Cooperative Stroke Registry: a prospective registry. Neurology 1978; 28:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/11/10426/abstract/23\">",
"      Pessin MS, Hinton RC, Davis KR, et al. Mechanisms of acute carotid stroke. Ann Neurol 1979; 6:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/11/10426/abstract/24\">",
"      Russo LS Jr. Carotid system transient ischemic attacks: clinical, racial, and angiographic correlations. Stroke 1981; 12:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/11/10426/abstract/25\">",
"      Flossmann E, Rothwell PM. Prognosis of vertebrobasilar transient ischaemic attack and minor stroke. Brain 2003; 126:1940.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/11/10426/abstract/26\">",
"      Purroy F, Montaner J, Molina CA, et al. Patterns and predictors of early risk of recurrence after transient ischemic attack with respect to etiologic subtypes. Stroke 2007; 38:3225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/11/10426/abstract/27\">",
"      Sheehan OC, Kyne L, Kelly LA, et al. Population-based study of ABCD2 score, carotid stenosis, and atrial fibrillation for early stroke prediction after transient ischemic attack: the North Dublin TIA study. Stroke 2010; 41:844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/11/10426/abstract/28\">",
"      Paul NL, Simoni M, Chandratheva A, Rothwell PM. Population-based study of capsular warning syndrome and prognosis after early recurrent TIA. Neurology 2012; 79:1356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/11/10426/abstract/29\">",
"      Donnan GA, O'Malley HM, Quang L, et al. The capsular warning syndrome: pathogenesis and clinical features. Neurology 1993; 43:957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/11/10426/abstract/30\">",
"      Johnston SC, Rothwell PM, Nguyen-Huynh MN, et al. Validation and refinement of scores to predict very early stroke risk after transient ischaemic attack. Lancet 2007; 369:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/11/10426/abstract/31\">",
"      Rothwell PM, Giles MF, Flossmann E, et al. A simple score (ABCD) to identify individuals at high early risk of stroke after transient ischaemic attack. Lancet 2005; 366:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/11/10426/abstract/32\">",
"      Stead LG, Suravaram S, Bellolio MF, et al. An assessment of the incremental value of the ABCD2 score in the emergency department evaluation of transient ischemic attack. Ann Emerg Med 2011; 57:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/11/10426/abstract/33\">",
"      Amarenco P, Labreuche J, Lavall&eacute;e PC. Patients with transient ischemic attack with ABCD2 &lt;4 can have similar 90-day stroke risk as patients with transient ischemic attack with ABCD2 &ge;4. Stroke 2012; 43:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/11/10426/abstract/34\">",
"      Sanders LM, Srikanth VK, Blacker DJ, et al. Performance of the ABCD2 score for stroke risk post TIA: meta-analysis and probability modeling. Neurology 2012; 79:971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/11/10426/abstract/35\">",
"      Perry JJ, Sharma M, Sivilotti ML, et al. Prospective validation of the ABCD2 score for patients in the emergency department with transient ischemic attack. CMAJ 2011; 183:1137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/11/10426/abstract/36\">",
"      Tsivgoulis G, Heliopoulos I. Potential and failure of the ABCD2 score in stroke risk prediction after transient ischemic attack. Stroke 2010; 41:836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/11/10426/abstract/37\">",
"      Tsivgoulis G, Stamboulis E, Sharma VK, et al. Multicenter external validation of the ABCD2 score in triaging TIA patients. Neurology 2010; 74:1351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/11/10426/abstract/38\">",
"      Chandratheva A, Geraghty OC, Luengo-Fernandez R, et al. ABCD2 score predicts severity rather than risk of early recurrent events after transient ischemic attack. Stroke 2010; 41:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/11/10426/abstract/39\">",
"      Ay H, Arsava EM, Johnston SC, et al. Clinical- and imaging-based prediction of stroke risk after transient ischemic attack: the CIP model. Stroke 2009; 40:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/11/10426/abstract/40\">",
"      Calvet D, Touz&eacute; E, Oppenheim C, et al. DWI lesions and TIA etiology improve the prediction of stroke after TIA. Stroke 2009; 40:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/11/10426/abstract/41\">",
"      Fothergill A, Christianson TJ, Brown RD Jr, Rabinstein AA. Validation and refinement of the ABCD2 score: a population-based analysis. Stroke 2009; 40:2669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/11/10426/abstract/42\">",
"      Cancelli I, Janes F, Gigli GL, et al. Incidence of transient ischemic attack and early stroke risk: validation of the ABCD2 score in an Italian population-based study. Stroke 2011; 42:2751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/11/10426/abstract/43\">",
"      Giles MF, Albers GW, Amarenco P, et al. Early stroke risk and ABCD2 score performance in tissue- vs time-defined TIA: a multicenter study. Neurology 2011; 77:1222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/11/10426/abstract/44\">",
"      Galvin R, Geraghty C, Motterlini N, et al. Prognostic value of the ABCD&sup2; clinical prediction rule: a systematic review and meta-analysis. Fam Pract 2011; 28:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/11/10426/abstract/45\">",
"      Quinn TJ, Cameron AC, Dawson J, et al. ABCD2 scores and prediction of noncerebrovascular diagnoses in an outpatient population: a case-control study. Stroke 2009; 40:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/11/10426/abstract/46\">",
"      Josephson SA, Sidney S, Pham TN, et al. Higher ABCD2 score predicts patients most likely to have true transient ischemic attack. Stroke 2008; 39:3096.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/11/10426/abstract/47\">",
"      Ray G, Wright F, Stott DJ, Langhorne P. A prospective study using the ABCD2 score in screening for minor stroke or transient ischaemic attack in referrals to a fast track clinic. Stroke 2009; 40:e467; author reply e468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/11/10426/abstract/48\">",
"      Sheehan OC, Merwick A, Kelly LA, et al. Diagnostic usefulness of the ABCD2 score to distinguish transient ischemic attack and minor ischemic stroke from noncerebrovascular events: the North Dublin TIA Study. Stroke 2009; 40:3449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/11/10426/abstract/49\">",
"      Asimos AW, Rosamond WD, Johnson AM, et al. Early diffusion weighted MRI as a negative predictor for disabling stroke after ABCD2 score risk categorization in transient ischemic attack patients. Stroke 2009; 40:3252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/11/10426/abstract/50\">",
"      Purroy F, Montaner J, Rovira A, et al. Higher risk of further vascular events among transient ischemic attack patients with diffusion-weighted imaging acute ischemic lesions. Stroke 2004; 35:2313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/11/10426/abstract/51\">",
"      Sciolla R, Melis F, SINPAC Group. Rapid identification of high-risk transient ischemic attacks: prospective validation of the ABCD score. Stroke 2008; 39:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/11/10426/abstract/52\">",
"      Arsava EM, Furie KL, Schwamm LH, et al. Prediction of early stroke risk in transient symptoms with infarction: relevance to the new tissue-based definition. Stroke 2011; 42:2186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/11/10426/abstract/53\">",
"      Giles MF, Albers GW, Amarenco P, et al. Addition of brain infarction to the ABCD2 Score (ABCD2I): a collaborative analysis of unpublished data on 4574 patients. Stroke 2010; 41:1907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/11/10426/abstract/54\">",
"      Lovett JK, Coull AJ, Rothwell PM. Early risk of recurrence by subtype of ischemic stroke in population-based incidence studies. Neurology 2004; 62:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/11/10426/abstract/55\">",
"      Merwick A, Albers GW, Amarenco P, et al. Addition of brain and carotid imaging to the ABCD&sup2; score to identify patients at early risk of stroke after transient ischaemic attack: a multicentre observational study. Lancet Neurol 2010; 9:1060.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/11/10426/abstract/56\">",
"      Ay H, Gungor L, Arsava EM, et al. A score to predict early risk of recurrence after ischemic stroke. Neurology 2010; 74:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/11/10426/abstract/57\">",
"      Maier IL, Bauerle M, Kermer P, et al. Risk prediction of very early recurrence, death and progression after acute ischaemic stroke. Eur J Neurol 2013; 20:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/11/10426/abstract/58\">",
"      Rothwell PM, Giles MF, Chandratheva A, et al. Effect of urgent treatment of transient ischaemic attack and minor stroke on early recurrent stroke (EXPRESS study): a prospective population-based sequential comparison. Lancet 2007; 370:1432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/11/10426/abstract/59\">",
"      Lavall&eacute;e PC, Meseguer E, Abboud H, et al. A transient ischaemic attack clinic with round-the-clock access (SOS-TIA): feasibility and effects. Lancet Neurol 2007; 6:953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/11/10426/abstract/60\">",
"      Kernan WN, Schindler JL. Rapid intervention for TIA: a new standard emerges. Lancet Neurol 2007; 6:940.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/11/10426/abstract/61\">",
"      Rothwell PM, Eliasziw M, Gutnikov SA, et al. Endarterectomy for symptomatic carotid stenosis in relation to clinical subgroups and timing of surgery. Lancet 2004; 363:915.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1123 Version 27.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-122.72.80.101-F119FB24C4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_11_10426=[""].join("\n");
var outline_f10_11_10426=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INITIAL EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Hospitalization versus ambulatory evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Brain imaging studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Neurovascular evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Anterior circulation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Posterior circulation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Intracranial large vessels",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Small vessels",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Cardiac evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Echocardiography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Cardiac monitoring",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Other",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Blood tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H311703\">",
"      TIA etiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      ABCD2 score",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H979759\">",
"      Importance of infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      URGENT TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4629697\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/1123\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/1123|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?2/4/2122\" title=\"figure 1\">",
"      Cerebral arterial circulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/34/42531\" title=\"figure 2\">",
"      Cerebral vascular territories",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?9/51/10042\" title=\"figure 3\">",
"      Middle cerebral artery territory",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?21/7/21630\" title=\"figure 4\">",
"      Risk vascular events after TIA or minor stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/1123|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?18/54/19308\" title=\"table 1\">",
"      ABCD2 score",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/32/36361?source=related_link\">",
"      Ambulatory monitoring in the assessment of cardiac arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/35/2618?source=related_link\">",
"      Antiplatelet therapy for secondary prevention of stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42506?source=related_link\">",
"      Antithrombotic therapy to prevent embolization in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/27/40378?source=related_link\">",
"      Carotid endarterectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/21/18773?source=related_link\">",
"      Definition of transient ischemic attack",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/37/36439?source=related_link\">",
"      Differential diagnosis of transient ischemic attack and stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/4/12361?source=related_link\">",
"      Echocardiography in detection of intracardiac sources of embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/46/40678?source=related_link\">",
"      Etiology and clinical manifestations of transient ischemic attack",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/19/31033?source=related_link\">",
"      Evaluation of carotid artery stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/29/33242?source=related_link\">",
"      Initial assessment and management of acute stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/61/2010?source=related_link\">",
"      Intracranial large artery atherosclerosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/59/4026?source=related_link\">",
"      Lacunar infarcts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/1/21530?source=related_link\">",
"      Management of symptomatic carotid atherosclerotic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/56/17290?source=related_link\">",
"      Neuroimaging of acute ischemic stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/47/28410?source=related_link\">",
"      Overview of the evaluation of stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/55/24435?source=related_link\">",
"      Patient information: Stroke (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?37/37/38484?source=related_link\">",
"      Patient information: Stroke symptoms and diagnosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?20/18/20772?source=related_link\">",
"      Patient information: Transient ischemic attack (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?34/22/35170?source=related_link\">",
"      Patient information: Transient ischemic attack (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/22/39273?source=related_link\">",
"      Posterior circulation cerebrovascular syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/33/32281?source=related_link\">",
"      Secondary prevention for specific causes of ischemic stroke and transient ischemic attack",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/61/30682?source=related_link\">",
"      Secondary prevention of stroke: Risk factor reduction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_11_10427="Comorbidities and medications affecting recognition";
var content_f10_11_10427=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F53777&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F53777&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Anaphylaxis: Comorbidities and concurrent medications that might interfere with recognition of trigger or symptoms",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Comorbidities",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Impairment of vision or hearing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neurologic disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Psychiatric illness (eg, depression, ADHD, autism spectrum disorder, cognitive disorder, substance abuse)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Concurrently administered medications",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sedatives (eg, sedating H",
"        <sub>",
"         1",
"        </sub>",
"        -antihistamines)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypnotics",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ethanol",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Recreational drugs",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     ADHD: attention deficit-hyperactivity disorder.",
"    </div>",
"    <div class=\"reference\">",
"     Modified with permission from: Simons FER. Anaphylaxis, killer allergy: Long-term management in the community. J Allergy Clin Immunol 2006; 117:367. Copyright &copy; 2006 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_11_10427=[""].join("\n");
var outline_f10_11_10427=null;
var title_f10_11_10428="ACAAI ACOG chronic asthma preg";
var content_f10_11_10428=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F55513&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F55513&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Preferred pharmacologic step therapy of asthma during pregnancy: NAEPP update 2004",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Category",
"       </td>",
"       <td class=\"subtitle1\">",
"        Step therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mild intermittent",
"       </td>",
"       <td>",
"        Inhaled short-acting beta2 agonist* as needed (for all categories)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Mild persistent",
"       </td>",
"       <td>",
"        Low dose inhaled glucocorticoid",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"5\">",
"        Moderate persistent",
"       </td>",
"       <td>",
"        Medium dose inhaled glucocorticoid",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Low dose inhaled glucocorticoid",
"        <sup>",
"         &bull;",
"        </sup>",
"        plus long-acting beta agonist",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Medium dose inhaled glucocorticoid",
"        <sup>",
"         &bull;",
"        </sup>",
"        plus long-acting beta agonist",
"        <sup>",
"         &Delta;",
"        </sup>",
"        , if needed",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        Severe persistent",
"       </td>",
"       <td>",
"        High dose inhaled glucocorticoid",
"        <sup>",
"         &bull;",
"        </sup>",
"        plus long-acting beta agonist",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prednisone if needed",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Albuterol is preferred inhaled short acting beta2 agonist during pregnancy.",
"     <br>",
"      <span class=\"bullet\">",
"       &bull;",
"      </span>",
"      Budesonide is preferred inhaled corticosteroid during pregnancy.",
"      <br>",
"       &Delta; Salmeterol is preferred long-acting beta agonist during pregnancy.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Based on data from: Quick Reference. NAEPP Expert Panel Report Managing Asthma During Pregnancy: Recommendations for Pharmacologic Treatment-Update 2004. US Dept of Health and Human Services, Bethesda, MD. NIH Publication No. 04-5246, March, 2004.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_11_10428=[""].join("\n");
var outline_f10_11_10428=null;
var title_f10_11_10429="Using powder inhalers 2 PI";
var content_f10_11_10429=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F59737&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F59737&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Technique for use of various dry powder inhalers - II",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        HandiHaler",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Capsules should be stored in sealed blisters and only removed immediately before use.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Peel back the foil using the tab until one capsule is fully visible.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Open the dust cap by pulling it upwards, then open the mouthpiece.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Place the capsule in the center chamber (it does not matter which end of the capsule is placed in the chamber).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Close the mouthpiece firmly until you hear a click, leaving the dust cap open.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hold the HandiHaler with the mouthpiece upwards and press the piercing button completely in once and release.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Breathe out completely. Do not breathe into the mouthpiece at any time.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Close your lips tightly around the mouthpiece.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Breathe in rapidly and steadily, as deeply as possible; hold breath.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        To ensure you get the full dose, repeat the inhalation from the HandiHaler as described.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        After the dose, open the mouthpiece, tip out the used capsule, and dispose. Do not handle used capsules.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Close the mouthpiece and dust cap for storage; store device in cool, dry place.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Turbuhaler",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Twist and remove cover.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hold inhaler upright with mouthpiece facing up.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Turn grip right then left until it clicks.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Inhaler may be held upright or horizontal.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Breathe in rapidly and steadily, as deeply as possible; hold breath.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Remove device from mouth and exhale outside device.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Replace cover and twist to close; store device in cool, dry place.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Twisthaler",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hold the inhaler straight up with the pink portion (the base) on the bottom.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Remove the cap while it is in the upright position to make sure you get the right amount of medicine with each dose.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hold the pink base and twist the cap in a counter-clockwise direction to remove it.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        As you lift off the cap, the dose counter on the base will count down by 1. This action loads the medicine that you are now ready to inhale.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Make sure the indented arrow located on the white portion (directly above the pink base) is pointing to the dose counter.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Breathe out normally - do not exhale into the device.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Place the mouthpiece into your mouth, with the mouthpiece facing towards you, and close your lips tightly around it.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Inhale dose with a rapid and steady flow while holding the Twisthaler horizontal.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Remove the mouthpiece from your mouth and hold your breath for 5 to 10 seconds (or as long as you comfortably can).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        When you exhale, be sure that you are not exhaling into the device",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Immediately replace the cap and turn in a clockwise direction as you gently press down until you hear a click.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Firmly close the Twisthaler to assure that your next dose is properly loaded.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Be sure that the arrow is in line with the dose-counter window.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Store device in cool dry place.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        The dose counter displays the number of doses remaining. When the unit reads 01, this indicates the last remaining dose. When the counter reads 00, the unit must then be discarded.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_11_10429=[""].join("\n");
var outline_f10_11_10429=null;
var title_f10_11_10430="Contents: Interventional pulmonology";
var content_f10_11_10430=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?8/24/8590\">",
"       Pulmonary, Critical Care, and Sleep Medicine",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Interventional pulmonology",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Interventional pulmonology",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/0/34823\">",
"           Airway stents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/28/41414\">",
"           An overview of medical thoracoscopy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/57/24468\">",
"           Argon plasma coagulation in the management of airway disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/25/38292\">",
"           Bronchoscopic cryosurgery: Indications, contraindications, and outcomes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/13/10453\">",
"           Bronchoscopic cryosurgery: Principles and technique",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/47/38645\">",
"           Bronchoscopic laser resection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/30/37351\">",
"           Diagnosis and management of central airway obstruction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/18/32038\">",
"           Endobronchial brachytherapy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/11/11447\">",
"           Endobronchial electrocautery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/32/19976\">",
"           Endobronchial ultrasound: Indications, advantages, and complications",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/26/43427\">",
"           Endobronchial ultrasound: Technical aspects",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/16/12552\">",
"           Endoscopic ultrasound-guided fine-needle aspiration in the mediastinum",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/10/15526\">",
"           Fibrosing mediastinitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/31/27126\">",
"           Flexible bronchoscopy balloon dilation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/50/43816\">",
"           Flexible bronchoscopy: Equipment, procedure, and complications",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/15/38135\">",
"           Flexible bronchoscopy: Indications and contraindications",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/0/21511\">",
"           Fluorescence bronchoscopy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/41/31382\">",
"           Imaging of pleural plaques, thickening, and tumors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/55/29558\">",
"           Overview of massive hemoptysis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/10/11434\">",
"           Overview of the management of postoperative pulmonary complications",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/42/11945\">",
"           Overview of tracheostomy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/55/37749\">",
"           Photodynamic therapy of lung cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/33/37394\">",
"           Rigid bronchoscopy: Instrumentation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/15/7412\">",
"           Rigid bronchoscopy: Intubation techniques",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/45/39637\">",
"           Therapeutic uses of medical thoracoscopy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/42/18088\">",
"           Tracheomalacia and tracheobronchomalacia in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/35/3642\">",
"           Transbronchial needle aspiration",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-6E22AC4200-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f10_11_10430=[""].join("\n");
var outline_f10_11_10430=null;
var title_f10_11_10431="Stensens duct infxn SS";
var content_f10_11_10431=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F52846&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F52846&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Ascending salivary gland infection affecting Stensen's duct in Sj&ouml;gren's syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 304px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Xerostomia in Sj&ouml;gren's syndrome predisposes patient to salivary gland infections and, as shown here, of Stensen's duct. The picture demonstrates pus from the opening of the duct.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Robert Fox, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_11_10431=[""].join("\n");
var outline_f10_11_10431=null;
